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Production of high affinity antibodies is a hallmark of the humoral immune response and occurs 
in the germinal center (GC). It depends on a stage-wise developmental process that includes B 
cell activation, antigen processing and presentation to T follicular helper (Tfh) cells, proliferation 
and somatic hypermutation in GC, selection and eventual differentiation into antibody-secreting 
plasma cells (PC) or memory B cells. Previous studies have shown that B cell development and 
activation in GC are controlled by different molecular mechanisms, such as protein 
phosphorylation, transcription, microRNA, and epigenetic modification. My thesis tries to extend 
these studies by exploring the potential role of protein ubiquitination in the GC reaction. 
We have found that both CBL and CBLB are highly upregulated in GC B cells as compared to 
naïve B cells and, within the GC B cells, light zone (LZ) GC B cells expressed higher level of 
CBLs compare to dark zone (DZ) cells. To understand the function of CBLs in the GC reaction, 
we have examined GC B cell development and differentiation in the mutant mice in which CBLs 
are either conditionally ablated before GC initiation (in CBLdKO-Mb1 mice) or during GC progression 
(in CBLdKO-Cg mice). Our findings reveal that CBLs play critical roles in both GC entry and exit 
checkpoints. At the entry checkpoint of the GC reaction, CBLs are required for naïve B cell 
antigen uptake, processing, and presentation to Tfh cells. They regulate this process by promoting 
B cell antigen receptor (BCR) internalization and sorting to lysosome for degradation via 
ubiquitination Iga, a component of the BCR complex. However, after entering the GC stage, 
CBLs control selection for high affinity antibodies but not the production of total antibodies, 
because in the absence of CBLs GC B cells can still develop relatively normally but fail to 
selectively expand high affinity BCR producing clones as compared to control B cells. Our 





ubiquitination of IRF4, a transcription factor that is upregulated in the later stage GC B cells with 
high affinity BCR. Together, our studies provide clear evidence that CBL-mediated 
ubiquitination is an important and novel regulatory mode in B cells that controls different stages 
of GC reaction and antibody responses. Modulation of the CBL pathway can be a potentially 
useful approach not only to interfere humoral immunity for the treatment and prevention of 


















La production d'anticorps de haute affinité est une des caractéristiques de la réponse immunitaire 
humorale; elle a lieu dans le centre germinatif. Elle dépend d'un processus de développement 
séquentiel qui comprend: l'activation des lymphocytes B par l'antigène, le traitement et la 
présentation de l'antigène aux lymphocytes T auxiliaires, la prolifération et l'hypermutation 
somatique  dans le CG, la sélection des lymphocytes B produisant des anticorps de haute affinité 
et finalement la différenciation en plasmocytes sécréteurs ou en lymphocytes B mémoire. Des 
études antérieures ont montré que le développement et l'activation des lymphocytes B dans le CG 
sont contrôlés par des mécanismes moléculaires, tels que la phosphorylation des protéines, la 
transcription, les microARNs et la modification épigénétique. Ma thèse vise à poursuivre ces 
études en explorant le rôle potentiel de l'ubiquitination des protéines dans le développement du 
CG. 
Nous avons établi que l'expression de CBL et CBLB (protéines CBL) est considérablement 
augmentée dans les lymphocytes B du CG comparée à celle des lymphocytes B naïves. De plus 
dans le CG, les protéines CBL sont exprimées préférentiellement dans les lymphocytes B de la 
zone claire, plutôt que dans ceux de la zone foncée. Nous avons examiné le rôle des protéines 
CBL dans le développement et la différenciation des lymphocytes B du CG en utilisant des souris 
mutantes dans lesquelles l'expression des protéines CBL est, soit réduite conditionnellement 
avant l'initiation du GC (souris CBLdKO-Mb) ou  pendant la réaction de formation du CG (souris 
CBLdKO-Cg). Nos résultats révèlent que les protéines CBL jouent des rôles critiques dans le contrôle 
de la formation du CG. En effet les protéines CBL sont requises pour l'absorption, le traitement et 
la présentation de l'antigène aux cellules T auxiliaires par les lymphocytes B naïves. Ces 
molécules contrôlent ce processus en favorisant l'internalisation du récepteur de l'antigène des 





composant du complexe BCR. Cependant après le début de la réaction dans le CG, les protéines 
CBL contrôlent la sélection d'anticorps de haute affinité, sans toute fois affecter la production 
totale d'anticorps. En effet en absence des protéines CBL, les lymphocytes B du CG peuvent 
encore se développer plus ou moins normalement, mais ne peuvent pas produire des clones ayant 
des BCRs de haute affinité, comparé aux lymphocytes B de type sauvage. Nos analyses ont aussi 
révélées que les protéines CBL contrôlent cette étape du développement des cellules B du CG en 
favorisant l'ubiquitination de IRF4, un facteur de transcription exprimé tardivement dans les 
lymphocytes B du CG ayant vraisemblablement acquis un BCR de haute affinité. L'ensemble nos 
études montrent que l'ubiquitination induite par les protéines CBL est un mécanisme de 
régulation important des lymphocytes B. Ces ubiquitines ligases contrôlent les différentes étapes 
de la réaction CG et d'une façon plus large la génération d'anticorps. Le contrôle des protéines 
CBL pourrait permettre non seulement de modifier la réponse immunitaire humorale pour le 
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Overview of immunity, the T-dependent immune response and B cells 
Currently, people are living in the world with various types of pathogens, such as viruses, 
bacteria, worms and fungi. Our immune system can efficiently distinguish invading 
pathogens from self-antigens and mount effective immune responses to clear pathogen 
infections. In mammalian immune system, there are two branches, each with unique 
features and functions: the innate immune system and the adaptive immune system. To 
mount an efficient innate immune response, several types of innate immune cells are 
involved, such as natural killer cells (NKs), dendritic cells (DCs), innate lymphoid cells 
(iLCs) and macrophages. The innate immune system is considered the first defence line 
against pathogen invasion since these innate immune cells can be directly activated by 
pathogens or the complement system and can rapidly produce large amounts of cytotoxic 
cytokines to eliminate pathogens. For example, macrophages can engulf invade 
pathogens through ‘phagocytosis’, and the internalized pathogens was destroyed in 
lysosome under low pH environment. DCs also have the capacity to eliminate the 
pathogens through phagocytosis, but the purpose of the capture pathogens is to trigger 
adaptive immune responses through presenting antigen to T cells. In contrast, NKs 
possess capacity to eliminate pathogens infected cells and transformed cells through 
cytotoxic ways, such as releasing perforin and granzymes or binding to FAS ligand[1]. 
Recently, one novel innate lineage immune cells, called innate lymphoid cells (iLCs), are 
identified, which differ from T cell, B cell and NK cells[2, 3]. iLCs are further classified 





cytokine production. Multiple studies have been shown their important role in protective 
immunity and modulating immune response[4, 5].  
Once the pathogens escape from the innate immune system, the adaptive immune system 
is activated. The adaptive immune cells, including T and B cell, can generate an antigen-
specific immune response to target pathogen-infected cells. T cells can differentiate into 
T helper (Th) cells and cytotoxic T cells, whereas B cell can give rise to antigen-specific 
antibody secreting plasma cells (PCs). The adaptive immune system can generate not 
only a more efficient and antigen specific response but also long-lived memory cells that 
are responsible for recalling the immune response. The T-dependent immune response 
can generate antigen-specific antibodies to neutralize foreign pathogens such as bacteria 
and viruses. CD4+ T cells, B cells and DCs are required for mounting an efficient T-
dependent humoral immune response. Antigen-experienced DCs can activate B cells and 
CD4+ T cells; then, the CD4+ T cells can provide critical ‘help’ for B cell functional 
maturation, in which receptor- and ligand-involved cell-cell interactions are required. To 
ensure that antibodies can neutralize various types of pathogens, the germline B cell 
receptor (BCR) repertoire is dramatically diversified due to isotype switching and 
somatic hypermutations (SHM) within germinal center (GC) reactions. The PCs derived 
from GCs can produce high affinity antigen-specific antibodies. Given that GC B cells 
are a critical component of the T-dependent antibody response, it is necessary to 
understand how to increase the affinity of an antigen specific antibody through GC-
dependent mechanism. Basic research may promote the enhancement of vaccination 





immunization antigens. However, the GC reaction is a double-edged sword since the GC 
reaction in rare cases can lead to B cell lymphoma due to the off-targeting of activation-
induced cytidine deaminase [6] mediated DNA modification. Therefore, it is pivotally 
important to understand the mechanism of GC-related B cell tumourigenesis since it can 
provide novel, potential therapeutic targets with respect to human B cell lymphoma. 
1.1 Development of B Lymphocytes 
B cells are one of the key lineages of adaptive immune cells. They are distributed in 
multiple secondary lymphoid organs in a highly organized way, together with other 
lineages of haematopoietic cells, including T cells, DCs, and macrophages/monocytes 
and lymphoid tissue stromal cells such as follicular dendritic cells (FDCs). The main 
function of mature B cells is to generate the humoral antibody responses, including T-
dependent and T-independent antibody response. Splenic B cells can be further divided 
into two sub-lineages: marginal zone [7] and follicular (FO) B cells, which may execute 
distinct functions. MZ B cells can rapidly differentiate into short-lived extra-follicular 
PCs and are the source of evolutionally selected multivalent, cross-reactive, low affinity 
antibodies that may provide the first line of defence against blood-borne pathogens[8].	In 
contrast, the FO B cells mainly respond to T-dependent antigens through the GC reaction 
and further develop into long-lived high-affinity antibody secreting PCs of different Ig 
isotypes and memory B cells. Both mature MZ and FO B cells are derived from bone 
marrow haematopoietic stem cells. In the following sections, I will provide a general 





1.1.1 Early B cell development in the bone marrow 
Early B cell development occurs in the bone marrow and starts from haematopoietic stem 
cells (HSC). According to the current model, the HSCs first generate common lymphoid 
progenitor (CLP) cells, which retain the multi-potential to differentiate into T, B and NK 
lineages of cell	[9]. CLPs are characterized by cell surface c-Kit+ and IL-7Ra+ but lack 
the surface expression of multiple lineage markers, including B220, CD4, CD8, CD11b, 
GR1 and Ter119. Based on the surface marker expression, Richard Hardy and colleagues 
further demonstrated that early B cell development can be fractionated into several 
developmental stages sequentially from fraction A to D (Fr. A-D), also termed Richard 
Hardy Fractions[10]. In this scheme, Fr. A cells are characterized by cell surface markers 
B220+, CD19-, HSAlow, CD43+ and AA4.1+. These cells start to express recombination-
activating gene 1 (Rag1) and recombination-activating gene 2 (Rag2), and rearrange their 
D and J gene segments of the immunoglobulin genes. The transition from Fr.A to Fr. B 
cells is dependent on IL-7 mediated signalling. At the Fr. B stage, which is characterized 
by cell surface markers B220+, CD24+ and BP-1-, the successfully rearranged heavy 
chain can  pair with a surrogate light chain, l5VpreB, and Ig accessory proteins Iga and 
Igb to form the pre-B cell receptor (pre-BCR) [11]. The pre-BCR can drive the 
development and expansion of Fr. B cells, a process called pre-B selection. The 
signalling of the pre-BCR is tonic and independent of antigen triggering, and the 
importance of the pre-BCR in this stage of early B cell development has been 
demonstrated in severe combined immunodeficiency (SCID) mice[12], Rag-, Iga-, and 





cells at the same Fr. B to Fr.C transition stage	 [13]. At the Fr. C stage, antigen-
independent pre-BCR signalling supports the robust proliferation of Fr.C’ cells, while the 
expressions of RAG and TdT are downregulated through allelic exclusion. The pre-BCR 
signalling promotes the transition from Fr.C’ to Fr.D, during which the re-expressed 
RAG specifically targets the light chain of the immunoglobulin genes (Figure 1.1). Once 
the light chain of immunoglobulin genes is successfully rearranged, the surface IgM, 
composed of light chains and heavy chains, is successfully expressed at the small pre-B 
stage. These small pre-B cells may undergo BCR-based positive selection, migrate out of 
the bone marrow, and continue further maturation in the secondary lymphoid organs[14]. 
In contrast, if the cells express an inappropriately paired BCR or an auto-reactive BCR, 
they will undergo apoptosis either by neglect or by negative selection. 
	
Figure 1.1 B cell development 
B cell lineage is derived from HSCs in bone marrow. The early B cell development, from 
Pro-B to Immature B, occurs in bone marrow, during which the immature B cells 
generate mature BCR complex dependent on RAG. Once they pass the positive and 
negative selection, they migrate to secondary lymphoid organs to further differentiate into 






1.1.2 Migration and maturation of newly generated B cells in secondary lymphoid 
organs 
Once immature B cells complete positive selection with mature BCR surface expression, 
immature B cells enter the blood stream and the lymph, homing to secondary lymphoid 
organs. The migration of immature B cells is dependent on adhesion molecules and 
chemokine receptors. The sphingosine-1-phosphate (S1P) receptor has been shown to be 
responsible for the egress of immature B cells from the bone marrow[15], as the 
migration of immature B cells from the bone marrow to secondary lymphoid organs is 
blocked upon the deletion of S1p receptor 1 in mice[16]. In addition to S1P, Cannabinoid 
receptor 2 (CB2) has been shown to play a role in the retention of immature B cells in the 
bone marrow for sufficient repertoire generation[17]. Cb2-deficient mice show a reduced 
frequency of Igl+ B cells in secondary lymphoid organs and blood. In contrast, although 
CXCR4 (C-X-C chemokine receptor type 4) is required for the retention of HSC and B 
cell precursors in the bone marrow, it does not seem to be required for the migration of 
immature B cells[18].  
1.1.3 Transitional 1 (T1) and Transitional 2 (T2) B cells 
In the secondary lymphoid organs, newly immature B cells undergo further stage-wise 
maturation before becoming mature B cells. The most recently generated immature B 
cells in the bone marrow and spleen are defined as T1 B cells, which express 
B220+AA4.1+HSA+CD23-CD21/CD35-. In the follicles, T1 B cells mature into T2 B 





study has shown that T1 and T2 B cells also undergo negative selection, indicating that 
this is another critical stage of B cell development for immune tolerance induction[19].  
1.1.4 B-1 vs B-2 B cells 
Mature B cells in peripheral tissues and secondary lymphoid organs can be divided into 
B1 and B2 cells with distinct functions and locations. The function and development of 
B2 B cells will be introduced in the next section. B1 cells, located at peritoneal and 
pleural cavities, are long lasting and self-renew since the majority of them are generated 
at the foetal liver stage. Based on surface marker CD5, B1 B cells can be further 
characterized as B-1a (CD5+) and B-1b (CD5-). They express relatively low levels of 
B220 and IgD, high levels of IgM, intermediate levels of Mac-1. In addition to these 
typical B cell surface markers, they also express a high level of migration-related 
integrin, such as a4, a6, b1 and b7[20, 21]. Upon commensal bacterial stimulation, B1 
cells can rapidly differentiate into IgM or IgA antibody producing PCs[22]. B1 cell-
derived PCs produce antibodies with low affinity and poly-specificity[23]. 
The generation of B1 cells is derived from B1 specified progenitor cells (B1P), 
characterized as Lin-CD45Rlo/negCD19+ cells[24]. The development of B1P cells is 
dependent on cytokines IL-7 and thymic stromal lymphopoietin (TSLP)[25, 26]. Previous 
studies have showed that BCR-mediated signalling is critical for the maturation of B1 
cells because deficiency of BCR signalling key components, such as CD19, B cell linker 
(BLNK), CD21, VAV and bruton tyrosine kinase (BTK), leads to a greater reduction in 





CD5+ B cells was detected in a BCR signal hyper-activation mouse model by the 
deletion of Shp-1 or Lyn[30].  
However, the maintenance of peritoneal B1 cells is still not clear. There are two possible 
sources: (i) new generation from bone marrow B1 progenitors as there is little input from 
the bone marrow in adulthood, and (ii) antigen-stimulated expansion. Upon bacteria 
stimulation, B1 cells migrate to the omentum and mesenterum, which contain multiple 
types of lymphocytes[31]. In lymphocyte-enriched regions, type 2 innate lymphocytes 
(iLC2) can promote the proliferation of B1 cells through an IL-5 dependent 
mechanism[32]. 
1.1.5 Marginal zone vs follicular B cells 
In the secondary lymphoid organs, T1 and T2 B cells further mature into multiple mature 
B cell lineages, including B1, MZ B, and FO B cells. In contrast to FO (B220+HSA+ 
AA4.1CD21hiCD23hiIgMlo IgDhi) B cells, which reside in B cell follicles, MZ B cells are 
characterized as B220+HSA+AA4.1CD21/CD35hiCD23loIgMhi IgDlo and are distributed in 
the MZ, an anatomically distinct location at the interface between the red pulp and white 
pulp. This region contains not only MZ B cells but also specialized macrophages and 
reticular stromal cells. Due to their unique location, MZ B cells can rapidly respond to 
blood-borne pathogens. At present, the mechanism for the fate choice between MZ and 
FO B cells is not yet clear; however, it is generally believed that this cell fate choice is 
determined when mature T2 B cells migrate to the spleen and requires different signals to 





1.1.5.1 NOTCH signalling pathway in MZ B cell commitment 
It has been shown that NOTCH2-mediated signalling is critical for both precursor and 
mature MZ B cells commitment since Notch2-deficient mice exhibit defective MZ B cell 
development [33]. Consistently, the downstream targets of the NOTCH signalling 
pathway, such as recombining binding-protein suppressor of hairless (RBP-Jk) and 
Mastermind-like 1 (MAML1), are also required for MZ B cell development [34-36]. Both 
Rbp-jk- and Maml1-deficient mice show MZ B cell deficiency and consequently an 
impaired T-independent antibody response. Furthermore, the deletion of Notch signalling 
suppressor MSX2-interacting nuclear target protein leads to an enlarged MZ B cell 
population in the spleen [37, 38]. The physiologically relevant ligand for NOTCH 
signalling, delta ligand 1 (DL1), is highly expressed in both red pulp and the marginal 
zone [39]. Knockout mice lacking Dl1 also show defects in MZ B cell development. The 
endocytosis of DL1 has been shown to be regulated by E3 ubiquitin ligase Mindbomb1 
(MIB1), which is required for both T cell and MZ B cell development [40]. NOTCH 
signalling can indirectly target three different transcription factors, including E2A, ID2 
and ID3, to execute its function in MZ B cell development. The expression of helix-loop-
helix transcription factor E2A is regulated by NOTCH signalling mediated-ubiquitination 
[41]. E2a-deficient mice show an increased MZ B cell population, which suggests that 
E2A-mediated gene transcription has a suppressive role in MZ B cell development. Other 
members of E protein family proteins, inhibitor of DNA binding 2 (ID2) and inhibitor of 
DNA binding 3 (ID3), are negative regulators of E2A. Compared to the enlarged MZ B 





development, which suggests an indirect regulatory role of NOTCH signalling in MZ B 
cell development via regulating the expression of Id2 and Id3 [42]. 
1.1.5.2  BCR signal strength in FO and MZ B cell development 
In the past decade, experiments have revealed a critical role of BCR signal strength 
during the fate decision between FO B and MZ B. It has been shown that weak BCR 
signalling is required for the commitment of MZ B cells, whereas a strong BCR signal 
favours the survival of FO B cells. For example, it has also been found that impairment of 
the BCR-BTK pathway by genetically deleting Btk or phospholipase Cg2 (Plcg2) leads to 
the loss of FO B cells and the relative preservation of MZ B cells [43]. Consistently, in 
the absence of the positive regulator of BCR signalling CD21/CR2, MZ B cells are 
significantly expanded compared to WT mice [44]. It has been shown that genetic 
modification of the tyrosine residues on immunoreceptor tyrosine activation motif 
(ITAM) of Iga leads to the loss of only MZ B cells, due to the enhanced BCR signalling 
[45]. In contrast, mice lacking sialate O-acetyl esterase (SIAE) or CMP N-acetyl 
hydroxylase (CMAH), the ligand of the CD22-mediating BCR inhibitory signalling 
pathway, display a dramatic reduction of MZ B cells [6]. A question that remains 
unresolved is whether there is a crosstalk between BCR and Notch-signalling that 
collectively determines MZ vs FO B cell fate determination. 
1.1.5.3 Other regulators in MZ and FO B cell development 
B-cell activating factor (BAFF), a trimeric member of TNF family protein, is highly 
expressed in lymphoid follicles and is critical for the survival of T2 B cells and mature 





development through activating both non-canonical and canonical NF-kB pathway 
through different substrates [46]. Deletion of p50 and p65 of the canonical NF-kB 
pathway leads to defective MZ B cell development [47]. In addition to BAFF, chemokine 
receptors and integrin may play a role in the migration and retention of MZ B cells. For 
example, lymphocyte function-associated antigen 1 (LFA-1) and a4b1 have shown to 
contribute to the retention of MZ B cells in the marginal zone [48].  The abnormal 
integrin signalling through mutating protein tyrosine kinase 2(Ptk2) leads to the blockade 
of MZ B cell development, suggesting that migration- and retention-related factors are 
critical for MZ B development [49]. Interestingly, Martin Turner’s group recently 
showed that RNA-binding proteins of the ZFP36 family regulate MZ B cell development 
through post-transcriptional mechanism [50]. It will be interesting to determine whether 
ZFP36 proteins regulate MZ B cell development through the aforementioned molecules. 
1.1.6 Follicular B cells   
Most mature B cells migrate to secondary lymphoid organs and become follicular B cells, 
which can be simply identified as IgMlo/hiIgDhi B cells. B cell follicles are always close to 
the T cell zone, which provides a convenient way for activated B cells to interact with 
activated T helper cells at the interface of the T cell and B cell zones during T-dependent 
immune responses. Unlike MZ and B1 B cells, FO B cells have a broad BCR repertoire 






1.2 The Germinal Centre Reaction 
The GC is a temporary micro-lymphoid structure in secondary lymphoid organs such as 
the spleen and lymph nodes, which emerges upon pathogen infection or vaccination [51]. 
In 1884, Walther Flemming first described the GC as a distinct micro-anatomical 
structure in secondary lymphoid organs that contains dividing cells. After this first report, 
a series of studies from multiple different groups proposed that the GC is a possible 
source of lymphocytes throughout the body. In 1936, Hellmann contested this conclusion 
based on his studies in which the germ-free guinea pigs completely lacked a GC but had a 
normal lymphocyte distribution. Subsequently, several immunization experiments 
demonstrated that the great majority of germinal centre cells are highly proliferating B 
cells during immune responses. Visible GCs appear at approximately 6 days, and those 
foci increase rapidly in size and reached their peak at approximately 14 days in the B cell 
follicles of the lymph nodes and spleen. Once the GC reaction has passed its peak, the 
latitude of the GCs starts to decline due to limited antigens and enhanced differentiation 
of PCs [52]. Although the GC sizes start to shrink after the peak, they can be detected up 
to at least 95 days. This observation thus provides an explanation for why vaccination can 
induce a prolonged production of high affinity antibodies in the protective immune 
response. In the following section, I will review what we know about the regulation of 





1.2.1 Cell types in the GC 
1.2.1.1 GC B cells 
The predominant cell types in the GC are activated B cells, which are quite different from 
naïve B cells in terms of size, phenotypic marker expression and function. For example, 
GC B cells are larger than naïve B cells and display a highly polarized morphology [53, 
54]. GC B cells are highly proliferating, with extensive protein synthesis and DNA 
replication, whereas naïve B cells are at a steady state. Based on surface phenotypic 
markers, GC B cells are characterized as expressing high levels of apoptotic receptor 
FAS and GL7, as binding to peanut agglutinin (PNA),  and as having lost of naïve B cell 
markers such as IgD and CD38[55-57]. Two critical intracellular/nuclear proteins for GC 
B cell phenotype and function are the transcription factor B-cell lymphoma 6 (BCL6) and 
AID [58-60]. BCL6 is highly upregulated in GC B cells. Bcl6-deficient mice cannot form 
GCs or generate high affinity antibody secreting PCs [61]. The transcriptional repressor 
BCL6 selectively silences PC-related gene expression such as PR domain zinc finger 
protein 1 (Prdm1) and interferon regulatory factor 4 (Irf4), which demonstrates that BCL6 
is critical for the maintenance of GC B cell identity [62]. Another important feature of 
GC B cells is a proneness to apoptosis since BCL6 suppresses anti-apoptotic protein 
BCL2 expression [63]. Since GC B cells undergo massive DNA replication and mutation, 
BCL6 is required for the tolerance to DNA damage through BCL6-mediated silencing of 
p53 and ATR [64, 65]. The DNA deaminase AID is mainly expressed in GC B cells. 
Both BCR isotype switching and affinity maturation are dependent on AID activity in GC 





gene [60]. On the basis of different surface markers and cell statuses, GC B cells can be 
divided into two sub-populations: centroblasts and centrocytes, which will be reviewed in 
the next section. 
1.2.1.2 The follicular dendritic cells 
FDCs are strictly located in the LZ of the GC, where they are considered the maker for 
LZ in histology and fluorescence microscopy [66, 67]. In GCs, FDCs are the primary 
source of antigens that can stimulate the maturation and selection of GC B cells. FDCs 
can capture antigens through complement receptors 1 (CR1) and 2 (CR2), which can help 
them retain immune-complex-coated bodies on the cell surface [68]. Antigen-specific GC 
B cells selectively acquire antigen complexes from FDCs based on the affinity of the 
BCR, leading to further proliferation, mutation, and maturation. In addition to their role 
as APCs in GCs, FDCs also secrete chemokines and cytokines that can support the 
formation of GCs. For instance, the ablation of intercellular adhesion molecule 1(ICAM-
1) and vascular cell adhesion protein 1 (VCAM-1) on FDCs leads to reduced GC size and 
impaired affinity maturation [7]. The cytokines IL-6 and BAFF secreted from FDCs play 
critical roles in GC maturation [69-71]. The organization of LZ is also dependent on the 
chemo-attractant signals provided by FDCs since they produce the ligand for CXC-
chemokine receptor 5 (CXCR5). 
1.2.1.3 Follicular T helper cells and follicular regulatory T cells 
 Tfh cells are one subset of CD4+ T helper cells that are mainly present in GCs. They 
express the chemokine receptor CXCR5, which is critical for the migration from T cell 





such as inducible co-stimulator (ICOS) and PD-1, as well as signalling lymphocyte 
activation molecule 6 (SLAMF6) and SLAM-associated protein [72, 73]. The 
development of early Tfh cells is dependent on the cytokine IL-6 produced by antigen-
experienced DCs [74, 75]. Tfh cells provide a pivotal survival signal to GC B cells 
through those receptors that involve a cognate interaction. Based on their cytokine 
production, Tfh cells are further divided into two subpopulations: IL-21+ Tfh and IL-4+ Tfh. 
The Il-21r-deficient mice display impaired affinity maturation and generation of long-
lived PCs, suggesting that IL-21 is a key component for optimal GC reaction [76, 77]. 
The isotype switch of GC B cells is dependent on IL-4 [78-80]. Those two distinct 
populations display a unique function in GC B cell maturation: IL-4+ Tfh promoting class 
switch recombination (CSR) and differentiation of PCs, and IL-21+ Tfh supporting clonal 
selection, and expansion [81].  
Recently, a new sub-population of follicular T cells is identified as follicular regulatory T 
cells (Tfr), characterized as CD4+CXCR5+PD-1+BCL6+FOXP3+ [82, 83]. Tfr cells display 
suppressive function on GC B cell and Tfh cell growth. Similar to Tfh cells, Tfr cell 
development depends on GC B cells, SAP and BCL6. This suppressive population is 
derived from natural Treg cells, not naïve T or Tfh cells. However, their antigen 
specificity is still unknown. 
1.2.1.4 Other populations 
In addition to Tfh and GC B cells, GCs also contain tangible-body macrophages (TBMs) 
and a small population of DCs. TBMs can eliminate apoptotic B cells that are 





erythematosus [84], suggesting they may control immune tolerance in the GC [85]. 
Although DCs are observed in GCs, their role in GCs is still unclear [86]. 
A unique subset of T cells, called invariant natural killer T cells (iNKT cells), is also 
found in the GC region. The TCR repertoire of iNKT cells is restricted, composed of the 
a-chain variable region 14-a-chain joining region 18 paired with the Vb8.2, Vb7 or Vb2 
TCR b-chain [87]. After the cognate interaction with antigen-specific B cells, iNKT cells 
produce cytokine IL-21, which can promote GC formation, affinity maturation and the 
IgG antigen response [88]. Interestingly, iNKT cells can further differentiate into NKTfh 
through a CD28-BCL6-dependent mechanism [89]. However, the NKTfh cell-induced GC 
displays limited affinity maturation.  
1.2.2 The Structure of the GC 
Matured GCs are characterized as having two functional regions: DZ and LZ [90]. The 
original definition of DZ and LZ came from early conventional histology techniques. The 
DZ was visualized as a darkly stained region because of highly proliferating centroblasts; 
the LZ contained smaller, non-proliferating B cells known as centrocytes, as well as 
antigen-coated FDCs and antigen-specific Tfh cells. The current model indicates that 
these two segregated regions of the GC may have different functions. In the DZ, GC B 
cells proliferate and undergo SHM of the Ig variable region. In contrast, the LZ area is 
where GC B cells expressing a mutated BCR undergo antigen-receptor-based selection 






Figure 1.2 Germinal center. 
The GC is composed of DZ and LZ. The different regions contain different cell types and 
carry out distinct functions. The LZ contains centrocytes, Tfh and FDC. Tfh and FDC both 
provide unique survival and differentiation signals to centrocytes. For example, antigen 
loaded-FDC provides antigens to centrocytes through BCR affinity based competition, 
while the Tfh provide survival signals to them through cognate interaction. Once 
centrocytes acquire survival signals, they migrate to DZ through upregulation of CXCR4 
and c-Myc. In the DZ, the centroblasts turn on the expression of FOXO1 and AID, which 
can promote the clonal expansion and SHM. After 2-3 round of proliferation, centroblasts 
migrate back to LZ through the upregulation of CXCR5. Due to the limited amount of 
‘help’ provided by FDC and Tfh, B cells with low affinity BCR undergo apoptosis. The 
high-affinity B cells have three potential fates: re-entry into DZ for further expansion and 
mutation; exit from GC into PCs or memory B cell. 
 
1.2.2.1  Dark zone of the GC 
To generate a broad BCR repertoire against pathogens, AID is highly upregulated in DZ 





U:G mismatch caused by AID can lead to the conversion of C:G to T:A during cell 
replication. Since the frequency of SHM in Ig V genes is significantly enhanced (106-
fold) compared to the natural somatic mutation rate in the genome, it allows GC B cells 
to acquire many point mutations in IgV genes within the cell cycle, leading to 
improvements in both the affinity and the specificity of the BCR [91]. The CSR from the 
IgM isotype to other isotypes of Ig is also dependent on the activity of AID through 
targeting the switch regions of the BCR heavy chain gene. When AID targets single 
strand DNA during transcription, the AID may target some regions other than the Ig 
locus, called off-target regions. This process may cause a very low frequency of 
mutations in oncogenes, such as Myc and p53, consequently leading to the initiation of 
chromosome translocations that eventually contribute to the development of GC B-cell-
derived lymphomas [92].  
1.2.2.2 Light zone of the GC 
The LZ of the GC is heterogeneous in terms of its cell composition, which includes 
FDCs, Tfh cells, centrocytes, and TBMs. The main function of the LZ is to provide an 
environment for FDC- and Tfh-dependent affinity-based selection and differentiation of 
centrocytes [93] . The FDC is considered an antigen-presenting cells within GCs and has 
been shown to be necessary for the maturation and maintenance of GCs [51, 94]. Due to 
the limited availability of antigens captured by FDCs, the centrocytes must compete for 
antigens based on the affinity of the BCR, so that only the B cells with high affinity 





and clonal expansion. In contrast, due to insufficient FDC and T cell help, B cells 
expressing low affinity BCRs undergo apoptosis and are then rapidly cleaned by TBMs.  
The cognate interaction between antigen-specific GC B cells and Tfh cells is critical for Tfh 
expansion and re-entry of centrocytes into the DZ. This interaction involves multiple 
receptors and ligands on both T and B cells. For example, ICOS-mediated signalling is 
critical for Tfh cell expansion since the expression of BCL6 and IL-21 is induced by ICOS 
signalling [95, 96]. The interaction of CD40 with CD40 ligand (CD40L) is required for 
GC B cell proliferation and differentiation. The signalling lymphocytic activation 
molecule (SLAM)-SLAM has been shown to be necessary for both B and Tfh cell survival 
[97]. Those interactions execute their biological functions through their corresponding 
downstream signal pathways to promote the establishment of the GC reaction. In addition 
to promoting GC B cell proliferation, FDC and Tfh are also required for the differentiation 
of PCs and long-lived memory B cells. I will review the detailed mechanism of post-GC 
fate decision in section 1.2.6.  
1.2.3 The Initiation of the germinal centre reaction 
The spleen can be structurally divided into red pulp and white pulp. The majority of T 
and B lymphocytes are located in the white pulp, which can be further characterized into 
B cell follicles containing IgM+IgD+ naïve B cells and a T cell zone comprising CD4+ 
and CD8+ T cells. In this subsection, how activated B cells interact with antigen specific 





1.2.3.1 T-B cognate interaction 
In the spleen, naïve B cells are activated by exogenous T-dependent antigen-loaded FDCs 
within the follicle. The activated B cells migrate to the border of the T cell and B cell 
zone where they cognately interact with antigen-specific T cells. Afterwards, a small 
fraction of activated B cells directly differentiates into short-lived plasmablasts through 
an extra-follicular reaction. In addition to extra-follicular PCs, Marc Jenkins’ group 
reported that some of the GC B cell precursors (CD38+GL7+) directly differentiated into 
IgM+ or isotype-switched Ig+ memory B cells in a GC-independent fashion[98], while a 
small fraction of activated B cells differentiated into GC B cells.  Michel Nussenzweig 
and colleagues proposed that entry into GCs is determined by the amount of peptide-
major histocompatibility complex (pMHC) presented to cognate T cells within clusters at 
the T-B border, which means that T-cell-mediated signals control the clonality and 
antigen specificity of GC B cells [99]. This T-B cognate interaction ensures that only 
antigen specific T and B cells can enter GC cycle. Although B cells are dispensable for 
the priming of CD4+ T cells and initial Tfh programme, they are critical for the functional 
maturation of Tfh cells during the early stage of GC reaction [100-102].  
1.2.3.2 Antigen presentation by B cells 
The cognate interaction of B and T cells is initiated by the interaction between antigen-
peptide-loaded major histocompatibility complex II (MHCII) and antigen-specific T cell 
receptor (TCR), followed by the ligation of multiple co-stimulatory molecules and 
ligands. At this stage, B cells act as classic APCs, which can acquire both soluble and 





Catron used fluorescence-coupled small soluble antigens to track how B cells capture 
antigens for subsequent T cell-dependent activation. Their system clearly showed that 
small antigens can be rapidly supplied to the lymph node through the afferent lymph 
vessels and then diffuse to the B follicle without the help of DC or B cell migration [103].  
Complex antigens, such as viral particles, immune complexes or antigen-coated 
microspheres, cannot directly diffuse to the B cell zone; thus the capture of antigens by B 
cells is dependent on the specialized APCs. In the draining lymph node, a population of 
CD11b+CD169+MHCII+ macrophages in the subcapsular sinus is specializes in 
preserving intact antigens. It has been shown that subcapsular sinus macrophages can 
capture antigens through two different mechanisms: complement receptor 3 (CR3) or the 
FcgRIIB-mediated complement-IgG-opsonized immune complex, or SIGLEC-1 and the 
mannose receptor [104]. The neighbouring follicular B cells can rapidly capture antigens 
through receptor CD21 from antigen-coated macrophages and antigens transported into 
the FDCs located in the B cell follicle [103]. Interestingly, this type of antigen 
transportation is independent on the BCR. For example, influenza A virus is captured and 
presented to B cells by subcapsular sinus macrophages [105]. However, several studies 
have shown that antigen-specific B cells are directly bound to their cognate antigens on 
subcapsular sinus macrophages through ICAM-1- and VCAM-1-mediated cell adhesion 
[106, 107]. After acquiring cognate antigens, activated B cells migrate back to the T/B 
border for T-B cognate interaction. 
 Given that B cells enter lymph nodes through high endothelial venules (HEVs), they can 





studies identified a population of DCs located in the paracortex that can present intact 
antigens to B cells [108, 109]. Additionally, a recent study showed that lymph node 
resident DCs are loosely distributed in the T cell zone and T/B border where they 
continuously interact with T and B cells[86, 110]. The lymph node resident DCs can 
capture influenza A viral particles through receptor SIGN-R1. Depletion of this 
population suppresses the antiviral immune response [105]. Furthermore, Ronald 
Germain’s group by using two-photon intravital microscopy showed that B cells located 
in the extra-follicular region survey locally antigen-coated DCs, which leads to migration 
arrest, activation and antigen acquisition [111]. Once the B cells acquire antigens, they 
upregulate migration-related proteins, such as CC chemokine receptor7 (CCR7) and 
Epstein-Barr virus-induced G protein-coupled receptor 2 (EBI2), to guide those activated 
cells to the T cell border for full activation through T-B cognate interaction [112, 113].  
The recognition of the antigens on the membrane of APCs through BCR engagement 
leads to the formation of a stable immunological synapse. The BCR has two main 
functions: first, BCR engagement triggers intracellular signalling cascades, leading to B 
cell activation, proliferation and differentiation; second, the BCR can capture, internalize 
and process the antigen-BCR complex into peptides to be presented to T cells via MHCII 
[114]. These two functions are interdependent since the BCR-associated signalling is 
required for BCR internalization and promoting the transport of antigen-BCR complexes 
to lysosomes for degradation [115]. To maintain the stable immunological synapse, the 
LFA-1/ICAM-1 interaction increases the adhesion of B cells under the circumstance of 





The stabilization of this synapse is also dependent on the BCR-induced rapid actin-
involved membrane-spreading response. After the formation of stabilized synapses, the 
antigens are transported into BCR micro-clusters and sorted to central clusters through 
ERM (ezrin, radixin and moesin) and the microtubule-based motor protein dynein-
dependent rearrangement of cortical actin cytoskeleton [117, 118]. The GTPase Ras-
related protein (RAP) can activate the actin-severing protein cofilin to support this 
process. Moreover, RAP also controls the polymerization of the actin cytoskeleton 
through F-actin [119]. 
The BCR is a multimeric protein complex including antigen-binding arms consisting of 
Ig heavy chains and Ig light chains that are non-covalently associated with two signal-
transducing heterodimers of Iga and Igb. The BCR signals are initiated by SRC-kinase-
mediated tyrosine phosphorylation of ITAM on Iga and Igb, followed by the 
ubiquitination of the BCR complex through a SYK-dependent pathway [120]. Two 
different E3 ubiquitin ligases, ITCH and CBL, have been shown to be responsible for this 
process. Both ubiquitin ligases can directly target the phosphorylated Iga and Igb 
complex, leading to the internalization of the BCR complex [121, 122]. The spatial 
organization in the membrane micro-domain is also critical for the internalization of the 
BCR complex since the tyrosine-phosphorylated clathrin is associated with rafts upon 
BCR stimulation [123]. The internalized BCR is trafficked through early endosomes to 
the late endosomes and LAMP-1+ multi-vascular compartments, during which mitogen-
activated protein kinase (MAPK), extracellular signal-regulated kinase 1/2 (ERK1/2), 





actin cytoskeleton related proteins, such as actin-binding proteins (ABP1) and BTK, are 
also involved in the sorting of the BCR complex[125]. To maintain prolonged production 
of the antigenic peptide-MHCII complex, the excessive MHCII molecules are co-
localized in degradation lysosomes. The transport of the MHCII and BCR-Ag complex is 
highly regulated through actin-associated motor myosin II. Taken together, BCR-induced 
downstream signals activate multiple genes and re-organize the actin cytoskeleton, both 
of which are highly coordinated and required for intracellular vehicle transport and B cell 
antigen processing/presentation. 
1.2.4 Early GC formation and progression 
1.2.4.1 Initiation of early GC and Tfh 
Due to the broad usage of intravital microscopy, three independent groups have shed new 
light on the early dynamics of GC formation in lymph nodes. Cortty and collaborators 
found that DC-primed antigen-specific CD4+ T cells to exhibited an early Tfh phenotype 
that was characterized as CXCR5+, programmed cell death 1+ (PD-1) and GL7+ at day 2 
of LCMV infection. ICOS signalling can induce the expression of CXCR5 on Tfh cells 
through a BCL6-dependent mechanism, which supports the migration of Tfh cells to the 
GC region [100]. In addition, Takaharu Okada and colleagues, by using the Bcl-6 reporter 
mice, found that BCL6 expression in B cells was continuously upregulated after day 3 of 
immunization. Strikingly, some fractions of Tfh cells gradually lost the Bcl6 expression 
after day 3 of immunization, which might lead to memory Tfh cell phenotypes such as 
terminated proliferation and upregulation of the IL-7 receptor [102, 126].   Although the 





dependent on antigen-specific B cells since the Tfh population in B cell deficient mice 
was dramatically reduced at day 4 of immunization. In terms of Tfh function, these Tfh 
cells were functionally immature, as evidenced by the reduced IL-4 and IL-21 
production, suggesting a critical role of cognate T-B cell interaction in the maintenance 
or functional maturation of Tfh cells in the GC. Collectively, the commitment of early Tfh 
and pre-GC B cells occurs at the IF (inter-follicular) zone, and Tfh cell differentiation and 
migration precedes pre-GC B cells by 1 day. It would be interesting to dissect which 
signals are responsible for the initiation of pre-GC B cells.  
1.2.4.2 Transcriptional regulation of Tfh and GC B cells 
Since BCL6 is critical for GC initiation, extensive studies have been carried out on the 
BCL6 transcription and its regulatory modes. Several transcription factors, including Irf4, 
interferon regulatory factor 8 (Irf8), basic leucine zipper transcription factor 2 (Bach2), 
paired box 5 (Pax5), and Prdm1, have been shown to be dynamically regulated by BCL6. 
For example, BCL6 and BLIMP1 mutually suppress each other’s function since these 
two transcription factors bind to each other’s promoters and repress each other’s 
expression, which consequently antagonizes the functions of two opposite groups of 
genes manifested by GC B cells and PCs [127]. It was shown that BACH2, IRF8 and 
PAX5 stabilizes the expression of BCL6, which in turn suppresses PCs differentiation 
[127]. However, IRF4 is an unusual component in this gene regulatory network, since 
IRF4 has diverse, dose-dependent and context-dependent functions in Tfh and GC B cell 
development. Michael Lohoff’s group showed that the Irf4-deficient mice failed to 





the administration of WT CD4+ T cells. This result suggested that IRF4 is required for Tfh 
development [128]. Moreover, the strength of the TCR signal determines the 
concentration of IRF4 that is required for both BCL6-expressing Tfh and BLIMP-1-
expressing T effector cells [129]. Mechanically, abundant IRF4 expression leads to low-
affinity binding sites within Prdm1 including Teff cis- regulatory components [130]. Not 
surprisingly, IRF4 is also critical for the GC B cells since the Irf4-deficient B cells driven 
by CD19-Cre failed to differentiate into GC B cells. Based on chromatin 
immunoprecipitation followed by sequencing (ChIP-seq) analysis of in vitro antigen-
activated B cells, IRF4 could directly induce the Bcl6 and Pou2af1 expression by binding 
to the region 24k bp upstream of the bcl6 gene [131]. In contrast, Cg1-Cre-driven Irf4 
deletion did not affect the proper formation of GCs since the Cg1-Cre-mediated deletion 
occurred at approximately day 2 after immunization. Although these mutant mice were 
able to mount a proper GC, PCs were undetectable in both the spleen and bone marrow 
after hapten NP-carrier antigen immunization [132]. Thus, IRF4 is not only required for 
the initial pre-GC B development for a limited time window but also necessary for 
promoting post-GC PCs differentiation. Interestingly, IRF4 and IRF8, a transcription 
factor structurally related to IRF4, can directly bind to DNA motifs Pu.1, Spi-b and Batf 
[133]. However, the expression of these two transcription factors leads to distinct 
consequences in terms of lymphocyte lineage commitment and cell activation. The loss 
of IRF8 protein in B cells leads to a reduced GC reaction and enhanced PCs 





double-negative feedback loop mechanism that determines the fate choice of extra-
follicular plasmablast or GC reaction in the early stage of the GC reaction.  
1.2.4.3 The survival of GC B cells 
Once B cells differentiate into GC B cells, several surface receptors and ligands are 
upregulated to support their survival and maturation. Among these molecules, the death 
receptor FAS (also called CD95) is highly expressed. FAS is a member of the tumour 
necrosis factor receptor (TNF-R) family [135]. Activation of FAS by its physiological 
ligand FASL has been proven to trigger apoptosis. The upregulation of FAS in GC B 
cells suggests that FAS is the negative regulator of autoimmune disorders relate to GC 
reaction. Consistent with this hypothesis, Fas-deficient B cells showed hyper-activation 
and enhanced proliferation. Other apoptotic proteins, such as BCL2L1 (BCL-XL), BCL2 
and BIM, are also involved in the caspase-mediated cell apoptosis [136-138]. Although 
multiple apoptotic factors are involved in this negative selection, so far, only one pro-
survival molecule, MCL1, has been shown to regulate GC B cell survival, as identified 
by David Tarlinton’s group. The Mcl1-deficient mice driven by Aicda-cre could not form 
proper GC reactions and memory B cells, suggesting that MCL1 is continuously required 
throughout the entire GC reaction [139]. More importantly, the requirement to obtain an 
effective GC reaction is dependent on the level of MCL1 expression. Cellular extrinsic 
factors, such as T cell and FDC ‘help’, also provide critical survival signals for GC B cell 
survival. In LZ, Tfh cells express high levels of CD40L, for which it was shown that the 
CD40-CD40L interaction could rescue FAS-induced apoptosis of centrocytes through the 





CD9 on human GC B cells, which is a member of the transmembrane 4 superfamily, also 
supports the survival of GC B cells. In human tonsillar tissues, CD9+ GC B cells were 
highly enriched in the LZ area of GCs compared to CD9- GC B cells, which suggested 
that the CD9-meditated interaction could promote GC B cell survival through interacting 
with FDC. Consistently, in vitro CD9+ GC B cells survive better than CD9- GC B cells in 
the presence of FDC line HK cells [142]. 
1.2.5 Interzonal movement and maturation of GC B cells 
The early GC emerges at approximately day 4 post-immunization and is derived from the 
extensive expansion of activated antigen specific B cells. The mature GC featuring two 
different cell zones appears until day 7 post immunization. After the establishment of DZ 
and LZ, the antigen-specific B cells undergo interzonal migration for clonal expansion, 
affinity maturation and selection. In this subsection, I will review the recent findings 
about this interzonal migration and maturation theory. 
1.2.5.1 GC B interzonal migration 
The DZ and LZ functionally segregate GC B cells into two subpopulations: centroblasts 
(characterized as CXCR4hiCD83lowCD86low) and centrocytes (characterized as 
CXCR4lowCD83hiCD86hi).  The Cxcr4-deficient GC B cells are mainly located in the LZ 
of the WT GC structure, which demonstrates that CXCR4 is required for the migration of 
centroblasts towards the CXCR4 ligand SDF-1 (CXCL12) expressed in the DZ. The 
chemokine receptor CXCR5 guides the migration of centrocytes to the CXCL13-enriched 
LZ since the ablation of CXCL13 leads to a deficiency of LZ organization in these 





antigen-specific B cells are physically restricted to the GC but migrate bi-directionally 
between the DZ and LZ [143, 144]. More recent works have focused on the molecular 
mechanism that controls the migration between DZ and LZ. Two groups found that 
transcription factor c-Myc is repressed by BCL-6 in the DZ but induced among antigen-
driven selected LZ GC B cells for the re-entry into the DZ. This finding suggests that c-
Myc is required for the DZ-LZ circulation of GC B cells [84, 145]. Interestingly, the 
induction of AP4 is dependent on c-MYC during T-B cognate interaction, while the IL-
21 can maintain the AP4 expression in GC B cells. Although the ablation of Ap4 did not 
affect DZ-LZ organization, the Ap4-deficient GC B cells displayed a decreased GC B cell 
population and a reduced SHM and humoral antibody response against LCMV infection, 
coupled with a reduced proliferation rate of DZ GC B cells [146]. These findings suggest 
that AP4 is required for the clonal expansion of DZ GC B cells and the subsequent 
antibody response. The expression of transcription factor forkhead box protein O1 
(FOXO1) is restricted to DZ GC B cells, whereas the LZ GC B cells display a high level 
of PI3K activity. The PI3K signalling and FOXO1 play opposite roles in the organization 
of DZ and LZ GC B cells. The ablation of Foxo1 or the hyperactivation of PI3K activity 
results in impaired LZ organization with blocked CSR and impaired affinity maturation, 
despite normal AID expression, which may be due to the downregulation of chemokine 
receptor CXCR4 [147, 148]. Surprisingly, although CXCR4 is required for the formation 
of DZ, the Cxcr4-deficient mice display normal antibody responses against hapten 
antigens and slightly reduced responses against influenza [149, 150]. Further study 





Collectively, it is still unclear why the GCs segregate the affinity-based selection from 
proliferation and SHM. 
1.2.5.2 Clonal selection and expansion 
Current models propose that the maturation and selection of GC B cells are driven by 
BCR affinity. Micheal Nussenzweig’s group revealed that 50% of DZ GC B cells rapidly 
and continuously migrate to the LZ by 4 hrs of photon-activation, while less than 15% of 
LZ GC B cells can translocate to the DZ within 6 hrs post photon-activation. This study 
further demonstrated that the ability of interzonal migration is determined by the 
availability of antigen-specific Tfh help. The number of the GC B cell divisions per DZ-
LZ cycle, varies from 1 to 6, is determined by the number of antigens acquired from 
FDCs. Since the GC B cells capture antigens from FDCs through the BCR, the GC B 
cells with high-affinity BCRs acquire more antigens in the LZ, leading to the clonal 
expansion of these high-affinity GC B cells and outcompeting the lower-affinity GC B 
cells. Consequently, the greater number of proliferation cycles in GC B cells is associated 
with a higher mutation frequency of the BCR repertoire and enrich for the high-affinity 
mutations due to the BCR-based affinity selection [91]. Later, the “Brainbow” transgenic 
mouse was applied to study the relationship between clonal diversity and expansion 
[152]. This transgenic mouse relied on stochastic Cre-mediated recombination to turn on 
one of four possible fluorescent proteins, which can generate ten different colour 
combinations. The early GCs (8 days post-immunization) were composed of equal 
proportions of CFP+, YFP+ and RFP+ cells and a lower proportion of GFP+ and doubly 





multiple different clones [153]. In the late GCs (20 days post-immunization), selective 
clonal expansion may have led to the single-colour dominance of each late GC, while a 
small proportion of GCs were still highly diversified in terms of colour dominance. 
However, affinity maturation occurred in both single-colour dominant GC and colour 
diversified GC. This phenomenon suggests that GC selection does not inevitably lead to 
high clonal dominance. Similarly, another independent study showed that GC B cells 
from complex-antigen-immunized mice exhibited enrichment of high-affinity clones. 
However, this in vitro single cell analysis also demonstrated that GC reactions to 
complex antigens generate a broad range of specificity and affinities, which could result 
in advantages for broad protection [154]. These studies provide new insights that GC 
selection is not as strict as we expected. 
1.2.6 Post-GC cell fate decision 
PCs secreting high-affinity antibodies and long-lived memory B cells are derived from 
the optimal GC reaction. The high-affinity antibody-secreting PCs mainly home to the 
bone marrow, while the long-lived memory B cells circulate in the lymph and blood 
system. However, the differentiation of these cell lineages is generated at different time 
points and determined by distinct mechanisms. The fate decision of GC B cells is 
determined by multiple factors, which will be reviewed in this section. 
1.2.6.1 Memory B cell formation 
Based on the surface Ig isotype expression, three types of memory B cell are derived 
from the GC reaction, including IgG1+, IgM+ and IgA+. The underlying molecular 





advantage of different transgenic mouse models, several studies have provided new 
insights about memory B cell differentiation. The GC B-cell-specific inducible in vivo 
tracking mouse model clearly showed that GC-dependent IgG1+ memory B cells are 
derived from IgG1+ LZ GC B cells with a relatively low affinity at the early stage of the 
GC reaction, through a CD40-BACH2 dependent mechanism [155]. Recently, Shlomchik 
and colleagues showed that maturation of the GC reaction promotes the sequential 
formation of memory B cell subsets and long-lived PCs[156]. Consistent with a previous 
study, the differentiation of IgG1+ memory B cells occurs in the early phase of the GC 
reaction and reaches its peak at day 8 post-immunization, while the generation of long-
lived PCs starts from day 14 until more than 5 weeks post-immunization. Due to the 
longevity of memory B cells, the anti-apoptotic proteins are also required for memory B 
cell formation. For example, forced over-expression of BCL2 and BIM leads to the 
expansion of IgG+ antigen-specific memory B cells [138]. Cytokine IL-21, which is 
critical for Tfh expansion, serves as a negative regulator of GC-dependent memory B cell 
formation since IL-21R-deficient mice show biased expansion of antigen-specific 
memory B cells with germline Ig sequences [76]. Although SHM and CSR are both 
required for the affinity maturation and diversity of Ig class antibodies, their specific 
functions in the post-GC decision are difficult to distinguish since both functions are 
initiated by AID. A recent study separating the function of CSR and SHM, using Aicda 
engineered CSR reporter mice with impaired SHM, demonstrated that IgG1+ BCR 
promotes the formation of bone marrow PCs and attenuates memory B cell fate without 





BCRs show a reduced lifespan, suggesting that AID-mediated SHM can negatively affect 
the longevity of memory B cells. Consistently, Marc K. Jenkins also showed that IgM+ 
memory B cells possess a longer lifespan compared to isotype-switched subsets. 
However, the IgG1+ memory B cells have dominant roles in the secondary response 
since these cells can be rapidly activated and differentiated into PCs [158]. The less-
mutated IgM+ memory B cells may be the backup reservoir for memory responses when 
the isotype-switched memory B cells disappear [159].   
1.2.6.2 PCs differentiation 
The molecular mechanism behind PCs differentiation has been well studied during the 
past decade. The generation of PCs requires transcriptional re-programming towards a PC 
transcriptome in GC B cells, such as upregulation of PC master transcription factors Irf4, 
Blimp1 and Xbp-1. As discussed above, IRF4 is a unique protein in both the GC B and 
the PC transcription regulatory networks. In GC B cells, IRF4 binds to Pu.1 and Batf to 
form a stable complex to promote the GC fate and CSR in a dose-dependent manner 
[160, 161]. Once reaching a certain threshold, high levels of IRF4 can repress Bcl6 and 
activate Prdm1-related transcription factor zinc finger and BTB domain-containing 
protein 20 (Zbtb20), which activates the downstream targets that can initiate the PC 
transcriptome [162].  
BLIMP1 is a transcriptional repressor of B cell-linage genes (Pax5, Bach2 and Bcl-6) and 
is exclusively expressed in plasmablasts and PCs. However, plasmablasts and PCs 
possess different levels of BLIMP1, and its function in initiating PC differentiation and 





cells were able to differentiate into PCs with a low amount of immunoglobulin 
production, suggesting that BLIMP1 is required for the full PC differentiation and 
function, but not the initiation [163]. These Prdm1-deficient PCs also had a smaller size 
than control PCs had, with severe disruption of the distinctive, dense endoplasmic 
reticulum and impaired lysosomal trafficking, which could explain the insufficient 
immunoglobulin secretion in Prdm1-deficient PCs [164]. Notably, the function of 
BLIMP1 in the unfolded protein response (UPR) is not only restricted to the activation of 
key transcription factors such as Atf6, Xbp1 and Ern1 but also directly bound to 38% of 
UPR genes expressed in PCs. Thus, the transcription repressor BLIMP1 is critical for the 
functional maturation of PCs through a UPR-dependent mechanism. 
Several other factors are also involved in this post-GC fate decision. For instance, the 
epigenetic modifier histone methyltransferase enhancer of zeste homologue 2 (EZH2) can 
protect GC B cells from AID-induced genotoxic damage [165, 166]. Moreover, Stefano 
Casola and colleagues found that EZH2 could directly modify histone H3K27me3 to 
repress PC programming through modifying the expression of Irf4 and Prdm1. Another 
histone acetyltransferase, epigenetic modifier monocytic leukaemia zinc finger protein 
(MOZ), is also involved in the regulation of the post-GC decision [167]. Although the 
Moz-deficient mice show a decreased GC reaction and reduced affinity maturation, the 
antigen-specific memory B-cell formation was enhanced, which suggested that the MOZ 
could influence the lineage commitment between PCs and memory B cells. Interestingly, 
the NF-kB subunit RELA, not c-REL, is specifically required for PC differentiation from 





Although the signal that triggers memory B cell differentiation is still unknown, the 
driven stimulus for high-affinity GC B cell differentiation into PCs has been well studied. 
The IRF4+ plasmablast precursor is initiated in the LZ and then migrates to the DZ to 
complete the process of PC differentiation [169, 170]. Based on current data for affinity-
based selection, migration pattern, cell-cell interaction and asymmetric cell division, a 
mathematical model LEDA (GC B cell selection, division and exit) has been developed. 
It shows that high-affinity GC B cells that acquire help from Tfh cells and antigens from 
FDCs migrate to the DZ for asymmetric division into two distinct daughter cells. The 
cells without antigens differentiate into PCs and leave the GC [171]. Consistent with the 
LEDA model, Robert Brink and colleagues have shown that a majority of early PC 
precursors (characterized as IgG1hi and BLIMP1lo GC B cells) are located in the LZ, 
while late PC precursors (characterized as IgG1lo and BLIMP1hi GC B cells) are located 
in the DZ [172]. The CD40 signal from Tfh cells and the BCR signal from FDCs are both 
required; the CD40 signal is responsible for the initiation of PC programming and BCR 
signalling is required for the completion of the programme. Mechanically, Riccardo 
Dalla-Favera’s group found that CD40 signalling can directly promote BCL6 degradation 
and IRF4 upregulation, which lead to the loss of GC B cell identity and direct cell 
differentiation into plasmablasts [173].   
1.3 Protein Ubiquitination 
Protein ubiquitination is a post-translational modification process. The researchers Avram 
Hershko, Aaron Ciechanover and Irwin Rose were rewarded the 2004 Nobel Prize in 





initial studies showed that the degradation of reticulocytes is dependent on the 
availability of ATP and requires one small heat-stable protein. Moreover, they found that 
the substrates become larger in terms of molecular weight [175]. Later, they identified 
that the heat-stable protein was ubiquitin protein (Ub). Then, this novel proteolytic 
pathway was termed UPS, the ubiquitin-proteasome system, including proteasomal-
mediated degradation and non-proteasomal fates of ubiquitination. 
Ubiquitination is a broad and diverse intracellular event, as recent proteomic studies have 
revealed a large number of ubiquitinated proteins that have yet to be described. The 
translocation of membrane, cytosolic and nuclear proteins is initiated through 
ubiquitination. Histone and transcription factors can also be ubiquitinated, which leads to 
the regulation of gene expression. Ubiquitination is also involved in several branches of 
signalling pathways by the modification of key regulators or adaptor proteins. It has also 
been shown that cell metabolic pathways are regulated through a ubiquitin-dependent 
mechanism. Proteins can be ubiquitinated on a single or multiple lysine residues, leading 
to two different types of protein ubiquitination: monoubiquitination and 
multiubiquitination. Proteins can also be subjected to polyubiquitination through several 
rounds of adding Ub to proteins to form polyubiquitination chains. The detailed process 
of ubiquitination will be introduced in the following section. 
1.3.1 The process of ubiquitination 
This step-wised intracellular event requires three enzymes: E1 (ubiquitin-activating 





enzymes, 37 E2 enzymes and more than 600 E3 ligases have been identified [176, 177]. 
The first enzyme, E1, activates ubiquitin through an ATP-dependent manner. The 
ubiquitin carboxyl group located at the C-terminal is adenylated and transferred to a 
cysteine residue on E1. Then, the activated ubiquitin is transferred from E1 to E2. The E2 
enzyme further associates with the complex containing E3 and the substrate. There are 
two types of E3 ligase: RING/U-box and homologous with E6-associated protein C-
terminus (HECT). E2-ubiquitin can directly transfer ubiquitin to RING/U-box-associated 
substrates. In the case of HECT-type E3, E2-ubiquitin must first transfer the ubiquitin to 
an E3 cysteine sulfhydryl before transfer to the substrate. The ubiquitination can 
repetitively occur on the same substrate through either additional sites or the same site. 
Different types of ubiquitination can result in diversified downstream outcomes. For 
example, polyubiquitinated proteins can be recognized by ubiquitin-binding proteins and 
sorted to the proteasome complex [178]. In the proteasome, the substrates are de-
ubiquitinated, unfolded and degraded into peptides. 
Ubiquitin is a 76-amino acid polypeptide with a molecular weight of approximately 8500 
Da, containing seven lysine residues: K6, K11, K27, K29, K33, K48 and K63. All these lysine 
residues can be potentially ubiquitinated and form isopeptide-linked ubiquitin chains [72, 
179, 180]. Among those chains, more than 50% of the linkage in cells is the K48-linked 
chain, which is characterized as the label for proteasome-mediated degradation [181]. 
The K63 linkage chain is considered a non-degradative signal that is involved in 
inflammatory signalling and NF-kB activation [182]. The remaining ‘atypical’ ubiquitin 





chains are highly upregulated upon UV genotoxic stress, indicating their important role in 
the DNA damage response [183]. Combined with Met1-linked chains, K11-linked chains 
are involved in cell cycle regulation[184]. The K29-linked chain is assembled by the 
HECT E3 ligase and involved in proteasome degradation since the K29-linked chain is 
highly enriched in proteasome-inhibitor-treated human cell lines [185].  K33-linked chains 
are assembled by HECT E3 ligase AREL1, which is responsible for post-Golgi 
membrane protein trafficking [186].  Therefore, the formation of the ubiquitin chain type 
is dependent on the availability of E3 ubiquitin ligases.  
1.3.2 E3 ubiquitin ligases 
E3 ubiquitin ligases are a large and diverse group of proteins, which can be divided into 
three types based on their functional domains and the method of transferring ubiquitin to 
substrate proteins. RING E3s are the most abundant type of ubiquitin ligase, 
characterized by the presence of a unique zinc-binding (RING finger domain) domain or 
a U-box domain [175]. Due to the RING finger domain and U-box domain, the RING 
E3s can act as a scaffold protein to promote E2-ubiquitin-complex direct transfer of 
ubiquitin to substrate proteins. The RING E3s can function as monomers, homodimers or 
heterodimers. For instance, cullin-RING ligases (CRLs) form the E3 ubiquitin ligase 
complex, composed of a cullin scaffold, RING-BOX domain and adaptor protein, as well 
as a substrate receptor. In the RING E3 family, the anaphase-promoting 
complex/cyclosome (APC/C) is another important multi-subunit member. CBL proteins 





Another two types of E3 ligase are HECT E3 and RBR (RING-between-RING). The C-
terminus of HECT contains the functional domain, with a bi-lobar architecture, the N-
terminal lobe, for interacting with ubiquitin-E2 [187]. The C-terminal determines the 
catalytic activity and substrate specificity. In humans, there are three subfamilies of 
HECT, including the NEDD4 family, the HERC family and others. Similar to HECT E3s, 
the RBR E3s also require a two-step reaction to transfer the ubiquitin from E2 to the 
substrate. There are two predicted RING domains on the RBR, which are separated by an 
IBR (in-between-RING) domain.   
1.4 Structure and Function of the CBL Family of Proteins 
The CBL (Casitas B-lineage Lymphoma) family proteins in mammalian cells are 
composed of three evolutionary conserved members, including CBL, CBLB and CBLC. 
In 1989, Herbert Morse III and colleagues first identified the short version of CBL 
protein (called v-CBL) from a murine retrovirus, which can induce pre-B and pro-B cell 
lymphomas [188]. Sequencing results revealed that this 100 kDa protein carried by this 
retrovirus showed no homology with any known oncogenes. v-CBL does not have any 
kinase activity but is expressed in a range of haematopoietic lineage. Later, W. 
Langdon’s group further discovered the 120 kDa full-length CBL protein localizing in the 
cytoplasm, with a cytosolic and cytoskeletal distribution [189]. Although v-CBL is 
oncogenic due to its nuclear distribution, the full-length CBL proteins cannot induce 
acute transformation. Another two mammalian members plus their invertebrate 
orthologues in Drosophila melanogaster (D-CBL) and C. elegans (SLI-1) have been 





CBL family proteins are E3 ubiquitination ligases, which can recruit ubiquitin-
conjugating enzymes (UBCs), as well as tyrosine kinase Sky and Zeta-chain-associated 
protein kinase (ZAP70), to form complexes. To date, extensive studies have been carried 
out to demonstrate their important role in different signalling pathways, which will be 
introduced in the following sections. 
1.4.1 The Structure of CBL proteins 
The domain structures of CBL proteins are depicted in Figure 1.3. The N-terminal region 
of all three CBL proteins include a tyrosine kinase binding (TKB) domain, a RING finger 
domain, and a linker region and is highly conserved between the three members of CBL 
family proteins. CBL and CBLB are ubiquitously expressed in all haematopoietic 
lineages, while CBLC is mainly expressed in the gastrointestinal tract, liver, kidney, 
pancreas and prostate [190, 191]. CBLC is shorter compared to the other two members 
due to the lack of the key C-terminal domains and carboxy-terminal leucine zipper (LZ) 
motif. The TKB domain consists of a four-helix bundle, a calcium-binding EF hand 
domain and a variant Src homology-2 (SH2) domain, which directly binds to specific pY-
containing peptide, such as epidermal growth factor receptor (EGFR), SYK, ZAP70 and 
the platelet-derived growth factor receptor (PDGFR) [192-195]. This protein-binding 
capacity allows CBL proteins to act as adaptor proteins for signal transduction. Apart 
from the adaptor function, CBL proteins can also serve as E3 ubiquitin ligases, as the 
RING finger domain was shown to be required for recruiting E2 ubiquitin-conjugating 
enzymes. Further studies have shown that the point mutation of a cysteine to an alanine 





BC373A) can completely block the ubiquitination of downstream substrates. The C-
terminal proline-rich domain of CBL and CBL-B provide a platform to interact with SH3  
 
Figure 1.3. The structure of CBL family proteins and corresponding functions 
 (A) The individual domain of the three members of the mammalian CBL family proteins 
is highlighted. All of those three members have TKB domain and RING finger domain. 
TKB domain includes 4H, EF and SH2 domain, the function of which is recruiting 
phosphorylated tyrosine kinases. The following domain is RING finger domain, which is 
critical for the E3 ubiquitin ligase function. Proline-rich domain and UBA domain locate 
at C-terminal, which are deleted in CBL-3. (B) The functional domains of CBL family 
proteins. The TKB domain can bind to phosphorylated tyrosine on tyrosine kinases, such 
as SYK, ZAP70 and SRC-family kinases. The RING finger domain is required for the 
recruitment of ubiquitin (Ub)-conjugate enzymes (E2s). Then the E2s are transferred to 
TKB domain leading to the proteasomal degradation of the binding substrates. The 
Proline-rich domain can associate with many SRC-homology 3 (SH3)-binding proteins, 
such as GRB2, NCK and FYN. There are several tyrosine and Serine residue at the C-
terminal region, which can be phosphorylated and interact with the proteins containing 







domain-containing proteins such as Src-family kinases, GRB2, CIN-85, etc. There is an 
LZ motif domain located near the C-terminus of CBL and CBL-B, which may help to 
form homo- or heterodimers of CBL. There are three tyrosine residues in this region, 
which can be phosphorylated upon cellular activation and are associated with different 
downstream signalling proteins, such as VAV2, p85 and CRKL [196-198]. Finally, the 
UBA domain of CBL and CBL-B is able to mediate ubiquitin-dependent dimerization 
and target polyubiquitinated proteins to 26S proteasome for degradation [199]. 
1.4.2 Roles of CBLs in the function of T Cells 
The function of CBL family proteins in T cell development and activation has been well 
studied during the past decade. The CBL family proteins regulate thymocyte 
development through two distinctive mechanisms, thymic selection and MHC-dependent 
signals. Thymic development consists of positive selection and negative selection based 
on the strength and duration of TCR signals. The optimal TCR signalling strength is 
required for the proper thymocyte development. Either too strong or too weak signalling 
can lead to negative selection or cell death [200, 201].  The deletion of CBL in 5C.C7 H-
Y TCR transgenic mice results in the expansion of CD4+ T cells in the thymus, which 
suggests that CBL, not CBLB, is a negative regulator of CD4+ T cell lineage commitment 
[202], which may be due to the ZAP-70 dependent hyper-activation of TCR signals in 
Cbl-deficient thymocytes [203]. In CD4 and CD8 double-positive (DP) thymocytes, CBL 
not only negatively regulates ZAP-70 activation but also suppresses TCR-induced 
activity of MAPKs and ERK1/2. As mentioned above, the MHC-dependent signals are 





positive thymocytes. The ablation of both CBL and CBLB can drive the differentiation of 
DP thymocytes into CD4+ and CD8+ single-positive thymocytes in the absence of TCR-
MHC engagement, which suggests that CBL proteins provide another layer of regulation 
of thymocyte development through an MHC-independent mechanism. The impaired 
ubiquitination of CD3z and pre-TCR down-modulation in Cbl and Cblb double-deficient 
DP thymocytes lead to constitutive activation of pre-TCR signals, which can bypass the 
positive selection signal.  
Two signals are required to achieve full T cell activation. The first signal is delivered by 
the cognate interaction between the TCR complex and the peptide-loaded MHC 
accompanied by the second co-stimulatory signal from antigen presenting cells. Among 
the co-stimulatory molecules expressed on T cells, CD28, the receptor of CD80 and 
CD86, is the most prominent one, which activates NF-kB, NFAT and AP-1 [204]. Two 
independent studies have shown that Cblb-deficient T cells produce a large amount of IL-
2 upon anti-CD3 stimulation alone without anti-CD28 co-stimulation, suggesting that 
CBLB is a negative regulator in CD28-induced signalling [90, 205]. In detail, CBLB 
regulates CD28 signalling through the VAV pathway since anti-TCR can solely induce a 
high level of VAV activation in CBLB-deficient T cells. In contrast, the induction of 
VAV activation requires both anti-CD3 and anti-CD28 stimulation in wild-type 
counterparts. Another downstream target of CD28 signalling is PI3K. In the Jurkat cell 
line, CBLB promotes the ubiquitination of p85 PI3-K and prevents the association of p85 
with CD28 after TCR stimulation [206]. However, a recent study showed that CBLB may 





inactivation[207]. CBLB is critical for this regulation, as it can recruit another E3 
ubiquitin ligase (NEDD4) to promote ubiquitination of PTEN. 
During the past decade, many studies have demonstrated that CBL proteins also play a 
significant role in immunosuppression and anti-tumour immunology. TGF-b,  secreted by 
tumour cells and tumour-infiltrating Tregs, can suppress T cell activity and promote the 
immune evasion of tumour cells. TGF-b-induced suppressive signal is regulated through 
CBL proteins. Cblb-deficient mice can efficiently reject or reduce the growth of three 
different tumour cell lines in vivo through CD28-independent mechanism [208, 209]. 
Cblb-deficient CD8+ T cells are resistant to TGF-b suppression since SMAD7, a negative 
regulator of TGF-b signalling, cannot be ubiquitinated [210]. Consistently, the ablation of 
SMAD7 in Cblb-deficient mice restores the TGF-b suppression signal and leads to 
tumour growth and similar survival rates as those in wild-type controls. Moreover, CBL 
proteins are also involved in negative regulation of PD-1 signalling in CD8+ T cells 
[211]. The blocking of programmed cell death ligand 1 (PD-L1) on DCs suppresses the 
up-regulation of CBLB in CD8+ T cells after OVA antigen stimulation, leading to 
enhanced cytotoxicity and an anti-tumour immune response in the EG.7 tumour mouse 
model. Another potential anti-tumour target, cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4), is also regulated by CBLB. Stimulation of CTLA-4 on CD8+ T cells leads to 
up-regulation of CBLB expression through transcriptional regulation [212]. Taken 
together, due to the negative role of CBL proteins in T cell activation, CBLs will be a 





1.4.3 Roles of CBLs in B cell activation 
The CBL-B protein becomes phosphorylated upon BCR stimulation, and the protein level 
reaches the peak at 2 min and then decreases to approach undetectable levels by 30 mins, 
which suggests that CBL-B protein plays a direct role in BCR signalling. The CBLB 
proteins have been clearly shown to associate with the protein tyrosine kinase SYK and 
promote ubiquitination of SYK after BCR stimulation. A few key target proteins of BCR 
signalling, such as BLNK, BTK and PLC-g2, are constitutively phosphorylated in CBLB-
deficient B cells, which leads to hyper-responsiveness of Ca2+ signalling. However, CBL-
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way Akt, but ERK1/2 and JNK showed prolonged phosphorylation upon BCR cross-
linking. Because of the hyper-activation of BCR-induced signalling, these mutant B cells 
form a prolonged BCR cap after BCR stimulation. Interestingly, although CBL and CBL-
B share similar structure domains and play several redundant functions in T cell 
activation, these two proteins show opposite functions in BCR-mediated signalling. In a 
Cbl-deficient DT40 B cell line, CBL negatively regulated the phosphorylation of PLC-g2 
though its adaptor function [213]. Mechanically, the SH2 domain of CBL competes with 
the PLC-g2 SH2 domain for the association with BLNK, leading to the inhibition of PLC-
g2 activation. Consistently, CBL in mouse B cells also serve as a positive regulator for 
BCR-mediated signalling [214]. Cbl-deficient B cells showed reduced phosphorylation of 
tyrosine kinases SYK and BTK, while CD19-mediated PI3-Kinase activity is enhanced. 
The TNF-R family member CD40 plays a critical role in B cell function and homeostasis. 





enhanced T-dependent antibody response through a cell intrinsic mechanism. CBL-B 
selectively suppresses the CD40-induced activation of NF-kB and JNK through 
inhibiting the association of TNF receptor-associated factor 2 (TRAF2) with CD40 for 
the activation of downstream signals. 
To study the function of CBL and CBL-B in B cell activation and to exclude the 
functional redundancy between the two proteins, B cell-specific deletion of both Cbl and 
Cblb transgenic mice were generated in our laboratory [215]. More than half of the 
mutant mice produced IgG-isotype anti-dsDNA and anti-nuclear antigens. Further 
pathological studies showed that these mice developed a spontaneous systemic lupus-like 
autoimmune disease characterized by massive infiltration of leukocytes in multiple 
organs and heavy IgG antibody deposits in the kidney glomeruli. Although mutant B cells 
displayed enhanced BCR signalling, the mutant mice were not hyper-responsive to in 
vivo or in vitro antigen stimulation, suggesting that the SLE autoimmune disease was not 
due to enhanced BCR signalling. By crossing CBL double-deficient mice to soluble HEL 
(sHEL) and HEL BCR (IgHEL) transgenic mice, the mutant mice clearly showed impaired 
B-cell anergy to self-antigens, which demonstrated that CBL proteins controlled the B-
cell tolerance through regulation of B-cell anergy.  
1.4.4 Role of CBLs in other immune cells 
CBL proteins are not only critical for T and B cell activation and functions but also 
involved in the regulation of innate lymphocyte lineages, such as DCs, myeloid cells and 





immune response, and NK cells are critically required for the immunosurveillance of 
increased proliferation and perforin levels, as well as increased cytotoxicity, resulting in 
 
Figure 1.4. Function of CBL family proteins in immune cells activation 
The function of CBL family proteins in adaptive and innate immune cells is highlighted. 
CBL regulates the CD4+ T cell development. Two different studies demonstrated that 
CBLB regulate T cell activation through CD28-dependent machinery and anti-tumor 
immunity. The CBL and CBLB proteins are negative regulator of TCR signalling and 
MHC-dependent thymocytes selection. These two proteins also negatively regulate B cell 
tolerance and signalling through BCR and CD40. In innate immune cells, CBL proteins 
also act as a negative regulator in terms of cell activation and function. 
 
increased proliferation and perforin levels, as well as increased cytotoxicity, resulting in 





Interestingly, NK cells with point mutations in the CBLB ring finger domain showed a 
similar phenotype as Cblb-deficient NK cells, which suggests that the E3 ligase activity is 
necessary for this effect. The TAM family of cell-surface tyrosine kinase receptors on 
NK cells were identified as the top ubiquitination target of CBLB in vivo and in vitro 
through the downregulation of these receptors. Small molecule inhibitors of TAM 
receptor kinases increase NK cell cytotoxicity, as seen in Cblb knockout mice. CBL plays 
a critical role in NKG2D- and CD244-mediated synergistic activation signals [217], 
which is mediated by the phosphorylation of a combination of tyrosine residues on the 
adaptor protein SLP-76[218]. Taken together, CBL proteins played a negative role in the 
modulation of NK cell activation and cytotoxic function. 
Recently, David Spencer’s group reported that CBL modulates the activation status of 
DC through Toll-like receptor (TLR) [219]. Upon the TLR stimulation, many pro-
inflammatory cytokines and chemokines, such as IL-1a, IL-1b, IL6, IL-12p70 and 
CXCL1/KC, were upregulated in Cbl-deficient DCs, correlating with a greater potency of 
DC-based vaccines against established tumour. In detail, Cbl deficiency reduced both p50 
and p105 levels, which led to increased NF-kB activity. By using the ectopic expression 
of different forms of CBL mutants, this pro-inflammatory phenotype of Cbl-deficient DC 
was caused by the lack of E3 ubiquitin ligase activity. Not surprisingly, CBLB is also 
highly expressed in DCs and acts as a negative regulator for TLR-mediated DC activation 
[220]. Bone-marrow-derived DCs with CBL-B deficiency exhibit higher levels of pro-





In comparison with other cell types, the role of CBL proteins in the myeloid lineage has 
been less studied. CBLB proteins also act as a negative regulator of TLR-triggered 
signalling in macrophages. The tyrosine kinase SYK is activated by integrin CD11b, 
leading to degradation of the TLR adaptor proteins MYD88 and TRIF through CBLB-
mediated ubiquitination [221]. In the context of high-fat diet (HFD)-induced obesity, 
Cblb-deficient mice show exaggerated HFD-induced insulin resistance through saturated 
fatty-acid mediated macrophage activation, which is restored by blockade of TLR4 
signalling[222]. Cbl-deficient mice showed massive macrophage infiltration and 
activation, leading to peripheral insulin resistance[223]. 
1.5 Rationale 
GC reaction is a step-wised process each of which is controlled by different mechanisms 
and involved different subsets of cells. At the initiation stage of the GC reaction antigen 
activated B and T cells must meet each other to form cognate interaction so that only 
antigen specific B and T cells are allow to continue development into GC cells. In this 
interaction, GC B cells are the major player because they may capture antigen, process 
antigen into antigen peptide-MHC-II complexes, and present these antigenic complexes 
to T cells. However, while we already knew that antigen capturing requires BCR and 
antigen interaction, the molecular mechanisms that control B cell antigen processing 
remains not fully understand. Previous studies in our laboratory have shown that CBL 
proteins play a redundant, however, critical role in promoting antigen-induced TCR and 





regulator to control B cell antigen processing, hence the cognate interaction of T and B 
cells responsible for the initiation of the GC reaction.  
Once B cells enter the GC, SHM of the Ig genes, selection and expansion for the mutated 
high affinity B cells occur through the GC DZ and LZ cycle. At this stage, SHM B cells 
must decide whether to stay in the DZ and LZ cycle to continue this selection or opt to 
differentiate into PCs or memory B cells. While it has been shown that BCR and CD40 
signals are involved in this regulation, they seem to promote both GC B cell fate and PC 
differentiation. In this regard, it is reasonable to assume that some B cell intrinsic 
regulators are need to interpret the strength of incoming BCR and CD40 signals so that B 
cells with moderately improved affinity stay in the DZ and LZ cycle and only those B 
cells with sufficiently high affinity are allowed to differentiate into PCs. Our previous 
studies demonstrate that CBL proteins may modulate the strength of TCR signalling 
through ubiquitinating multiple TCR downstream signalling molecules. These results 
thus suggest that CBLs can be good candidates in this regulation and play a important 
role in resolving the strength of BCR and CD40 signalling in GC B cells, consequently 
determine the cell fate of GC B cells during GC B cell affinity selection.   
1.6 Hypothesis 
My central hypothesis is that CBL proteins may control the GC reaction at two critical 
checkpoints, the initiation stage of GC reaction and selection and expansion stage of high 
affinity GC B cells, through different cellular mechanisms. For the first stage, they 
control the initiation of GC B cell development through dictating T-B cognate 





through ubiquitinating the components of BCR complex, Iga and Igb, consequently 
controlling BCR-antigen complex internalization and sorting to the lysosomal 
compartment for antigen degradation and processing. For the second stage, CBL family 
proteins may regulate antibody affinity maturation by retaining GC B cells in the DZ and 
LZ GC cycle and preventing GC B cell from differentiation into PCs until high affinity 
BCRs are generated. This regulation is achieved through post-transcriptionally 
controlling the ubiquitination dependent clearance of IRF4, a transcription factor that is 
constantly induced in GC B cells by BCR and CD40 signals and may determine and drive 
B cell differentiation to PCs during GC reaction. By spatial and temporal control of IRF 
in GC B cells, CBLs determines that only high affinity B cells that may degrade CBLs 
are allowed to terminate GC fate and differentiate into PCs  
1.7 Aims and Objectives 
Aim 1: To understand the role and mechanisms of CBL-mediated ubiquitination in 
establishment of the cognate T-B cell interaction and initiation of the GC reaction. 
Objective: 
1. To establish an animal model that specifically ablated CBL and CBLB in naïve B 
cells (termed here as CBLdKO-Mb1 mice) and analyzed the general impact of such a 
mutation in B cell early development.  
2. To study the function CBL proteins in B cell function. This included comparing in 
vitro B cell activation and differentiation and in vivo T-dependent and T-





3. To investigate the impact of the CBLdKO-Mb1 mutation in GC reaction upon 
immunization with T-dependent antigens. 
4. To elucidate the cellular mechanism by which CBL used to control cell extrinsic 
factors, Tfh development, and FDCs network. 
5. To understand the molecular mechanism by which CBLs controlled T-B cognate 
interaction and Tfh cell development.  
6. To identify the direct targets of CBL proteins in the regulation of B cell antigen 
presentation by biochemical studies. To evaluate the relevance of ubiquitin 
modification of these targets to their function during GC reaction.  
7. To determine whether CBLs exert their GC regulatory function through E3 
ubiquitin ligase activity.  
Aim 2: To investigate the role of CBL proteins in the progression of the GC reaction and 
antibody affinity maturation. 
Objective: 
1. To understand the dynamics of CBL and CBLB expression during GC B cell 
development and differentiation by immunofluorescence and biochemical studies. 
2. To study CBLs function in already established GC B cells, I generated a mutant 
mouse model carrying the CBL and CBLB double null mutation in GC B cells 
using the Cg1-CRE transgenic allele (CBLfl/fl CBLB-/- Cg-Cre tg; termed as  
CBLdKO-Cg mice). I used this animal model to study antibody affinity maturation and 





3. To investigate the impact of CBLs on antibody affinity maturation by analyzing 
the SHM of Ig genes and clonal selection of GC B cells in immunized WT and 
CBLdKO-Cg mice. 
4. To study whether CBLs influence antibody affinity maturation through 
controlling the B cell proliferation or differentiation of PCs by both in vivo and in 
vitro methods. 
5. To identify the direct target(s) of CBLs in the regulation of GC B cell affinity 
selection by transcriptome and biochemistry studies. 
6. To determine whether CBLs control GC affinity selection through their ubiquitin 
ligase function. To examine whether the putative target(s) identified in my study 

























2 Chapter 2: CBL-mediated ubiquitination controls the 
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Germinal center (GC) is a microlympoid organ located in peripheral lymphoid tissues and 
its function is to generate high affinity antibody secreting PCs and memory B cells. 
While development of the GC requires the cognate interaction between antigen specific 
follicular (FO) B cells and CD4+ T cells, it remains unclear about the mechanisms as to 
how B cell intrinsic molecules control the cognate interaction. In my studies, I have 
found that E3 ubiquitin ligases CBL and CBLB (CBLs) controlled both T-independent 
antibody response and GC dependent antibody production. In the former case, CBLs are 
required for the development of marginal zone B cells, so that in the absence of CBLs the 
type-I T-independent antibody response is deficient. In contrast, in the latter case, 
although ablation of CBLs does not affect FO B cell development, it impairs the 
development of T follicular helper (Tfh) cells, thus the germinal center reaction. My 
further studies reveal that CBLs control BCR-mediated antigen internalization and 
sorting to lysosomes for degradation, impairment of which leads to defective B cell 
antigen presentation to T cells, consequently disrupting the cognate interaction between 
antigen specific B and T cells. Using biochemical and genetic approaches, I have found 
that CBLs control BCR internalization by promoting the ubiquitination of BCR-
associated molecules Iga and Igb. Disruption of Iga ubiquitination is sufficient to 
recapitulate the GC phenotypes observed in CBL-ablated mice. My findings for the first 
time identify a novel ubiquitination-dependent regulatory pathway in BCR-mediated 






GC reaction emerges in secondary lymphoid organs upon vaccination or infection, which 
can generate high affinity secretion PCs and long-lived memory B cells [51, 94]. The GC 
B cells are mainly derived from FO B cells. The initiation of GC B cells requires 
different cell-cell interaction such as B-DC and T-B, in which multiple receptors and 
ligands ligation are involved. Within GC reaction, the maturation and termination the fate 
of GC B cells are also dependent cell-cell interaction[52]. BCR mediated signals plays a 
critical role throughout the whole process.  
B cell development, survival and differentiation are all dependent on BCR mediated 
signals. The ligation between antigens and BCR lead to two distinct branches of 
activation. First, the adaptor proteins of BCR, Iga and Igb, are phosphorylated by 
tyrosine kinase SYK, then lead to phosphorylation of BLNK [224], which lead to the 
activation of multiple different signalling pathways such as PI3K, Erk1/2, NF-kB and 
Ca2+ influx [225, 226]. Second, the BCR complex can capture, degrade and deliver the 
antigen peptides to the MHC class II antigen-presenting compartment through endocytic 
pathway. The trafficking of membrane proteins to lysosomes for degradation is 
dependent on proper cell signalling and membrane metabolism. Ubiquitination promotes 
this process by marking which proteins should be transported to lysosome through 
multivesicular endosome pathway [227]. Upon BCR stimulation, Iga and Igb are 
ubiquitinated by multiple different E3 ubiquitin ligases such as ITCH, CBL and CBLB 
[120, 228, 229]. Although both Iga and Igb are required for receptor internalization upon 





signalling through the mutagenesis of ITAM motif suppress the optimal T-dependent 
immune response. However, previous experiments are mainly focus on function of 
Iga and Igb transduced signals not antigen presentation ability in T-dependent antibody 
response. The function of Iga and Igb mediated antigen presentation in GC formation is 
still unknown.  
CBL and CBLB (CBLs) are E3 ubiquitin ligase proteins, which play an important role in 
protein post-transcriptional regulation[232]. Several studies have been shown that CBLs 
negatively regulate BCR signalling through various molecular mechanisms. However, 
their function in T-dependent and T-independent immune response is still unclear. Here 
our findings clearly showed that CBL family proteins played an important role in bone 
marrow and splenic B cell development. Because Fr.C and Fr.D bone marrow immature 
B cells were extensively expanded in Cbls-deficient mice. The development of MZ B 
cells was blocked in mutant mice, which lead to the impaired antibody responses against 
Type-I and Type-II T-independent antigens. In addition, we showed that CBLdKO-Mb1 
mice displayed severely impaired GC formation after two different types of T-dependent 
antigen immunization, which is due to impaired T-B cognate interaction. Our results 
clearly demonstrate CBL proteins regulate T-B cognate interaction through B-cell 
intrinsic mechanism. The E3 ubiquitin ligase function of CBL proteins regulates B cell 
antigen presentation through targeting BCR adaptor Iga and Igb proteins. Furthermore, 
the ubiquitination of Iga is critical for the formation of GC B cells since this process 






2.3.1 CBL dKO-Mb1 mutation controls the development of MZ B cells  
2.3.1.1  Generation of CBL dKO-Mb1 mice 
To study the function of CBL family proteins in B cell development and activation, we 
generated B-cell specific Cbl and Cblb knockout mice by crossing Mb1-cre transgenic 
mice with CBLF/F CBLB-/- mice, termed as CBLdKO-Mb1. The resulting mutant mice carried a 
germline Cblb mutation and a conditional Mb1-cre-meidated Cbl deletion, resulted with 
specifically deletion of both Cbl and Cblb in B cell-linage. To examine whether CBL 
protein was specifically deleted in B cell linage, we crossed CBLdKO-Mb1 mice to 
TomatoRosa26 reporter mice, in which Tomato was turned on by the Mb1 gene promoter 
driven Cre-mediated recombination[233]. Our results clearly showed the Cre 
recombinase constantly expressed in B-lineage cells starting from B cell progenitors to 
multiple different subsets of mature B cells (Figure 2.1 A). By contrast, DCs and T cells 
displayed minimal expression of Cre recombinase (Figure 2.1 A). We further validated 
the deletion of CBL in splenic mature B cells by western blot (Figure 2.1 B). This result 
showed that CBLdKO-Mb1 mice indeed carried specific Cbl and Cblb mutations in majority of 
naïve B cells. 
2.3.1.2 CBL mutations affect MZ and B1 B cell development 
To determine whether the CBLs double mutation affected early B cell development, we 
examined immature B cell subsets in the bone marrow and mature B cell subsets in 





had significant expansion of Fr. C and Fr. D B cells in the bone marrow as compared to 
WT mice (Figure 2.2 A), while Fr.A and Fr.B B cells were slightly reduced (Figure 2.2 
A). B cell development in spleen appeared to be altered in CBLdKO-Mb1 mice, with the 
mutant mice possessed comparable number of FO (B220+CD24lowAA4.1lowCD21+CD23+) B 
cells, however, four times less MZ (B220+CD24lowAA4.1lowCD21lowCD23high) B cells and two 
times more B1 (B220+ CD24low AA4.1low CD21low CD23low) (Figure 2.2 B).  
Immunofluorescence analysis confirmed the impaired architecture of the marginal zone 
but normal B cell follicle region in the spleen based on CD1d and SIGN-R1 staining in 
CBLdKO-Mb1 mice (Figure 2.2 C).  The above results clearly showed that CBL family 
proteins negatively regulated the expansion of Fr.C, Fr.D immature B cells and B1-B 
cell. CBLs are required for the development of MZ B cells while they are dispensable for 
FO B cell development. 
2.3.2 CBL proteins regulate humoral immune response 
2.3.2.1 Impaired T-independent and T-depdent antibody responses in CBLdKO-Mb1 
mice 
To examine whether the CBLdKO-Mb1 mutation affected B cell function, we compared T-
dependent and T-independent antibody responses between the mutant and WT mice. The 
main responder of T-independent antigens was MZ B cell since MZ B cell can rapidly 
differentiate into antigen-specific antibody secreting PCs upon T-independent antigen 
stimulation. As expected, we found that CBLdKO-Mb1 mice produced significantly less 
amount of anti-NP IgM and IgG3 isotype antibodies upon type-I (NP-LPS) and type-II 





B). This deficiency in mutant mice could be attributed to the reduced number of MZ B 
cells in the mutant mice. Upon immunization with T-dependent antigen NP36-KLH, the 
mutant mice produced lower level of antigen-specific IgG1 isotype antibody; 
furthermore, at day 14 post-immunization they produced 5 folds less both low and high-
affinity antibodies of IgG1 isotypes, and this trend continued up to day 31 after 
immunization (Figure 2.3 C and D). The above results thus indicated that the CBL 
proteins were required for the both T-independent and T-dependent immune response. 
The defective of high affinity anti-NP IgG1 antibody production in T-dependent antigen 
immunized mutant mice further suggested the CBLdKO-Mb1 mutation impaired GC 
reaction.  
2.3.2.2 Crippled GC reaction in CBL dKO-Mb1 mice 
High affinity antigen-specific IgG1 antibody secreting PCs were derived from GC B 
cells. Since high affinity antibody production was impaired in CBLdKO-Mb1 mice, we 
examined whether the deletion of CBL proteins on B cells affected the development of 
GC B cell in SRBC immunized mutant mice. Flow cytometry analysis revealed that the 
development of GC B cells was severely attenuated in terms of both the cell number and 
percentage compare to WT control mice (Figure 2.4 A). Consistent with the flow 
cytometry result, immunofluorescence staining results revealed few GCs in the spleen of 
CBL dKO-Mb1 mice based on PNA staining (Figure 2.4 B), which further demonstrated that 
the CBL dKO-Mb1 mutation affected GC reaction. The impairment of GC reaction was also 
found in the mutant mice immunized with another type of T-dependent antigen NP36-KLH 





particular antigens. Although CBL and CBLB are two different proteins, they share 
similar structure and play redundant functions in the regulation of TCR and BCR induced 
signalling pathways. To investigate whether CBL and CBLB played redundant function 
in the regulation of GC formation, we examined the development of GC B cells in CBLKO-
Mb1CBLB+/- and CBL-B-/- single knockout mice post 10 days of SRBC immunization. 
Interestingly, the CBLKO-Mb1CBLB+/- and CBLB-/- mice showed similar GC B cells numbers as 
compared to WT controls (Figure 2.4 D). Thus these results indicated that CBL family 
proteins were critical for GC reaction, and this function was redundant between CBL and 
CBL-B. 
2.3.3 CBLdKO-Mb1 B cells are defective in supporting Tfh development   
The development of GC B cells is dependent on both cell intrinsic and extrinsic factors. 
Amongst extrinsic factors the FDC network and Tfh cells have been shown to be critical 
for GC formation[67]. Ablation of FDCs in B cell follicle leads to the disappearance of 
GCs. Previous study showed that the formation of FDC is regulated by GRB2 mediated 
lymphotoxin B secreted by B cells [234]. Since GRB2 can associate with CBL, we first 
examined whether the network of FDC was affected by CBLs mutation. Previous studies 
have been shown that FDCs within primary B cell follicles expressed extremely high 
level of CD35, and the anti-CD35 antibody was used as marker for FDC network [67, 
235]. The immunofluorescence analysis revealed that the WT and mutant mice displayed 
comparable FDC networks based on CD35 staining in B cell follicles (Figure 2.5 A). This 
result indicates that the GC B deficiency in our mutant mice is unlikely caused by lack of 





Tfh development, we examined the Tfh development in the mutant mice. We found that 
the number of Tfh cells in the mutant mice was 4 folds lower than that in WT controls at 
day 10 post-immunization of SRBC (Figure2.5 B). Since development of Tfh cells and 
GC B cells are mutually dependent, we hypothesised whether the presence of normal Tfh 
rescued CBLdKO-Mb1 GC B cell development. We generated BM chimeras between WT 
(CD45.1+) and CBLdKO-Mb1 (CD45.2+) mice, and then immunized these mice with SRBC. We 
found that in the immunized BM chimeras the development of Tfh cells derived from both 
WT and the mutant donors appeared to be normal, demonstrating that presence of WT 
(CD45.1+) B cells is sufficient to restore Tfh development in CBLdKO-Mb1 (CD45.2+) donor 
cells. However, even in the presence of Tfh cell, only WT (CD45.2+) donor cells but not 
CBLdKO-Mb1 donors (CD45.2+) can give rise to GC B cell population (Figure 2.5 C). This 
finding indicated that B cell intrinsic CBL proteins were essential for the development of 
Tfh cells. In addition, it also suggested that the cognate interaction between antigen 
specific B and Tfh cells, rather than bystand Tfh cell or soluble factors produced by Tfh 
cells, was necessary for GC B cell development. 
2.3.4 CBL proteins regulate B cell antigen presentation 
2.3.4.1  CBLdKO-Mb1 B cells are defective in antigen presentation to cognate T cells 
Cognate interaction between Tfh and GC B cells requires TCR recognition of MHCII-
peptide antigen complexes expressed by GC B cells. In addition, interaction between co-
stimulatory molecules such as ICOS-ICOSL, CD40L-CD40, Dock8 and SLAM-SLAM 
expressed by Tfh and B cells, respectively, are also pivotal for the formation of stable T-B 





accessary molecules, except PD-L1, was not significantly altered in CBLdKO-Mb1 B cells 
(Figure 2.6 A), we decided to examine whether the CBLdKO-Mb1 mutation affected antigen 
presentation by the mutant B cells to T cells. To mimic as closely as possible the antigen 
uptake, processing, and presentation by naive B cells to T cells, we generated mini 
antigens (Anti-IgM F(ab)2 conjugated with OVA protein) that can target OVA antigen to 
the BCR, which can be used to test the antigen capture, internalization, processing and 
presentation on B cells (Figure 2.6B). Naive B cells were pre-treated with mini antigens 
or processed OVA323-339 peptides, then co-cultured with Celltrace-labeled OT-II CD4+ T 
cells for 3 days and proliferation of T cells were evaluated by flow cytometry based on 
Celltrace dilution. We found that 22% of proliferating CD4+ T cells was detected in WT 
B cell co-cultured group while T cells co-cultured with mutant B cells cannot proliferate 
(Figure 2.6 C). This result indicated that CBLs deficient B cells failed to form cognate 
interaction and present antigens to OT-II CD4+ T cells. Since the mutant B cells loaded 
with OVA323-339 peptide supported CD4+ T cell proliferation as efficiently as did by the 
WT T cells (Fig.2.6 C), we concluded that that antigen presentation post intracellular 
antigen processing remained normal in the mutant cells. 
2.3.4.2 Processed peptide antigen partially rescues in vivo GC B development in 
CBLdKO-Mb1 mice 
Since the OVA323-339 peptide can directly loaded to MHC and bypass the defective 
antigen processing on CBLdKO-Mb1 B cells, we investigated whether administration of the 
processed OVA323-339 peptide could restore the deficiency of in vivo cognate T-B 





immunized the mutant mice that have received adaptively transferred OT-II CD4+ T cells 
at day 0 with NP16-OVA antigen, followed by two doses of the processed OVA323-339 
peptide on day 2 and day 5, and then analyzed GC B cell development on day 7 (Figure 
2.7A). We found that the mutant mice received processed antigenic peptide possessed 
four to five folds more GC B cells and Tfh cells than the mutant mice without 
administration (Figure 2.7 B and C). However, the development of both GC B cells and 
Tfh cells was not fully restored as the mutant mice still had slightly lower numbers of GC 
B and Tfh cells than WT control mice, suggesting that impaired antigen processing in 
CBLdKO-Mb1 B cells can only partly explain the defective GC phenotypes. The reason for 
this will be described in Chaptor4 in my thesis. 
2.3.5 The CBLdKO-Mb1 mutation attenuates BCR downmodulation and degradation in 
naïve B cells 
BCR-mediated antigen processing included internalization of BCR-antigen complexes 
and subsequent sorting of the internalized complexes to lysosomes for degradation. To 
further pinpoint at which checkpoints the CBL family proteins affected the antigen 
processing, we examined BCR-mediated antigen downmodulation and translocation to 
lysosomal vehicles. To track BCR complex internalization and lysosome sorting, we first 
labelled surface IgM BCR with anti-IgM [236]2-biotin on ice, and then calculated 
internalization rate of BCR complex for various periods. We found that CBL dKO-Mb1 B 
cells displayed decreased BCR internalization rate compare to WT B cells, as the rates of 
cell surface BCR downmodulation was attenuated at various time points (Figure 2.8. A). 





by the co-localization between BCR and LAMP-1+ lysosomes. While most of the 
internalized antigen complexes co-localized with LAMP-1+ lysosomes in WT Naïve B 
cells within 30 min, mutant B cells cannot transport the BCR complex to lysosome for 
degradation. (Figure 2.8 B). To further validate whether CBL family proteins regulate 
BCR complex degradation, we used an antigen degradation sensor to track the sorting of 
the internalized antigen to acidic lysosomes as previously described [239]. In brief, the 
antigen degradation sensor was composed by three parts: Alexa633-DNA-Quench 
sequence, Streptavidin and FITC labelled Anti-IgM F(ab)2. At steady state, this sensor 
was FITC emission positive and Alexa633 negative because the emission of Alexa633 
was absorbed by the Quench sequence. Once the antigen degradation sensor entered 
naïve B cells after incubation at 37°C, the Quench sequence was disassociated with 
Alexa633, leading to FITC and Alexa633 double positive (Figure 2.9 A). 
In this experimental setting, the antigen sorted to the lysosomes could be quantitatively 
determined by FACS and visualized through confocal microscopy. We found that the 
CBLs deficient naïve B cells showed severely decreased degradation rate of the antigen 
sensors based on the percentage of FTIC and Alexa633 double positive population 
compare to WT naïve B cells at early time points examined by FACS (Figure 2.9 B). 
Similarly, after 30mins of 37°C incubation, the red and green double positive dots can be 
visualized from confocal microscopy in WT naïve B cells while there is very low level of 
red dots in mutant B cells (Figure 2.9 C). Taken together, the above results strongly 
demonstrate that CBLs regulated B cell antigen presentation through dictating the BCR 





2.3.6 CBL family proteins promote Iga and Igb ubiquitination  
Transportation of the internalized endosomes associated membrane proteins to lysosome 
compartment is guided by protein ubiquitination. Due to the unique transmembrane 
domain and short cytoplasmic tail of IgM, IgM complex need to associate with Iga and 
Igb proteins, which is necessary to stabilize IgM expression on the cell surface and 
transduce BCR signals. Since CBL proteins are E3 ubiquitin ligases that may initiate the 
BCR complex internalization through ubiquitination of ga and Igb proteins, we 
examined whether Iga and Igb expressed by the naïve B cells was ubiquitinated upon 
anti-IgM [236]2 crosslinking. After 5 minutes of BCR stimulation, ladder-like poly-
ubiquitinated Iga and Igb proteins were detected in WT B cells (Figure 2.10 A and B), 
which suggested that Iga and Igb proteins were poly-ubiquitinated by CBLs upon BCR 
stimulation. By contrast, the ladder-like poly-ubiquitinated Iga and Igb proteins cannot 
be detected in stimulated mutant B cells (Figure 2.10 A and B). Together these findings 
suggested that the impaired BCR complex internalization and degradation in CBLdKO-Mb1 
naïve B cells was due to block of Iga and Igb ubiquitination.  
2.3.7 Ubiquitin ligase activity of CBL proteins is required for the initiation of GC 
reaction  
As mentioned in first chapter, the CBL family proteins serve as both adaptor proteins and 
E3 ubiquitin ligases. To distinguish which function was involved in the initiation of GC 
reaction, we crossed CBLKO-Mb1CBLB-/-mice with CBLBC373A/C373A mutant mice to obtain 





form of CBLBC373A with another non-functional allele. The CBL-BC373A carried a 
cysteine (373) to alanine mutation at the RING finger domain of CBL-B, which 
inactivated the E3 ubiquitin ligase but not the adaptor function of CBL-B. After 
immunization with NP36-KLH, the CBLKO-Mb1 CBLBC373A/- mice displayed a severely 
reduction in GC B cells compared to WT control mice (Figure 2.11 A). Consistently, the 
mutant mice could not support normal Tfh population (Figure 2.11 B). Furthermore, 
mutant B cells could not undergo GC-dependent antibody affinity maturation, CSR, and 
differentiate into high-affinity IgG1 secreting plasma cells since mutant mice lack of both 
total and high affinity antigen-specific IgG1 secreting PCs based on the ELISPOT results 
(Figure 2.11 C). Since CBL KO-Mb1 CBLBC373A/- mice completely recapitulated the 
phenotype of the CBLdKO-Mb1 mice, we concluded that the GC phenotype we found in 
CBLdKO-Mb1 mice could be attributed to CBL proteins mediated E3 ubiquitin ligase 
function. This finding of course will not pre-exclude the possible role of CBL’s 
scaffolding function in the GC reaction. 
2.3.8 E3 ubiquitin ligase activity of CBL proteins regulates B cell antigen 
presentation 
Since the CBLKO-Mb1CBLBC373A/- mice completely recapitulated the phenotype of the 
CBLdKO-Mb1 mice, we decided to determine whether CBL ubiquitin ligase activity is 
required for naïve B cell antigen presentation. To investigate the antigen presentation of 
CBLKO-Mb1CBLBC373A/- naïve B cells, mini antigen or OVA323-339 peptide treated naïve B 
cells were co-cultured with Celltrace labeled OT-II CD4+ T cells for 72 hrs. Proliferation 





WT naïve B cells can stimulate around 20% of CD4+ OT-II T cells to proliferate. Similar 
to CBLdKO-Mb1 B cells, we observed that mini antigen treated CBLKO-Mb1CBLBC373A/- B 
cells could not efficiently (1% of CD4+ OT-II T cells) promote OT-II CD4+ T 
proliferation, despite that both CBL KO-Mb1 CBLBC373A/- and WT control B cells promoted 
OTII T cells proliferation efficiently (90% of CD4+ OT-II T cells) in the presence of the 
processed OVA323-339 peptide (Figure 2.12 A). This result thus demonstrate that CBL 
mediated E3 ubiquitin ligase activity is required for B cell antigen presentation. To 
further investigate how CBLs mediated E3 ubiquitin ligase activity regulates the B cell 
antigen presentation, we examined which step of antigen presentation process was 
affected by the lacking of CBLs mediated E3 ubiquitin ligase activity. CBL KO-Mb1 
CBLBC373A/- and WT control naïve B cells were treated with anti-IgM [236]2-biotin on 
ice, then incubated at 37°C for various time. We found that BCR internalization rate of 
CBL KO-Mb1 CBLBC373A/- B cells was up to 40%. Compared to 70% in WT B cells, CBL 
KO-Mb1 CBLBC373A/- B cells showed significantly reduced antigen internalization rate 
(Figure 2.12 B). Similar to CBL dKO-Mb1 B cells, CBL KO-Mb1 CBLBC373A/- B cells also 
failed to efficiently sort the internalized BCR complex to lysosomes, as 70% of the 
internalized antigen complexes co-localized with LAMP-1+ lysosomes in WT within 30 
min. (Figure 2.12 C). Similar result was obtained by using DNA sensor to quantify the 
rate of antigen degradation.  Those CBL KO-Mb1 CBLBC373A/- B cells show significantly 
delayed and decreased rate (25% of degradation after 30mins treatment) based on the turn 
of Alexa633-DNA-sensor while around 55% of WT naïve B cells can degrade the quench 





we concluded that the E3 ubiquitin ligase function of CBL proteins was critical for the 
initiation of GC reaction, and this function was mainly executed via promoting BCR-
antigen complex internalization and sorting to lysosome for B cell antigen processing and 
presentation. 
2.3.9 Blockade of Iga ubiquitination is sufficient to block GC formation 
Previous results revealed that CBL family proteins regulated GC reaction through 
ubiquitination of two potential targets Iga and Igb. However, it is not clear whether the 
ubiquitination of Iga and Igb is sufficient for CBL-mediated regulation in the GC 
reaction. To examine whether Iga ubiquitination was critical for the formation of GC, 
three potential ubiquitination lysine residues (K161, K167 and K219) at cytoplasmic tail 
were mutated to arginine residues (K161R, K167R and K219R, here termed as: 3M-Iga) 
(Figure 2.13 A). The 3M-Iga and WT-Iga was respectively introduced into Iga-deficient 
bone marrow hematopoietic stem cells through a GFP-based retrovirus-mediated gene 
transfer, so GFP+ B cells from bone marrow chimeric mice carried the retroviral vector 
introduced transgene (Figure 2.13 B). We found that B cell development as well as the 
BCR signalling between WT Iga and 3M-Iga retrovirus-infected chimeras was 
comparable, except the slightly reduced Ca2+ signalling (Figure 2.13 C-F). While B cell 
expression WT-Iga protein could efficiently differentiate into GC B cells, the GC B cells 
were undetectable in those 3M-Iga chimera mice upon NP36-KLH immunization (Figure 
2.13 G). This result indicated that the ubiquintiation of Iga protein was an essential step 





2.3.10 The ubiquitination of Iga is required for B cell antigen presentation 
To investigate how the blockade of Iga ubiquitination affected the formation of GC B 
cells, we examined B cell antigen presentation ability of 3M-Iga B cells. Mini antigen 
treated WT-Iga and 3M-Iga B cells were co-cultured with Celltrace labelled OT-II CD4+ 
T cells. Strikingly, the 3M-Iga B cells could not support the proliferation of the cognate 
OTII CD4+ T cells based on the Celltrace dilution assay while WT-Iga control B cells 
can promote 10% of OTII CD4+ T cells proliferation (Figure 2.14 A), indicating that the 
antigen presentation of B cells depends on the ubiquitination of Iga protein. As 
mentioned above, the BCR-mediated antigen presentation involves three steps: BCR 
internalization, BCR degradation in lysosomes, and peptide loading to MHCII. To 
distinguish which steps were affected by the mutation, we first examined BCR 
internalization. The BCR downmodulation rate of WT-Iga naïve B cells went up to 
around 60% upon anti-IgM F(ab)2 stimulation. By contrast, the 3M-Iga B cells showed 
dramatically reduced BCR downmodulation rate (30%) (Figure 2.14 B). Next we 
examined if the BCR degradation was also affected by 3M-Iga mutation.  The DNA-
sensor treated 3M-Iga B cells  were unable to turn on the expression of Alexa633, while 
30% of  WT-Iga B cells  can efficiently degrade the DNA-sensor(Figure2.14 C).  Thus, 
the above results demonstrated that the ubiquitination of Iga protein played a critical role 





2.3.11 K161 and K167 lysine were responsible for the BCR-mediated antigen 
presentation 
To further identify which lysine in the Ig-a tail is responsible for the antigen presentation 
mediated GC formation, we individually mutated three lysine residues (termed as: 
K161R, K167R and K219R) (Figure 2.15 A). These different mutants were transferred 
into Iga-deficient bone marrow stem cells and generated bone marrow chimeric mice, 
respectively (Figure 2.15 B). The development of GC B cells in these mice was analyzed 
after NP36-KLH immunization. We found that B cells reconstituted with K219R 
Iga mutant were able to differentiate into GC B cells (around 8% among B220+IgDlo 
population). By contrast, the K161R or K167R B cells failed to differentiate into GC B 
cells (Figure 2.15 C).  The above results demonstrated that K161 and K167, not K219R, 
were two critical potential ubiquitination sites on Ig-a, which were required for the 
initiation of GC reaction through antigen presentation dependent mechanism. 
Interestingly, there is an activated B cell population (B220+GL7+Fas-) detected in both 
K167R and 3M-Iga mutant mice, which could be the precursor of GC B cells. We will 
discuss this phenomenon in Chaptor 4. 
2.4 Discussion 
The MZ and FO B cells are respectively responsible for T-independent and T-dependent 
antibody response. Here I showed that the expansion of early bone marrow Fr.C and Fr.D 
B cell was negatively regulated by CBLs, whereas the development of splenic MZ B cells 
was positively controlled by CBLs. Ablation of Cbls in naïve B cells lead to severely 





evidence that CBLs regulated B cell antigen presentation through ubiquitination of BCR-
associated protein Iga and Igb. The Cbls-deficient naïve B cells displayed significantly 
reduced BCR internalization and impaired BCR-antigen complex degradation, which lead 
to insufficient promotion of cognate CD4+ T proliferation. The specifically inactivation 
of E3 ubiquitin ligase function was sufficient to recapitulate this GC phenotype, which 
demonstrated the important role of CBLs as E3 ubiquitin ligase in GC B cells formation. 
In addition, blocking the ubiquitination of CBLs downstream target Iga was sufficient to 
suppress GC B cells formation and block antigen presentation of B cells. Taken together, 
those results demonstrated that CBLs controlled the entry checkpoint of GC B cells 
through post-transcriptional regulatory pathway. 
Bone marrow, a central lymphoid organ, gives rise to mature B cells throughout life since 
the HSCs continuously differentiate into immature B cells under certain cytokine 
environment[240]. The CBLdKO-Mb1 mice displayed enlarged number of bone marrow 
Fr.C and Fr.D B cells with relatively comparable number of total splenic B cells, which 
indicated the accumulation of Fr.C and Fr.D B cells was not due to altered bone marrow 
B cell development. This result suggests that CBL family proteins selectively suppress 
the clonal expansion of early pre-B cells. Cytokine IL-7 is essential for mouse B cell 
development while humans with IL-7 mutation still can generate mature B cells in blood 
and secondary lymphoid organs[241]. IL-7R is a heterodimer protein composed of the a 
chain and the g chain. Previously studies showed that B cell development in Il-7 or Il-7r 
deficient mice was completely blocked at the early pro-B cell stage. In addition, IL-7R 





which was mediated through E3 ubiquitin ligase CIS[242]. Interestingly, I found 
enhanced IL-7R surface expression on CBLdKO-Mb1 deficient early pre-B cells (data not 
shown), which indicated that CBLs may regulate the internalization and degradation of 
IL-7R on early pre-B cells. However, I cannot exclude the possibility that CBLs may 
negatively regulate the IL-7 mediated signalling pathway through targeting the 
downstream protein such as signal transducer and activator of transcription 5(STAT5) 
and Janus kinase 3 (JAK3)[243, 244]. Thus, the detail molecular mechanism needs to be 
explored in the future study. 
There are two types of T-independent antigens: type I and type II. I found that ablation of 
Cbls in naïve B cells resulted in the significant reduction of antibody response against 
both type I and type II T-independent antigens. The impaired T-independent response 
could attribute to blocked MZ B cell development in CBLdKO-Mb1 mice. This result 
suggests that CBL family proteins are essential for the formation of MZ B cells. This 
phenomenon raises a question: How CBL family proteins regulate MZ B cell 
development. The MZ and FO B cells are derived from T2 B cells. Under insufficient 
BTK-mediated inhibitory signals, T2 B cells with poor BCR reactivity would 
differentiate into MZ-precursor cells, which further give rise to MZ B cells through 
NOTCH2 dependent signalling pathway[245]. The ablation of NOTCH2 signalling 
component or ligand leads to impaired MZ B cell development. The NOTCH signalling 
is negative regulated by ubiquitin-specific protease 12(USP12)[246]. Recent study 
showed that the USP12 associated with CBLB in Jurkat T cells[247]. Thus, I speculate 





through degradation of USP12. In addition, recent study has been shown that IRF4 
controls the positioning of mature B cells in the lymphoid microenvironment. The 
ablation of Irf4 in mature B cells lead to enlarged MZ B cell population since IRF4 
negatively regulate NOTCH2 signalling [248]. In Chapter 3, I demonstrate that CBL 
proteins can ubiquitinate IRF4 protein in 293T and GC B cells. Since CBLdKO-Mb1 mice 
displayed severely reduced MZ B cell population, this result leads us to speculate that 
CBLs may regulate T2 B cell fate decision through negatively regulation of IRF4 
expression. CBLdKO-Mb1 B cells may express relatively enhanced level of IRF4 protein, 
which can suppress NOTCH2 signalling pathway and block MZ B cell differentiation.  
Recent study has been shown that splenic MZ B cells migrate bidrectionally between 
marginal zone and follicle. This interfollicle movement is dependent on adhesion 
molecules such as sphingosine-1-phosphate receptor 1 (S1PR1) [249]. Consistently, the 
expression of S1PR1 and other integrin molecules are enhanced in Irf4-deficient marginal 
B cells, which could attribute to expand splenic MZ B cells population [248]. Previous 
study showed that CBL could negatively regulate a5 integrin in fibroblast through its E3 
ubiquitin ligase function [250, 251]. Thus, we speculate that CBL proteins may control 
the MZ B cell development through targeting some unknown integrin molecules to 
suppress their shuttling to marginal zone area.  
Thus, it would be interesting to investigate the molecular mechanism of how CBLs 
regulate MZ B cell development. The findings related to T-dependent antibody response 
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2.7 Material and Methods 
2.7.1 Animals and cell lines 
C57BL/6J mice were obtained from Jackson Laboratory (#000664, USA). Germline Cblb 
knockout mice were generated from our own lab at National Institutes of Health (NIH), 
USA. In brief, the Neo gene was inserted into the third exon of cbl-b gene. Then the 
CBL-B-/- mice had been backcrossed to C57BL/6J mice for over six generations from the 
mixed 129 and C57BL/6J genetic background, which had been further verified to contain 
99.9% C57BL/6J genetic background by Jackson Laboratory [205]. The Cblf/f mice were 





loxP sites into the targeting plasmid [202]. Then the Cblf/f mice with mixed 129 and 
C57BL/6J genetic background was backcrossed to C57BL/6J mice to obtain 99.9% 
C57BL/6J genetic background. The Mb1-Cre mice were obtained from Dr. Michael 
Reth[252]. To generate B cell-lineage specific deletion of Cbl and Cblb, I crossed the 
Mb1-Cre mice to Cblf/fCblb-/- mice (termed as CBLdKO-Mb1). To obtain Iga knockout 
mice, I crossed the Mb1-Cre mice with Mb1-Cre mice to get the homozygous mice. The 
TomatoRosa26 mice were obtained from Dr. Suh lab. The CBLdKO-Mb1TomatoRosa26	 mice	
were	generated	by	crossing	CBLdKO-Mb1	mice	to	TomatoRosa26	mice. The CBLB Ring finger 
domain mutant mice CBLBC373A/C373A was obtained from Dr. Wallace Langdon[253]. To 
investigate the function of CBLB-mediated ubiquitination, I crossed the CBLKO-
Mb1CBLB-/- mice with CBLBC373A/C373A to generate CBLKO-Mb1CBLBC373A/- mice. OT-II 
mice were obtained from Dr. Andre Veillette lab. Rag1-/- and B6/SJL mice were 
purchased from Jackson Laboratory. The Phoenix virus packaging cell line was obtained 
from Dr. Andre Veillette lab. The 40LB cell line was obtained from Dr. Daisuke 
Kitamura. 
2.7.2 Genotyping 
The genotype of transgenic mice was screened by PCR. In brief, the tails from different 
transgenic mice were digested in lysis buffer (100mM Tris-HCL, 50mM EDTA, 0.2% 
SDS, 200mM NACL, 50µg/ml Proteinase K) at 55°C for overnight. Followed by vertex 
and maximum speed centrifugation, the supernatant was collected and equal volume 
mixed with 100% ethanol to precipitate the genomic DNA. Then the genomic DNA pellet 





DNA pellet was re-suspended in 200ml 10mM Tris-HCL buffer, which was ready to use 
for PCR.   
For the genotyping of Iga-/- mice by FACS, 2-3 drops of blood were collected from mice 
and quickly mixed with Solution A buffer (20mM EDTA and 0.1% Sodium Azide in 
PBS). The blood sample from WT mice was used as positive control. Cell pellets were 
collect by centrifugation at 1800rpm for 4mins, then the erythrocytes were depleted by 
ACK lysing buffer. The peripheral blood mononuclear cells (PBMC) were stained with 
anti-CD19 and anti-B220 at the concentration of 0.2ng/µl of each antibody in FACS 
buffer (1% BSA and 0.05% Sodium Azide in PBS) for 20mins on ice. Samples were 
washed twice, and re-suspended in FACS buffer followed by analyzing on CYAN or 
Fortesa. 
2.7.3 Plasmid and cloning 
To investigate the function of Iga ubiquitination in antigen presentation and GC reaction, 
multiple mutant forms of Iga were generated. Briefly, to generate 3M-Iga, two 
fragments with three different point mutations of the Iga CDS region were amplified 
from cDNA, and fused these two PCR fragments together. The fused fragment was sub-
cloned into MIGR1-MSCV and verified by DNA sequencing. To generate K161R and 
K167R, two PCR fragments with each single point mutation was obtained from cDNA. 
Then those two mutants were respectively sub-cloned into MIGR1-MSCV and verified 





into MIGR1-MSCV. The primers for the generation of Iga mutants were listed as Table 
2.1. 
Table 2.1 The sequences of cloning primers 
Gene Name Primer Name Sequence 
WT-Iga 
CD79a WT Forward AGTCCTCGAGATGCCAGGGGGTCTAGAAG 
CD79a WT Reverse AGTCGAATTCTCATGGCTTTTCCAGCTGGG 
3M-Iga 
CD79a WT Forward AGTCCTCGAGATGCCAGGGGGTCTAGAAG 
CD79a Set1 Reverse CTCATTTTGCCACCGTCTCCTGAAT 
CD79a Set2 Forward CGGTGGCAAAATGAGAGATTTGGGG 
CD79a Set2 Reverse AGTCGAATTC TCATGGTCTTTCCAGCTGGG 
K161R 
CD79a WT Forward AGTCCTCGAGATGCCAGGGGGTCTAGAAG 
CD79a Set1 Reverse CTCATTTTGCCACCGTCTCCTGAAT 
CD79a Set3 Forward CGGTGGCAAAATGAGAAGTTTGGGG 
CD79a WT Reverse AGTCGAATTCTCATGGCTTTTCCAGCTGGG 
K167R 
CD79a WT Forward AGTCCTCGAGATGCCAGGGGGTCTAGAAG 
CD79a Set3 Reverse CTCATTTTGCCACCGTTTCCTGAAT 
CD79a Set2 Forward CGGTGGCAAAATGAGAGATTTGGGG 
CD79a WT Reverse AGTCGAATTCTCATGGCTTTTCCAGCTGGG 
K219R 
CD79a WT Forward AGTCCTCGAGATGCCAGGGGGTCTAGAAG 







To test T-independent antibody response in CBLdKO-Mb1 mice, two types of T-independent 
antigens, NP-LPS or NP-Ficoll, were injected through i.p. injection at the does of 50µg 
per mice. After 7 days, blood serum antibody was collected, antigen specific antibody 
response was quantified through ELISA. 
To test T-dependent antibody responses and germinal center reaction, mice were 
immunized with either 109 sheep red blood cells (SRBCs) (Innovative Research) in PBS 
by i.v. inejection or 50µg of NP36-KLH (BioSources) precipitated in alum adjuvant 
(Imject Alum, ThemoScientific) by i.p. injection. 
To monitor the antigen specific antibody affinity maturation, the mice were immunized 
with 50mg of NP36-KLH through i.p. injection. After that, the blood samples were 
collection at day7, day14, day24 and day31 post-immunization. The serum from those 
blood samples was applied for ELISA.  
To rescue the deficiency of GC initiation in CBLdKO-Mb1 mice, the following 
immunization schedule was used: at day-1, 2million of OT-II+ CD4+ T cells were 
adaptively transferred to the mice through i.v. injection; at day0, the mice were 
immunized with 50mg of NP16-OVA through i.p injecition; at day2 and day 5, the mice 
received two doses of OVA323-339 peptide through i.v. injection. 
2.7.5 Naïve B cell purification 
To obtain large quantity of naïve B cells for in vitro antigen presentation assay, BCR 





splenic cells were obtained from unimmunized WT, CBLdKO-Mb1 and CBLKO-
Mb1CBLBC373A/- mice. Then naïve B cells were purified from total splenic cells by using B 
cell enrichment kit (Stem cell). The efficiency of purification was confirmed by FACS 
(more than 95% of B220+ B cell). 
2.7.6 Flow cytometry and cell sorting 
Single cell suspension was prepared from spleen by using the 70mm nylon cell strainer 
(#352350, BD Bioscience). The erythrocytes were depleted by ACK lysing buffer. Total 
splenic cells or splenic B cells were resuspended in FACS buffer (5%BSA in PBS 
(PH=7.2)) and stained with the corresponding antibodies on ice for 30 min. Cells were 
washed twice with FACS buffer and then subjected to analysis on a BD Fortessa or Cyan 
or to cell sorting on a FACS Aria or Moflo. The following antibodies were used for the 
staining: anti-B220, anti-GL7, anti-CD11c, anti-CD11b, anti-Gr1, anti-F4/80, anti-
NK1.1, anti-TCRb, anti-CD3e, anti-CD86, and anti-CD38 (eBioscience); anti-Fas, anti-
CD138, anti-BCL6, anti-CXCR4, anti-IgG1, anti-CD45.2, anti-IgD (BD Pharmingen).  
2.7.7 ELISA and ELISOT 
Total splenic cells from NP36-KLH immunized mice were cultured at 37°C in antigen 
pre-coated 96-well Multiscreen-HA filter plates (Millipore) overnight. Spots of antibody 
secreting cells were stained with rabbit anti-mouse IgG1 antibodies conjugated to 
horseradish peroxidase (Invitrogen), and then developed by addition of AEC substrate 





microscopy. The antigens used for plate coating were NP4-BSA or NP30-BSA, 
respectively.  
To measure the NP-specific IgG1 and IgM antibody affinity maturation, the blood serums 
from sequential bleeding were used for this study. Briefly, capture antigen NP4-BSA or 
NP30-BSA was coated on 96-well ELISA plate overnight, and then blocked with 5%BSA 
in PBS. After that, diluted serum was added to each well to incubate for overnight. 
Secondary antibody anti-Mouse IgM or IgG1 antibodies conjugated with HRP 
(Invitrogen) were used to detect the serum antibody level. Finally, the plate was 
developed with 1-StepTM Ultra TMB-ELISA substrate (#34028, Thermo scientific).  
2.7.8 Immunoprecipitation and Immunoblotting  
30 million of naïve B cells were pre-treated with lysosomal blocker MG132 (20µM) for 4 
hours, and then non-stimulated or stimulated with anti-IgM F(ab)2 for 5mins. To 
immunoprecipitate Iga and Igb , samples were lysed in 800µl 1x TNE buffer (1% NP40, 
50mM Tris pH8.0, 2mM EDTA) with protease and phosphatase inhibitors. The total cell 
lysate was first incubated with 10µl Protein A agarose beads (#9863, Cell signaling 
Technology) to pre-clean the lysate for 1hr at 4°C with rotation. After the pre-clean, the 
lysate was incubated with 1µg of anti-Iga or anti-Igb antibody to pull-down the target 
proteins for overnight at 4°C with rotation. Then 20µl of Protein G agarose beads 
(Sigma) were added to the lysate for additional 2hrs incubation. The beads were collected 
by centrifugation and wash 4 times. The beads were re-suspended by 30µl 3xSDS 





blue, 0.185M Tris-HCL, pH6.8) and incubated at 100°C for 6mins. The supernatant was 
collected for immunoblotting. The samples and Kaleidoscope protein ladder (#1610395, 
Bio-Rad) were applied on 10% SDS-PAGE gel and 6% stacking gel. Proteins were 
transferred from the SDS-PAGE gel to a PVDF membrane (#IPVH00010, EMD 
Millipore). Then the membrane was incubated with blocking buffer (5% milk in TBS/T) 
for 1hr at room temperature. After blocking, the membrane was blotted with different 
primary antibodies for overnight at 4°C. Then incubate with HRP-conjugated secondary 
antibody. The membrane was developed by the ECLTM Primer Western Blotting 
Detection Reagent (#RPN2232, GE Healthcare).  
2.7.9 B cell antigen presentation assay 
To evaluate the antigen presentation ability of Naïve B cells, the following in vitro assay 
was developed. Two types of antigen were used: OVA323-339 peptide and OVA-BCR mini 
antigen. The OVA-BCR mini antigen included three different components: anti-IgM 
F(ab)2-Biotin, Streptavidin and OVA-Biotin. To generate this mini antigen, those three 
components were mixed at 4:1:4 mole ratio, and incubated on room temperature for 
30mins. The purified Naive B cells were incubated with either peptide antigen or mini 
antigens for 30mins at 37°C. Then washed twice to deplete the remaining antigens. 
Meanwhile, OT-II+ CD4+ T cells were purified and labelled with cell proliferation 
Celltrace e450 (#34557 Thermo). The antigen incubated Naïve B cells were co-cultured 
with Celltrace labelled OT-II+ CD4+ T cells at the ratio 1:5 for 72 hours. After the co-
culture, the samples were collected and stained with anti-B220 PE-CY7 (ebioscience) and 





presentation ability was the rate of OT-II+ CD4 T cell proliferation based on the Celltrace 
dilution. 
2.7.10 BCR down-modulation assay 
Naïve B cells were purified from spleen by B cell enrichment kit (Stem cell). Purified 
naïve B cells were stained with anti-IgM F(ab)2-Biotin on ice for 30min. Then put those 
anti-IgM F(ab)2-Biotin labelled cells back to 37°C for BCR internalization, and the 
reaction was stopped at various time points by adding 2%PFA in PBS. Then surface 
remaining anti-IgM F(ab)2-Biotin was stained with Streptavidin-PE-CY7 (ebioscience). 
Here was the formula to calculate the internalization rate: 
Normalized Internalization Rate= (MFI of PE-CY7 at 0’-MFI of PE-CY7 at desire time 
point)/ MFI of PE-CY7 at 0’ 
2.7.11 Measurement of antigen degradation 
To quantify the antigen degradation rate, the degradation sensor was used in this study. 
The degradation sensor was composed by three parts, including the special DNA 
oligonucleotides, Streptavidin and Anti-mouse IgM and IgG F(ab)2-FITC. To generate 
the special DNA oligonucleotides, the following two oligonucleotides were purchased 
from IDT with HPLC purification: Fluorescent strand sequence (5’-Atto647N-TCCGG 
CTGCCTCGCTGCCGTCGCCA-Biotin) and quencher strand sequence (5’-TGGCG 
ACGGCAGCGAGGCAGCCGGA-Iowa Black RQ)[239]. Both oligoes were re-
suspended to 100µM in duplex buffer (100mM potassium acetate, 30mM HEPES, 





anneal those two oligoes together, the mixture was denatured for 2mins at 94 and them 
put the tube on the bench to cool down gradually to room temperature (around 30mins). 
Then mix the antigen senor with Streptavidin and Anti-mouse IgM and IgG F(ab)2-FITC 
at the molar ratio of 4:1:4, and incubate at room temperature for 30mins.  
Purified naïve B cells or 40LB cultured iGC B cells were incubated with the antigen 
sensor BCR complex on the ice for 30mins, and washed once to deplete the rest of 
antigen sensor BCR complex. Put those labeled cells back to 37 for different incubation 
time (0’, 10’, 30’, 60’). To stop the internalization and antigen degradation, the cells were 
added into 2%PFA PBS solution and incubated for 10mins. To quantify the degradation 
rate of antigen complex, the samples were analyzed by FACS. 
2.7.12 Immunofluorescence 
Spleens were embedded in optimum cutting temperature compound (Sakura) and flash-
frozen in liquid nitrogen. Tissue sections were cut on Cryotome (Leica), fixed in ice-cold 
acetone (Sigma), blocked with PBS+5%BSA for 1 hour at 25°C, and stained with PNA –
Biotin (VectorLab). The following secondary antibodies were used to detect primary 
antibodies: Streptavidin Alexa-488 (Invitrogen), Anti-B220-APC (ebioscience). Images 
were acquired on a Zeiss LSM700 or 710 confocal microscopies. 
To visualize the DNA sensor BCR complex degradation, the samples collected from 
different stimulation time (0min and 30min) were put on positive charged slides through 





wash and mounting the slides with DAPI. Images were acquired on a Zeiss LSM700 or 
710 confocal microscopies. 
Another way to quantify the BCR complex degradation was used by checking the co-
localization of BCR complex and lysosomes through immunofluorescence. Navie B cells 
from WT, CBLdKO-Mb1 and CBLKO-Mb1CBLBC373A/- mice were incubated with Anti-IgM 
F(ab)2-Biotin on ice for 30mins. The uncoupled BCR complex was depleted by extensive 
wash. Then put those samples back to 37 to incubate for different time point (0min and 
30min). After the incubation time, the samples were put on positive charged slides 
through Cytospin, followed by 2% PFA fixation and 0.1% Triton X-100 permeablization. 
The primary antibody anti-LAMP1 was used to stain for the lysosomes in cytoplasma. 
The secondary antibodies, anti-rabbit Alexa568 and streptavidin Alexa488, were used to 
label the lysosomes and BCR complex. The slides were analyzed and acquired the image 
Zeiss LSM700 or 710 confocal microscopies. 
2.7.13 Generation of bone marrow chimeric mice 
The 50:50 bone marrow chimeric mice were generated from Rag1-/- mice. The recipient 
Rag1-/- mice were lethally irradiated at the dose of 9.5Gy. Those recipient mice received 
total 4 million of bone marrow cells in 1:1 ratio from B6.SJL background (CD45.1+) 
mice and either WT or CBLdKO-Mb1 mice with C57BL/6J background (CD45.2+). After 6-
8 weeks of reconstitution, those chimeric mice were immunized with SRBC through i.v. 





To generate Iga-WT, Iga-3M, K161R, K167R and K219R bone marrow chimeric mice, 
retroviral stocks were prepared by transfection of Phoenix cells with different forms of 
Iga expression retroviral vector together with the packaging vector pCL-Eco by the 
standard calcium transfection. Viral supernatants were collected 48 h and 72 h after the 
transfection, respectively. To obtain bone marrow stem cells, donor mice were treated 
with 5-FU (5 mg/mouse, i.p.). Four days later, bone marrow stem cells were collected 
and cultured under optimal stem cell culture condition. After two-rounds retroviral spin-
infections, bone marrow cells were adaptively transferred into lethally irradiated (9.5 Gy) 
Rag1-/- recipient mice. Five weeks later, mice were subjected to different immunization.  
2.7.14 Statistical analysis 
Statistical significance was determined by unpaired two-tailed Student’s t test using 






2.8 Figures and Figure Legends 
	
Figure 2.1 Generation of CBLdKO-Mb1 mice 
(A)FACS analysis deletion of Cbl gene in different cell linages from CBLdKO-Mb1TomatoRosa26 
mice based on the Tomato expression. Gating strategy: B cell Progenitor: B220+c-Kit+; 
Pre-pro B cell: B220+CD43+; Late-Pro B cell: B220+CD43-IgM-; Immature B cell: 
B220+CD43-IgMinter; Circulate B cell: B220hiCD43-IgMhi; MZ B cell: B220+ CD24low AA4.1low 
CD21low CD23high; FO B cell: B220+ CD24low AA4.1low CD21+ CD23+; B1B cell: B220+ 
CD24low AA4.1low CD21low CD23low; GC B cell:  B220+ Fashi GL7hi; PCs: B220lo/-CD138hi 
(B)Western blot analysis of CBL expression in purified splenic Naïve B cells from WT 







Figure 2.2 Impaired MZ and T1 B cell development in CBLdKO-Mb1 mice 
(A) Bone marrow B cell development in CBLdKO-Mb1 mice. The dot plot (left) and statistic 
analyses of BM B cell development (n=5). Gating strategy: Fr.A (B220+CD43+BP1-CD24-
); Fr.B (B220+CD43+BP1-CD24+); Fr.C (B220+CD43+ BP1+CD24+); Fr.D (B220+CD43-IgM-); 
Fr.E (B220+CD43-IgM+); Fr.F (B220hiCD43-IgM+). (B) Splenic B cell development in 
CBLdKO-Mb1 mice. The dot plot (left) and statistics analyses of splenic B cell development 
(n=5). Gating strategy: T1(B220+AA4.1+CD21-CD23-); T2(B220+AA4.1+CD21+CD23+); 
B1-B(B220+AA4.1-CD21-CD23-); MZ(B220+AA4.1-CD21hiCD23-); FO(B220+AA4.1-
CD21+CD23+). (C) Immunfluoresence staining of MZ region in spleen. Greed: IgD; 
CD1d: Red; SIGN-R1: Pink. *p<0.05, **p<0.001, ***p<0.0001 (un-paired two-tail T 









Figure 2.3 CBL family proteins were required for T-independent and T-dependent 
immune response 
 (A) Antibody response against Type-I T-independent antigen. The serum antibody titer 
of NP specific IgM and IgG3 antibody at day 7 post NP-LPS immunization (n=4-5). (B) 
Antibody response against Type-II T-independent antigen. The serum antibody titer of 
NP specific IgM and IgG3 antibody at day 7 post NP-Ficoll immunization (n=4-5). (C) 
Total IgG1 isotype antibody response against T-dependent antigen. The kinetics of serum 
total (anti-NP30) antibody of IgG1 isotype from NP36-KLH immunized mice (n=5). (D) 
High affinity IgG1 isotype antibody response against T-dependent antigen. The kinetics 
of serum high affinity (anti-NP4) antibody of IgG1 isotype from NP36-KLH immunized 
mice (n=5). *p<0.05, **p<0.001, ***p<0.0001 (un-paired two-tail T test, A-D). Data are 












Figure 2.4  Impaired GC B cell development in CBLdKO-Mb1 mice 
 (A) GC B cell development against T-dependent antigen SRBC in CBLdKO-Mb1 mice. The 
contour map (left) and statistics analyses of the development of GC B cells (gated as: 
B220+FashiGL7hi) from mice post 10 days of SRBC immunization (n=4). (B) The 
immunofluoresence analysis of GC reaction from post 10 days of SRBC immunization. 
Red: B220; Green: PNA. (C) GC B cell development against T-dependent antigen NP36-
KLH in CBLdKO-Mb1 mice.The contour map (left) and statistics analyses of GC B cells (gated 
as: B220+FashiGL7hi) from mice post 10 days of NP36-KLH immunization (n=5). (D) 
Redundant function of CBL and CBLB in GC B cell development. The dot plot (left) and 
statistic analyses of GC B cells (gated as: B220+FashiGL7hi) from different genotype 
control mice (WT, CBLKO-Mb1CBL+/-, CBLB-/- and CBLdKO-Mb1) at day 10 after SRBC 
immunization (n=5). **p<0.001, ***p<0.0001 (un-paired two-tail T test, A, C, D). Data 








Figure 2.5 CBL family proteins regulate Tfh development through B cell intrinsic 
mechanism 
 (A) Immunofluoresence staining of FDC network in spleen from WT and CBLdKO-Mb1 
mice post 10 days of SRBC immunization. Blue: CD3; Green: B220; Red: C35. (B) 
CBLdKO-Mb1 mutation block Tfh formation in mutant mice.The flow cytometric (top 
panel) and statistics (bottom panel) analyses of Tfh cells (gated as: Linage-
CD4+CD3e+CXCR5hi PD-1hi) from mice day 10 post SRBC immunization (n=5). (C) B 
cell intrinsic defect of GC B cell formation in CBLdKO-Mb1 mice. The dot plots (left) and 
statistics analyses of GC B cells (gated as: CD45.2+B220+Fas+GL7+) and Tfh cells (gated 
as: CD45.2+Linage-CD4+CD3e+CXCR5hi PD-1hi) from bone marrow chimeric mice at 
day 10 post SRBC immunization (n=6). Mixed bone marrow cells (WT/SJL and CBLdKO-
Mb1/SJL) were adaptively transferred to lethal irradiated Rag1-/- recipient mice through I.V. 
injection. After over one month reconstitution, chimera mice were immunized with 
SRBC. ***p<0.0001 (un-paired two-tail T test, B C). Data are from two or three 








Figure 2.6  Impaired antigen presentation to cognate CD4+ T cells in CBL double 
deficient B cells 
 (A) Intact co-stimulatory surface receptor expression on CBLdKO-Mb1 GC B cells. FACS 
analysis of surface receptors, including ICOSL, CXCR4, PDL1, CD40, CD86 and 
MHCII, expression on WT and Cbls-deficient GC B cells (gated as: B220+FashiGL7hi) 
from 10 days post-immunization mice. The WT naïve B cells (gated as: B220+Fas-GL7-) 
were set as control. (B) Strategy of in vitro B cell antigen presentation assay. Two types 
of antigen were used to test in vitro B cell antigen presentation to cognate T cells. Top 
panel: OVA323-339 peptide can directly bind to MHCII on B cells, then present to OT-II 
CD4+ T cell. Bottom panel: mini antigen can be captured through BCR, then internalized, 
processed and presented on MHCII. Celltrace labelled OT-II CD4+ T cells were co-
cultured with pre-treated WT and mutant B cells. (C) Cognate T-B in vitro co-culture. 
The contour map (left) and statistical analysis of in vitro B cell antigen presentation to 
OT-II CD4+ T cells after 72 hrs of T-B co-culture. **p<0.001 (un-paired two-tail T test, 







Figure 2.7 Partially rescue of GC B and Tfh development in CBLdKO-Mb1 mice through 
administration of processed peptides 
(A) Immunization strategy of peptide boost. At day -1, 2 million OT-II CD4+ T cells 
were adaptively transferred into WT and CBLdKO-Mb1 mice, and immunized with NP16-
OVA on day0. The group of CBLdKO-Mb1 boost mice received two doses of OVA323-339 
peptide at day2 and day5. Three groups of mice were sacrificed and analyzed on day7. 
(B) Partially rescue Tfh development through peptides boosting. Dot plot (left) and 
statistical analyses of GC B (gated as: B220+FashiGL7hi) development from with or 
without peptide treated NP36-KLH immunized mice (n=4). (C) Partially rescue GC B cell 
development through peptides boosting. Dot plot (left) and statistical analyses of Tfh 
(gated as: Linage-CD3+CD4+CXCR5hiPD-1hi) development from with or without peptide 
treated NP36-KLH immunized mice (n=4). **p<0.001, ***P<0.0001 (un-paired two-tail 






Figure 2.8 CBL proteins regulate Naïve B cell BCR downmodulation and lysosome 
sorting 
 (A) FACS analysis of BCR downmodulation from purified naïve B cells. The histogram 
(left) and statistics analyses of BCR downmodulation at various time points (n=3).  The 
downmodulation rate= (MFI of IgM at time 0’-MFI of IgM at desire time)/ MFI of IgM 
at time 0’. (B) Immunofluoresence analysis of BCR degradation in mutant naïve B cells. 
The co-localization of BCR complex and lysosome based on marker LAMP-1. Samples 
from two different time points (0’ and 30’) were examined. Grey: DAPI; Green: IgM; 
Red: LAMP-1. BCR-lysosome co-localization rate=MFI of BCR complex in LAMP-1 
region/ Total MFI of BCR complex. ***P<0.0001 (un-paired two-tail T test, A, B). Data 








Figure 2.9 Severely impaired antigen degradation in Cbls-deficient Naïve B cells 
 (A) The principle of antigen degradation sensor. The sensor included three parts: 
Alexa633-DNA sequence-Quench sequence, Streptavidin, FITC-anti-IgM F(ab)2. At 
steady state, the sensor was FITC+ Alexa633- since the quench sequence was associated 
with Alexa633. Once the sensor was internalized by naïve B cells through BCR and 
sorted to lysosome for degradation, the Alexa633 and Quench sequence were rapidly de-
associated, then the cells turned into FITC+Alexa633+. (B) Monitoring antigen sensor 
degradation by FACS. The dot plot (left) and statistics analyses of antigen sensor 
degradation at various time points (n=3). Naïve B cells were pre-treated with antigen 
sensor for 30mins on ice, then incubated at 37°C for various time points (0’, 10’, 30’, 
60’). (C) Visualization of the antigen sensor degradation by confocal microscopy. 
Samples were from two different stimulation time points (0’ and 30’). Blue: DAPI; 
Green: BCR; Red: Alexa633 sensor. ***P<0.0001 (un-paired two-tail T test, B). Data are 








Figure 2.10 Impaired Iga and Igb ubiquitination upon BCR stimulation 
 (A) Western blot analysis of Iga ubiquitination. The Naïve B cells were first treated with 
MG132 for 4hrs, then were non-stimulated (0’) or stimulated (5’) with Anti-IgM F(ab)2 
for 5mins. The Iga protein was pulled down through immunoprecipitation for western 
blot (n=2). (B) Western blot analysis of Igb ubiquitination. The Naïve B cells were 
treated with MG132 for 4hrs, then were non-stimulated (0’) or stimulated (5’) with Anti-
IgM F(ab)2 for 5mins. The Igb protein was pulled down through immunoprecipitation for 











Figure 2.11 E3 ubiquitin ligase function of CBL proteins regulate the initiation of 
GC reaction 
 (A)  GC B cell deficiency in CBLKO-Mb1CBLB373A/- mice. The dot plot (left) and 
statistical analysis of GC B cells (gated as B220+FashiGL7hi) at day 14 after NP36-KLH 
immunization (n=5). (B) Impaired Tfh development in CBLKO-Mb1CBLB373A/-. The flow 
cytometric (left) and statistical analysis of the Tfh cells (gated as Linage-
CD4+CD3e+CXCR5hiPD-1hi) at day14 post NP36-KLH immunization (n=5). (C) The 
statistical analyses of splenic total (top panel) and high affinity (bottom panel) anti-NP 
antibody secreting plasma cells from post 14 days NP36-KLH immunized mice (n=4). 
**p<0.001, ***P<0.0001 (un-paired two-tail T test, A, B, C). Data are from two or three 







Figure 2.12 E3 ubiquitin ligase function of CBL proteins was required for antigen 
presentation through BCR related mechanism 
 (A) In vitro B cell antigen presentation assay. The contour map (top panel) and statistics 
(bottom panel) analysis [254][250]of the Celltrace labeled OT-II CD4+ T cell 
proliferation after 72 hrs of co-culture with mini antigen or OVA323-339 peptide pretreated 
Naïve B cells (n=6). (B) The FACS analysis of BCR stimulation induced BCR 
downmodulation at various time point (n=3). The downmodulation rate= (MFI of IgM at 
time 0’-MFI of IgM at desire time)/ MFI of IgM at time 0’. (C) The BCR and lysosome 
co-localization was visualized (left) and quantified (left) by confocal microscopy and 
volocity. Green: BCR; Red: LAMP-1. The BCR-lysosome colocalization rate=MFI of 
BCR complex in LAMP-1 region/ Total MFI of BCR complex. (D) Monitoring DNA-
antigen sensor degradation by FACS. **p<0.001, ***p<0.0001 (un-paired two-tail T test, 









Figure 2.13 The ubiquitination of Iga was required for GC B cell development 
 (A) Schematic of Iga mutant protein. Three potential ubiquitination sites at the 
cytoplasmic tail of Iga were replaced from Lysine to Arginine (termed as 3M-Iga). (B) 
Generation of WT-Iga and 3M-Iga bone marrow chimeric mice. WT-Iga and 3M-Iga 
genes were respectively introduced into Iga-/- bone marrow stem cells (BMSC) through 
GFP based retroviral vector. Then BMSC were transferred to lethally irradiate Rag1-/- 
recipient mice. After one month of reconstitution, the chimeric mice were immunized 
with NP36-KLH. The GC reaction was analyzed at day 10 post-immunization. (C) Splenic 
B cell development in 3M-Iga mutant mice. The dot plot (top panel) and statistic (bottom 
panel) analyses of mature B cell development (MZ B gated as B220+AA4.1-CD21hiCD23-
; FO B gated as B220+AA4.1-CD21intCD23+) (n=3). (D) Intact surface BCR expression 
on 3M-Iga naïve B cells. The surface expression of IgM and IgD (Gated on: B220+GFP+) 
on splenic B cells was shown in histograms. (E) The flow cytometric analysis of the BCR 
induced Ca2+ flux signalling in splenic naïve B cells. (F) The histogram of BCR induced 
mitotic signalling (Gated on: B220+GFP+) in splenic naïve B cells. (G) GC B cell 
development in 3M-Iga mutant mice. The contour map (top panel) and statistic (bottom 
panel) analyses of GC B cells (Gated as B220+IgD-/loFashiGL7hi) development from post 
10 days of NP36-KLH immunization mice (n=5). **p<0.001, (un-paired two-tail T test, 







Figure 2.14 Blockade of Iga ubiquitination lead to impaired antigen presentation 
 (A) In vitro B cell antigen presentation assay. The contour map (left) and statistics 
analysis of the Celltrace labeled OT-II CD4+ T cell proliferation after 72 hrs of co-
culture with mini antigen pretreated naïve B cells (n=4). (B) The process of Iga 
ubiquitination is required for BCR internalization. Statistic analysis of anti-IgM F(ab)2 
induced BCR downmodulation at various time points (0’, 2’, 5’, 10) (n=4). (C) FACS 
quantification of DNA sensor degradation. ***P<0.0001 (un-paired two-tail T test, A, B). 














Figure 2.15 K161 and K167 are the ubiquitination site of Iga 
(A) Schematic of three Ig-a single mutants (termed as: K161R; K167R; K219R). Three 
potential ubiquitination sites at the cytoplasmic tail of Iga were individually replaced 
from Lysine (K) to Arginine (R). (B) Generation of bone marrow chimeric mice. K161R, 
K167R and K219R genes were respectively introduced into Iga-/- bone marrow stem cells 
(BMSC) through GFP based retroviral vector, then BMSC were transferred to lethally 
irradiate Rag1-/- mice. After one month of reconstitution, the chimeric mice were 
immunized with NP36-KLH. The GC reaction was analyzed at day 10 post-immunization. 
(C) The contour map (left) and statistic analysis of GC B cell (Gated on: B220+IgDlo/-
FashiGL7hi) development from mice post 10 days of NP36-KLH immunization (n=4-5). 
*P<0.05 (un-paired two-tail T test, B). Data are from three independent experiments. 















3 Chapter 3: CBL ubiquitin ligases control the exit 
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High affinity antibodies are generated by SHM of BCR in the DZ of GC. The resulting 
high-affinity B cells are then selected in the LZ to become PCs or return to the DZ for 
further SHM by a less understood regulatory mechanism. We found that ubiquitin ligases 
CBL and CBL-B (CBLs) in GC B cells controlled high affinity antibody production. 
Ablation of CBLs, while imposing little effect on SHM or on the DZ-LZ recirculation, 
impeded the expansion of high-affinity GC B cells and expedited differentiation into PCs. 
This effect could be attributed to CBL-mediated ubiquitination of the PC-promoting 
transcription factor IRF4. Thus, our finding reveals a critical GC LZ program that 
prevents B cells from exiting the DZ-LZ cycle before acquisition of high-affinity BCRs. 
3.2 Introduction 
Production of high affinity antibodies is central to T cell-dependent humoral immunity 
against pathogens and occurs in GC through a process termed antibody affinity 
maturation[255, 256]. Upon encounter with antigen, activated B cells enter GCs to 
undergo clonal expansion and somatically mutate their BCR genes via activation-induced 
cytidine deaminase-mediated SHM in the anatomically distinct dark zone [90, 94, 257-
260]. B cells with a mutant BCR then migrate to the LZ to compete for the antigen 
presented by FDC and the help from Tfh cells[94, 258, 261-263]. Higher affinity BCRs 
have advantages to compete for the antigen, allowing B cells to receive more help such as 
CD40L stimulation from Tfh cells[91, 94, 144, 171]. Surviving high affinity GC B cells 
may terminate the GC B cell fate and differentiate into memory B cells or PCs, or 





266]. The spatial and temporal circulation between the GC DZ and LZ enables B cells 
with higher affinity BCRs being preferentially expanded and selected to enter the 
memory or PC pool.  
Given the critical role of such a GC interzonal circulation in the generation and selection 
of high affinity BCR-expressing B cells, much effort has been invested to understand the 
mechanisms by which B cells are instructed to stay in or exit the DZ-LZ cycle to become 
memory B cells or PCs. At the transcriptional level, maintenance of the GC B cell fate is 
controlled by GC B cell promoting transcription factors such as BCL6[267]. In contrast, 
the identity of PCs depends on BLIMP1 and IRF4[132, 160, 268]. These two groups of 
transcription factors antagonistically regulate each other and dictate the steady-state 
distinctive characteristics of GC B cells and PCs, respectively[269, 270]. In addition to 
these transcription factors, MYC, FOXO1, and NFkB have been reported to provide 
additional layers of regulation during the GC reaction[84, 93, 145, 147, 148, 151, 168]. 
Inactivation of NFkB, or MYC in GC B cells resulted in the collapse of the GCs, due to 
the impaired recirculation of LZ B cells to the DZ. Foxo1 was found to be essential for 
the DZ phenotype, as mice with deletion of foxo1 in GC B cells have only LZ cells. A 
question that remains unanswered is what is the molecular mechanism that senses BCR 
affinity cues in GC B cells and instructs B cells to continue the DZ and LZ circulation or 
to initiate the differentiation program to PCs.  
CBL and CBL-B (CBLs) are two members of the CBL family of E3 ubiquitin ligases 
expressed in hematopoietic cells[271]. In B cells, they play a crucial role in the induction 





cells. It has been shown that inactivation of CBLs using the Cd19-cre allele results in a 
moderate increase in IgM and reduction in IgG isotypes of T-cell dependent antibody 
responses[215]. However, the function of CBLs in the GC reaction and antibody affinity 
maturation has not yet been investigated. Here, we show that CBLs are essential for the 
selection of high affinity GC B cells and antibody affinity maturation. In GC, CBLs are 
minimally expressed in DZ B cells, markedly upregulated in LZ B cells, and suppress 
IRF4 expression by promoting IRF4 ubiquitination. Ablation of CBLs in GC B cells 
upregulates IRF4, leading to impaired clonal expansion of high affinity B cells and 
expedited GC differentiation, despite normal SHM and DZ-LZ circulation of GC B cells. 
Consistent with this result, ectopic expression of IRF4 alone or inactivation of the 
ubiquitin ligase activity of CBLs is sufficient to recapitulate the GC phenotypes found in 
CBLs mutant mice. Thus, our data indicate that B cell-intrinsic CBLs-IRF4 axis 
constitutes an ubiquitination dependent regulatory cascade that temporally controls GC B 
cells to stay in the DZ-LZ circulation until the acquisition of high affinity BCRs.  
3.3 Results 
3.3.1 Expression patterns of CBLs in B cell subsets and the GC reaction  
To evaluate whether CBL proteins regulate T-dependent antibody response, we first 
examined the expression patterns of CBL and CBLB in naïve and GC B cells. We found 
decreased amounts of both Cbl and Cblb mRNA in GC B cells as compared to naïve B 
cells; however, GC B cells expressed higher amounts of CBL and CBLB proteins as 





seemed to be a GC phenomenon, since activation of B cells with anti-IgM or anti-CD40 
induced only a mild increase or a decrease in both CBL and CBLB proteins, respectively 
(Figure 3.2 B). Within GC B cell populations, the LZ GC B cells possessed significantly 
more CBL and CBLB proteins but not mRNAs compared to the DZ B cells (Figures 3.1 
C, 3.1 D, 3.2 C and 3.2 D). These results indicate that CBL proteins are post-
transcriptionally and dynamically modulated during the GC reaction. 
3.3.2 Ablation of CBL proteins in GC B cells impairs antibody affinity maturation  
We then generated c-Cblfl/fl, Cbl-b-/-, IgCg-cre Tg mice in which the IgCg-cre allele drove 
Cre recombinase expression in GC B cells so that only GC B cells carried the CBL and 
CBL-B double null (termed here CBLdKO-Cg) mutation, whereas other cells of the mice 
harbored the germline CBL-B mutation[202, 205, 272]. Ablation of CBL and CBL-B 
proteins in GC B cells was confirmed by Western blot analysis and immunofluorescent 
staining (Figure 3.3 A and B). Inspection of CBLdKO-Cg mice revealed normal development 
of B cells (Figure 3.3 C and D). Compared to WT mice, the mutant mice produced 
similar levels of total anti-NP (NP30) antibodies of IgM and IgG1 isotypes initially, after 
immunization with (4-Hydroxy-3-Nitrophenyl) Acetyl-Keyhole Limpet Hemocyanin 
(NP-KLH); however, they displayed a significantly lower level of IgG1 at day 28 (Figure 
3.4 A). In addition to the antibody titer, the CBLdKO-Cg mice exhibited impaired antibody 
affinity maturation, as the level of anti-NP4 as well as the ratio of high affinity anti-NP 
(NP4) vs total anti-NP (NP30) IgG1 was severely impaired in the mutant mice compared to 
the WT controls (Figure 3.4 B and C). Consistent with the antibody production, the 





antigen. In contrast, they had markedly reduced numbers of total (anti-NP30) as well as 
high affinity (anti-NP4) IgG1 ASCs relative to their WT counterparts (Figure 3.4 D).  
In T-cell dependent immune responses, ASCs or PCs are mostly derived from GC B 
cells. To examine whether the CBLdKO-Cg mutation affected the GC reaction, we analyzed the 
kinetics of GC B cell development during the course of immunization. At day 8 after 
immunization, WT and CBLdKO-Cg mice developed equal percentages of GC B cells; 
however, while WT mice exhibited a peak GC development at day 12 and declined GC B 
cell numbers thereafter, the mutant mice maintained GC B cells at a steady level up to 
day 18 (Figure 3.4 E). The altered kinetics of GC B cell development in the mutant mice 
could be partly attributed to a combinatory effect of expedited differentiation and reduced 
apoptosis, because CBLdKO-Cg GC B cells generated more plasma cells (see below) and 
expressed a lower number of active Caspase positive cells compared to the WT controls, 
respectively (Figure 3.4 F). The proliferation of GC B cells was not affected by the 
CBLdKO-Cg mutation (Figure 3.3 E). In addition to the altered kinetics of GC B cell 
expansion, the mutant mice had a markedly lower number of GC B cells expressing a 
high affinity cell surface IgG1 BCR against NP antigen relative to the WT mice 
throughout the course of immunization (Figure 3.4 G). The influence on high affinity 
BCR-expressing GC B cells was not caused by IgCg-Cre tg and appeared to be redundant 
between CBL and CBL-B, because IgCg-Cre tg mice had normal numbers of total and 
high affinity GC B cells, and ablation of Cbl or Cblb alone exhibited only a relatively 
mild effect on the numbers of high affinity NP-binding GC B cells compared to CBLdKO-Cg 





antibody affinity maturation rather than total antibody production. In addition, this 
regulation occurs at the stage of GC B cells. 
3.3.3 CBL proteins regulate GC selection for high affinity antibody-producing B 
cells 
Deficiency in generating high affinity antibody producing cells could be a result of 
impaired SHM or lack of selection for high affinity B cells in the GC. To distinguish 
these two possibilities, we analyzed SHM in IgH genes in GC B cells. We isolated Igl1+ 
GC B cells from NP-KLH immunized mice by FACS sorting at day 12 postimmunization 
and examined SHM in Ig VH186.2 by DNA sequencing according to the previous 
publication (Figure 3.5 A)[145]. We found that while all (20/20) VH186.2 genes isolated 
from WT GC B cells carried at least one mutation (range: 1-15 mutations), about ~85% 
(17/20) of VH186.2 genes from CBLdKO-Cg GC B cells were mutated (range: 1-9 mutations) 
(Figure 3.6 A)[52, 258]. In addition, VH186.2 genes from WT GC B cells carried five 
replacement mutations/clone and 65% (13/20) of VH186.2 genes harbored a tryptophan to 
leucine mutation at position 33 (W33L), a mutation known to encode a high affinity BCR 
(Figure 3.6 B and C). In contrast, VH186.2 genes from CBLdKO-Cg B cells possessed merely 
two replacement mutations per clone on average and only 15% (3/20) of clones carried a 
W33L mutation. Analysis of the replacement vs silent mutations (R/S ratio) in VH186.2 
genes revealed that while the VH genes from WT GC B cells had undergone strong 
selection (R/S = 4.4), those from CBLdKO-Cg B cells exhibited an R/S ratio equivalent to that 
expected for the random mutation (R/S = 2.2) (Figure 3.6 D). The frequencies of the 





(Figure 3.6 B), indicating that the SHM per se is not affected by the CBLdKO-Cg mutation. To 
ascertain that the above phenomenon in VH186.2 genes indeed reflected that in NP-
specific BCRs, we also compared SHM in VH186.2 genes isolated from NP38-binding GC 
B cells. Consistent with that observed in IgG1+ GC B cells, the number of VH186.2 genes 
carrying a W33L mutation was also significantly reduced in the mutant NP-specific GC 
B cells compared to WT controls (Figure 3.6 B and C).  
To directly examine whether CBLs regulated cellular selection of high affinity BCR-
expressing cells inside GCs, we compared the kinetics of high affinity NP (NIP5) and total 
NP (NP38)-binding GC B cell development at different time points upon NP-KLH 
immunization (Figure 3.6 E). At day 8 after immunization, WT mice had approximately 
20% of NIP5-binding and 31% NP38-binding GC B cells, indicating that approximately 
65% of total NP-specific GC B cells express a high affinity BCR as defined by NIP5-
binding capability. By day 14, the ratio of NIP5 vs NP38-binding GC B cells increased to 
more than 90%, indicating that the high affinity NP specific B cell population is 
selectively expanded within total NP specific GC B cells. In contrast to WT mice, CBLdKO-Cg 
mice possessed relatively lower numbers of NIP5 and NP38-binding GC B cells at day 8 
(average 5% and 9%, respectively), equivalent to approximately 61% of NIP5-binding 
cells among total NP38-binding cells. By day 14, this ratio only increased slightly to less 






Taken together, the above data demonstrate that CBLs are required for the selection of 
high affinity BCR expressing B cells during GC reaction. However, they appear to be 
dispensable for the regulation of SHM in GC B cells. 
3.3.4 The CBLdKO-Cg mutation expedites GC B cell differentiation 
During affinity maturation, GC B cells undergo multiple cycles of proliferation and SHM 
in the DZ and selection in the LZ[171, 273]. Disruption of these cycles may impair 
affinity-driven selection of GC B cells. To understand the mechanisms by which CBL 
proteins regulate GC affinity selection, we examined whether the CBLdKO-Cg mutation 
affected the development of DZ and LZ GC B cells or the differentiation dynamics of GC 
B cells to PCs. The DZ and LZ architecture in the immunized CBLdKO-Cg mice appeared to be 
normal (Figure 3.7 A). In addition, flow cytometric analysis of the DZ and LZ GC B cells 
could not reveal any difference between the WT and CBLdKO-Cg mice (Figure 3.7 B). These 
results indicate that the CBLdKO-Cg mutation does not significantly influence the development 
of DZ and LZ GC B cells at the population level. However, B220+ GL7hi Fashi GC B cells 
in CBLdKO-Cg mice possessed significantly more plasma cell precursor-like cells that 
expressed lower Bcl6 and slightly higher CD138 (Figure 3.7 C), suggesting that the 
CBLdKO-Cg mutation expedites GC B cells to PC differentiation. 
We then performed BrdU labeling experiment to determine whether GC B cell 
development into PCs was increased in the mutant mice. At day 12 after immunization, in 
both WT and CBLdKO-Cg mice approximately 90% of GC B cells incorporated BrdU after 





GC B cells are vigorously proliferating. In contrast, the mutant mice generated 50% more 
BrdU+ PCs as compared to WT mice (17% vs 11%) during the same period, which was 
equivalent to the genesis of 6,000 PCs/hour/spleen in CBLdKO-Cg mice compared to 
4,000/hour/spleen in WT controls (Figures 3.9 A and B). These BrdU+ PCs were mostly 
newly generated from NP-KLH activated B cells, rather than derived from spontaneous 
immune responses or existing PCs and proliferating plasma blasts, because twenty-four 
hours BrdU labeling of un-immunized WT and CBLdKO-Cg mice produced only 1-2% of 
BrdU+ PCs (Figure 3.8 B). Given that the mutant mice had less GC B cells than WT 
controls at day 12 after immunization (Figure 3.4 E), the increased PC genesis in    
CBLdKO-Cg mice is consistent with the idea that CBL proteins are responsible for retaining 
GC B cells in the DZ-LZ cycle and preventing them from differentiation into PCs. 
To directly assess the effect of CBLs on the fate choice of B cells in developing GCs in 
the context of affinity selection, we examined the development of high affinity NP-
specific GC B cells and PCs upon inducible ablation of CBLs. We transferred B cells 
from ER-Cre tg (Control) or Cblfl/fl Cbl-b-/- ER-Cre tg (termed CBLdKO-UBC) mice into µMT 
recipient mice and immunized the chimeric mice with NP-KLH so that the donor B cells 
could enter and initiate GC reaction. We then deleted CBL by tamoxifen at day 7 after 
immunization, at which stage about 60% of NP specific B cells already acquired a high 
affinity BCR (Figure 3.6 E), and analyzed NIP5-binding GC B cells and PCs at day 12 by 
flow cytometry. Mice ablated Cbls showed a marked reduction in the number of NIP5-
binding GC B cells; however, the total number of GC B cells was only reduced to a half 





the numbers of total and NIP5-binding PCs relative to mice without CBL deletion (Figure 
3.8 C and D). Given that high affinity PCs are mostly generated through GC reaction, 
concomitant reduction in NIP5-binding GC B cells and increase in NIP5-binding PCs 
supports the idea that loss of CBLs facilitates the high affinity GC B cells to choose the 
PC fate and differentiate into PCs. 
To determine whether CBLs control the PC differentiation program via these signaling 
pathways, we compared CD40 and BCR-induced B cell differentiation to PCs in vitro. 
Stimulation of naïve B cells from CBLdKO-Mb1 mice, with either membrane-bound CD40L 
expressed on 40LB feeder cells or soluble anti-CD40, generated significantly more B220-
CD138+ and B220+ CD138+ cells (Figures 3.9 D and 3.8 E). These cells appeared to be 
PCs or plasma blast-like cells because they expressed intracellular Ig, upregulated IRF4, 
and downregulated BCL6 (Figure 3.8 F). Similarly, culture of freshly isolated CBLdKO-Cg GC 
B cells on CD40LB feeders also generated more B220+CD138+ plasma blast-like cells 
relative to WT controls (Figure 3.9E). In contrast, anti-IgM stimulation alone produced 
comparable numbers of B220+CD138+ cells from the mutant and WT B cells, suggesting 
that BCR signaling induced PCs is not enhanced by the CBLs mutation (Figure 3.9 E). 
Neither CD40 nor BCR-induced proliferation of B cells was affected by the CBLdKO-Mb1 
mutation (Figure 3.8 G). Together, these data indicate that ablation of CBL proteins does 
not affect CD40 or BCR induced mitotic signaling but rather expedites CD40-induced B 
cell differentiation into PCs. 
The frequency of B cell differentiation into PCs increases with each cell division 





cell division, we labeled naïve WT and CBLdKO-Mb1 B cells with CellTrace, stimulated them 
with 40LB feeder cells, and then examined PC differentiation in different divisions of 
proliferating B cells by monitoring both the IRF4 and CD138 expression. Consistent with 
the above finding, ablation of CBLs did not affect the rate of B cell division; however, 
the mutant B cells generated 50% more IRF4hi cells relative to WT controls in the third 
and fourth cell division (Figure 3.9 F). A similar increase in CD138+ cells was also found 
in the CBLdKO-Mb1 compared to the WT B cell culture (Figure 3.8 H). These findings together 
indicate that, while still maintaining vigorous cell division, loss of CBLs induces more B 
cells to exit B cell fate and turn on the PC differentiation program in each cell division. 
3.3.5 The CBLdKO-Cg mutation enhances the expression of IRF4 protein but not 
mRNA in GC B cells 
The identities of GC B cells and PCs are respectively controlled by BCL6 and BLIMP1. 
IRF4 provides another layer of regulation by repressing BCL6 and promoting BLIMP1 
gene transcription[275]. To elucidate how the CBLdKO-Cg mutation affected the GC B cell 
differentiation program, we compared the gene expression profiles of GC B cell and PC 
identity genes in WT and CBLdKO-Cg GC B cells at day 12 after immunization. RNA-seq 
analysis revealed ~900 genes that were downregulated and ~50 genes upregulated for at 
least two-fold in CBLdKO-Cg GC B cells as compared to WT controls (Figure 3.10 A); 
however, this analysis revealed a slightly lower expression of several known GC B cell or 
PC identity genes such as Bcl6, Bach2, Irf4, and Aicda (Figure 3.10 B). qPCR analysis 
confirmed that while Bcl6, Bach2, and Aicda were slightly downregulated, the PC 





(Figure 3.11 A). Despite this observation, the mutant GC B cells elevated the expression 
of multiple genes related to RNA processing, protein translation, and secretion involved 
in PC function (Figure 3.11 B and 3.10 B), suggesting that some mutant B cells already 
initiate the PC differentiation program.  
To determine whether the CBLdKO-Cg mutation influenced the PC development program at 
the protein level, we examined CD40 and BCR signaling, as well as the levels of BCL6 
and IRF4 proteins in GC B cells. We found that activation of CD40 or BCR signaling 
pathways, including canonical NF-kB, AKT, S6K, and ERK, was not altered by the 
CBLdKO-Cg mutation (Figure 3.10 C-D). In contrast, the expression of IRF4 protein was 
markedly increased in freshly isolated mutant GC B cells compared to the controls 
(Figure 3.11 C). To gain insight into the expression of IRF4 and BCL6 during GC B cell 
differentiation at the single cell level, we examined intracellular BCL6 and IRF4 in 
developing GC B cells by flow cytometry. In WT mice, a majority of GC 
(B220+Fas+GL7+) B cells expressed a high level of BCL6 (BCL6hi), whereas only 
approximately 10% of GC B cells downregulated BCL6 (BCL6lo) and about half of them 
simultaneously upregulated IRF4 (BCL6loIRF4hi) (Figure 3.11 D). Stimulation of CD40 
and BCR for 3 hours significantly increased the BCL6loIRF4hi subset to ~40% of the total 
GC B population (Figure 3.11 E). In contrast to WT mice, CBLdKO-Cg mice already possessed 
significantly more (15%) BCL6loIRF4hi GC B cells in the absence of any stimulation, and 
CD40 and BCR stimulation boosted BCL6loIRF4hi population to more than ~60% of total 
GC B cells (Figure 3.11 D and E). Western blot analysis confirmed that IRF4 protein was 





BCR stimulation (Figure 3.11 F). This result, along with the mRNA expression data, 
indicates that CBLs do not affect the major signaling pathways downstream of CD40 or 
the BCR. Instead, they may retain GC B cells fate by suppressing the expression of IRF4 
protein rather than Irf4 transcription.  
3.3.6 CBLs promote nuclear IRF4 ubiquitination and degradation 
CBL proteins are known cytosolic E3 ubiquitin ligases, whereas IRF4 is a transcription 
factor that functions mainly in the nucleus. We therefore examined at which subcellular 
location CBL proteins exert their regulatory function on IRF4. Confocal microscopy 
analysis showed that IRF4 was barely detectable in freshly isolated WT GC B 
(B220+GL7+Fashi) cells and significantly accumulated in the nucleus after CD40 and BCR 
stimulation (Figure 3.12 A and B). In contrast, a significant proportion of CBLdKO-Cg GC B 
cells already possessed a high level of nuclear IRF4 in the absence of any stimulation 
(Figure 3.12 A and B). In agreement with this observation, Western blot analysis 
confirmed that IRF4 was expressed in both cytosol and nucleus, with the mutant GC B 
cells expressing several folds more IRF4 than WT cells in the nucleus even in the 
absence of any stimulation (Figure 3.12 C). As for CBLs, in freshly isolated WT GC B 
cells both CBL and CBL-B were expressed in the cytosol and nucleus in the absence of 
CD40 stimulation, with CBL more strongly in cytosol and CBL-B in the nucleus (Figure 
3.12 D). CD40 and BCR stimulation for one hour significantly diminished CBL-B and 
for three hours reduced both CBL-B and CBL in the nucleus. The stimulation 
concomitantly increased the level of nuclear IRF4 (Figure 3.12 D), suggesting that 





To determine whether CBL proteins regulated IRF4 expression by promoting IRF4 
ubiquitination, we co-expressed IRF4 with either CBL or CBL-B in 293T cells and 
examined IRF4 association with, and ubiquitination by, CBL or CBL-B by 
immunoprecipitation and Western blot analysis. IRF4 associated with, and became 
ubiquitinated by, either CBL or CBL-B in 293T cells (Figures 3.12 E and F). The 
association of IRF4 with CBL and CBL-B in freshly isolated WT GC B cells, as well as 
its ubiquitination in WT but not in CBLdKO-Mb1 iGC B cells, was confirmed by co-
immunoprecipitation and Western blot hybridization (Figure 3.12 G and H). Thus, the 
observed dynamic change of IRF4 expression in GC LZ B cells is at least partly regulated 
by CBL-dependent IRF4 ubiquitination and degradation.  
3.3.7 Lack of CBL ubiquitin ligase activity or increased IRF4 expression is 
sufficient to impair GC affinity selection 
Our aforementioned results suggest a hypothesis that the elevated level of CBLs in GC B 
cells removes IRF4 by promoting IRF4 ubiquitination, consequently allowing 
continuation of GC cycle until high affinity BCRs are acquired. If this was the case, we 
expect that inactivation of CBL ubiquitin ligase activity or an increased IRF4 expression 
in GC B cells impairs antibody affinity maturation. To examine whether CBL ubiquitin 
ligase activity is required for antibody affinity maturation, we bred CBLfl/flCBLB-/- mice to 
IgCg-Cre tg and CBL-BC373A/C373A mice[253], the latter expressed a mutant CBL-B whose 
ubiquitin ligase activity was inactivated by a cysteine to alanine mutation at position 373 
of the CBL-B. The resulting CBLfl/fl CBL-B-/C373A IgCg-Cre tg (termed CBLKO-CgCBL-B-/C373A) 





PCs were examined by flow cytometry and ELISPOT, respectively. CBLKO-CgCBL-B-/C373A 
mice recapitulated GC B cell phenotypes found in CBLdKO-Cg mice, as they produced a 
slightly lower number of GC B cells compared to CBLKO-CgCBL-B-/+ and WT controls at day 
12 after immunization (Figures 3.13 A and 3.14 A). In addition, the numbers of high 
affinity anti-NP (NP8) GC B cells as well as anti-NP8 IgG1 secreting PCs were all reduced 
in the mutant mice relative to the controls (Figures 3.13 B, 3.13 C and 3.14 A).  
To determine whether increased IRF4 was sufficient to abolish antibody affinity 
maturation, we ectopically expressed IRF4 in WT hematopoietic stem cells by a 
retroviral vector and generated BM chimeras (termed IRF4-MSCV BM mice). 
Expression of the transgenic IRF4 was confirmed by Western blot analysis (Figure 3.14 
B). These mice were then immunized with NP-KLH, and selection of high affinity NP-
binding GC B cells and PCs was analyzed by flow cytometry. Similar to that found in 
CBLdKO-Cg and CBLKO-CgCBL-B-/C373A mice, in IRF4-MSCV BM chimeras the transgene Irf4 
expressing B cells generated a slightly lower number of GC B cells at day 12 compared 
to empty retrovirus (MIGR-MSCV) infected B cells (Figure 3.14 D), indicating that Irf4-
overexpressing B cells can enter GC reaction. However, the production of high affinity 
anti-NP8 IgG1 expressing GC B cells was impaired in the mutant (IRF4-MSCV, GFP+) 
but not in WT controls (MIGR-MSCV, GFP+) (Figure 3.14 E). The numbers of PCs 
generated from IRF4-MSCV infected B cells were consistently increased as compared to 
empty vector infected cells (Figure 3.14 F). 
Together, these results indicate that lack of ubiquitin ligase activity of CBLs or excessive 






Selective expansion of high affinity BCR-expressing B cells in GCs is a critical step in 
antibody affinity maturation. Our study showed that CBLs play an indispensable role in 
this regulation, as ablation of CBL in GC B cells selectively impaired the development of 
GC B cells expressing high but not low affinity BCRs. We also provided evidence that 
the CBLdKO-Cg mutation did not significantly alter the efficiency of SHM, but rather impeded 
the clonal expansion of high affinity B cells. Since inactivation of CBL ubiquitin ligase 
activity is sufficient to recapitulate this GC phenotype, our studies thus support the notion 
that CBLs define a novel ubiquitination-dependent regulatory pathway that enforces 
affinity-driven clonal selection of high affinity GC B cells by preventing premature 
termination of GC recirculation. 
It is generally envisioned that high affinity BCRs facilitate clonal expansion and selection 
of GC B cells via two modes of regulation. First, high affinity BCRs may drive more 
vigorous cell proliferation, because they elicit stronger BCR signaling than low affinity 
BCRs. However, this proposition has received conflicting evidence, as attenuated rather 
than enhanced BCR signaling is favorable for GC B cell expansion and high affinity 
BCRs tend to cease GC B cell fate and initiates PC differentiation[172, 276]. As an 
alternative to the signaling role of the BCR in GC affinity selection, high affinity BCRs 
are thought to capture more antigen than BCRs with inferior affinity, thus giving high 
affinity B cells the advantage of competing for Tfh cell help mainly via the upregulated 
CD40L[91, 237]. Either way, a challenging question is how B cells interpret BCR affinity 





pathways of GC B cells. In our studies, we found that ablation of CBLs expedited GC B 
cell differentiation but not proliferation upon CD40 and/or BCR stimulation. This finding 
thus puts CBLs at the branch of signaling pathway to prevent the B cell differentiation 
rather than proliferation. In line with this view, we observed that the CBLdKO-Cg mutation did 
not affect CD40 and BCR induced mitotic signaling such as AKT, S6K, ERKs, and 
canonical NF-kB. Instead, it resulted in the accumulation of IRF4 protein in GC B cells. 
We also found that CBLs promote IRF4 ubiquitination. CD40 and BCR stimulation 
downregulated CBL and conversely upregulated IRF4 in GC B cells. These data together 
extend our previous understanding about the role of CD40 and BCR in GC affinity 
selection. By clearing IRF4 protein rather than regulating the mitotic signaling pathways, 
CBLs allow CD40 and BCR to promote GC B cell stay in the DZ-LZ circulation without 
activating the differentiation program into PCs. This regulation can be reversed in high 
affinity GC B cells in which strong CD40 and BCR signaling generated by the high 
affinity BCRs cue downregulates CBLs, consequently allowing these cells to upregulate 
IRF4 and be selected into the PC pool. 
The fates of GC B cells and PCs are determined by transcription factors BCL6, IRF4, and 
BLIMP[270, 275]. However, a recent transcriptome study revealed that transcription of 
Bcl6 was abruptly downregulated whereas that of Irf4 and Pmdr1 was abruptly 
upregulated in plasmablasts, hence raising the question as to what is the initial “push” 
that drives the transition of this transcriptional network from the equilibrium state of GC 
B cells to that of PCs[277]. Our data reveal that in WT mice a small population of GC B 





BCR for a short period increased this cell subset, suggesting that these cells represent 
emerging plasmablasts or plasma cell precursors. Development of this subset appeared to 
be controlled by CBLs, because they were significantly increased in the GCs of CBLdKO-Cg 
mice. In GC B cells, we showed that CBLs ubiquitinated IRF4. Strong CD40 and BCR 
stimulation decreased the expression of CBL proteins and concomitantly increased the 
expression of IRF4. We therefore propose that relief of IRF4 from CBL-mediated 
ubiquitination upon strong CD40 and/or BCR triggering is the earliest PC fate 
commitment event occurring in the LZ GC B cells, preceding the conversion of 
transcriptomes from the state of GC B cells to that of PCs. This of course will not refute 
the role of CD40 in promoting Irf4 gene transcription, which may be compromised in LZ 
B cells at the IRF4 protein level until CBLs are degraded.	
Previous studies have shown that selection of high affinity GC B cells depends on the 
transcription factors NFkB, MYC, and FOXO1, in a B cell-intrinsic fashion. Both MYC 
and canonic NFkB were expressed or activated in a small subset of LZ GC B cells[84, 
93, 168]. Ablation of Myc, Rel or Relb genes in GC B cells resulted in the collapse of the 
GC reaction, because these factors are required for the maintenance of the GC reaction by 
facilitating LZ to DZ recirculation. FOXO1 is required for sustaining the DZ program, as 
inactivation of Foxo1 gene disrupts the expansion of DZ B cells possibly by 
dysregulating the function of the transcription factor BATF[151]. In contrast to the above 
regulations, CBLs control GC affinity maturation by determining the time when a GC B 
cell is allowed to enter the PC pool. In this regard, CBLs seem to represent a new 





contributing to affinity selection. It will be interesting to determine whether this 
mechanism also contribute to the recently described temporal switch in the differential 
output of memory B cells and PCs during the GC reaction. 
Selection of high affinity B cells occurs in the GC LZ where BCR affinity cues can be 
accessed via interaction with antigen presented on follicular dendritic cells[278]. Our 
findings that CBLs were markedly upregulated in GC LZ B cells at the protein but not at 
the mRNA level, and that CD40 and BCR downregulated CBLs, raise an interesting 
question as to how the expression of CBLs is spatially and temporally controlled during 
the GC DZ-LZ circulation. CD40 is known to activate RING-domain containing TRAFs 
or cIAPs, both of which regulate their respective downstream signaling molecules by 
ubiquitination. Along this line, TRAF6 and TRAF2 have been shown to associate with 
CBL-B[279]. Alternatively, CD40 could downmodulate the translation of CBL proteins 
through a microRNA dependent mechanism. Consistent with this speculation, it has been 
found that CD40 stimulation enhances expression of multiple microRNAs among which 
miR155 may influence CBL-B expression in B cells[254, 280]. Nevertheless, it will be 
interesting to investigate whether the modulation of the CBL pathway can be used as a 
strategy to improve the clinical benefit such as the efficiency of vaccination in future.   
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3.7 STAR method 
Table 3.1 Key resource 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
anti-CD4 e450 Ebioscience/Thermo Cat#48-0042-82 
anti-CD8 e450 Ebioscience/Thermo Cat#48-0032-82 
anti-Gr1 e450 Ebioscience/Thermo Cat#48-5931-82 
anti-CD11c e450 Ebioscience/Thermo Cat#48-0114-82 
anti-CD11b e450 Ebioscience/Thermo Cat#48-0112-82 
anti-Ter119 e450 Ebioscience/Thermo Cat#48-5921-82 
anti-F4/80 e450 Ebioscience/Thermo Cat#48-4801-82 





anti-B220 PE-CY7 Ebioscience/Thermo Cat#25-0452-82 
anti-GL7 e450 Ebioscience/Thermo Cat#48-5902-82 
anti-GL7 FITC Ebioscience/Thermo Cat#53-5902-82 
anti-IgM PE Ebioscience/Thermo Cat#12-5890-81 
anti-CD23 PE-CY7 Ebioscience/Thermo Cat#5-0232-81 
anti-CD24 PE Ebioscience/Thermo Cat#12-0241-81 
anti-CD93 APC Ebioscience/Thermo Cat#17-5892-82 
anti-CXCR4 PE Ebioscience/Thermo Cat#12-9991-82 
anti-Irf4 PE Ebioscience/Thermo Cat#12-9858-80 
anti-B220 FITC Ebioscience/Thermo Cat#11-0452-82 
Strepavidin PE-CY7 Ebioscience/Thermo Cat#24-4317-82 
anti-CD86 Ebioscience/Thermo Cat#17-0862-81 
anti-phospho-S6(S235/S236) Ebioscience/Thermo Cat#12-9007-42 
anti-B220 APC Biolegend Cat#103212 
anti-CD38 APC Biolegend Cat#102712 
Alexa647 anti-BrdU Biolegend Cat#364108 
anti-Igl Biolegend Cat#407306 
anti-Fas PE BD Cat#554258 
anti-Fas PE-CY7 BD Cat#557653 
anti-IgG1 FITC BD Cat#553443 
anti-IgD FITC BD Cat#553439 
anti-CD21/CD35 FITC BD Cat#553818 





anti-CD138 PE BD Cat#553714 
anti-CD35 Biotin BD Cat#553816 
anti-CD138 e450 BD Cat#562610 
Alexa647 anti-AKT(p473) BD Cat#560343 







Purified anti-CD40 ENZO Cat#ALX-805-
046-C100 
Purified anti-IgMF(ab)2 Jasckson 
ImmunoResearch 
Cat#115-006-020 
anti-mouse Cbl Santa Cruz Cat#SC-170 
anti-mouse Irf4 Santa Cruz Cat#SC-6059 
anti-LAMINB Santa Cruz Cat#SC-374015 
anti-HA Santa Cruz Cat#SC-805 
HRP conjugated anti-b-ACTIN Abcam Cat#AB49900 
anti-Flag Sigma Cat#F1804-50UG 
anti-Goat IgG HRP Santa Cruz Cat#SC-2020 
anti-Rabbit IgG HRP Cell Signaling Cat#7074P2 
anti-Mouse IgG HRP Cell Signaling Cat#7076P2 
anti-Mouse Cbl-b Cell Signaling Cat#9498S 
anti-Mouse IgG1 HRP Thermo Cat#A10551 





anti-a-Tubulin Sigma Cat#T4026-.2ML 
PNA Biotin Vector Cat#B-1075 
PNA FITC Vector Cat#FL-1071 
Strepavidin Alexa488 Thermo Cat#S-32354 
Strepavidin Alexa568 Thermo Cat#S-11226 
Donkey anti-Goat Alexa594 Thermo Cat#A-11058 
Goat anti-Rabbit Alexa568 Thermo Cat#A-11036 
Bacterial and Virus Strains  
E.coli5 competent cells Thermo Cat#18265017 
Stbl2TM competent cells Thermo Cat#10268019 
Stbl3TM competent cells Thermo Cat#C737303 
Chemicals, Peptides, and Recombinant Proteins 
5-Fluorouracil Sigma Cat#F6627-5G 
MG132 Sigma Cat#C2211 
NHS-Biotin Thermo Cat#21335 
Recombinant mouse IL-4 protein R&D Cat#404-ML-050 
Recombinant mouse SCF protein R&D Cat#455-MC-050 
Recombinant mouse IL-6 protein R&D Cat#406-ML-
025/CF 
Recombinant mouse IL-3 protein R&D Cat#403-ML-
050/CF 
Celltrace Proliferation dye Ebioscience/Thermo Cat#C34557 














rProtein G Agarose  Thermo Cat#15920-010 
Tamoxifen Toronto Research 
Chemicals Inc. 
Cat#T006000 







1-StepTM Ultra TMB-ELISA Substrate 
Solution 
Thermo Cat#34029 
Critical Commercial Assays 
FITC-BrdU kit BD Cat#559619 
Nuclear Extract Kit Active motif Cat#40010 
AEC Substrate Set BD Cat#551951 
B cell negative selection kit Stem cell Cat#19854 
CaspaseGlowTM FITC Active Caspase 
Staining Kit 
Biodivision Cat#A10551 
Experimental Models: Cell Lines 
293T cell line Laboratory of Gu N/A 





40LB cell line Laboratory of D. 
Kitamura 
N/A 
Experimental Models: Organisms/Strains 
Cbl flox/flox conditional knockout mice Laboratory of Gu N/A 
Cbl-b germline knockout mice Laboratory of Gu N/A 
Mb1-cre mice Laboratory of Michael 
Reth 
 
Cg-cre mice Laboratory of K. 
Rajewsky 
N/A 
CblbC373A mutation mice Laboratory of W. 
Langdon 
N/A 
UBC-Cre-ERT2 mice The Jackson Laboratory Stock#007001 
µMT mice The Jackson Laboratory Stock#002288 
C57BL/6 mice The Jackson Laboratory Stock#000664 
B6.SJL mice The Jackson Laboratory Stock#002014 
Rag1-/- mice The Jackson Laboratory Stock#002216 
Oligonucleotides 

























































Mouse Cbl-b sequence-verified cDNA Laboratory of Gu N/A 
Mouse Cbl sequence-verified cDNA Laboratory of Gu N/A 
Mouse Irf4 sequence-verified cDNA Laboratory of Gu N/A 
HA-UB expression vector Dr.Chen N/A 
pCDNA vector Invitrogen Cat#V790-20 
MIGR1-MSCV retro-expression vector Addgene Plasmid#27490 
p3xFlag-CMVTM 7 vector Sigma Cat#E7533 
MSCV IkB-GFP fusion vector Dr.Huang N/A 
Software and Algorithms 
Prism(6.0-7.0) Graphpad  
FlowJo(v9-10) Treeview  
Volocity PerkinElmer  
   






3.8 Material and methods 
3.8.1 Mice 
C57BL/6 mice, B6.SJL mice, µMT mice, Rag1-/- and UBC-Cre-ERT2 mice were from the 
Jackson Laboratory. Cbl-floxed and Cblb-/- mice were described previously[202, 205]. To 
generate CBLdKO-Cg mice, Cbl floxed/floxed (Cblfl/fl) and Cblb-/- mice were crossed to Cg1-Cre 
transgenic mice kindly provided by S. Casola and K. Rajewsky[272]. CblbC373A mice were 
described previously[253]. Cg1-cre Cblf/f Cblb-/- mice were crossed with CblbC373A to obtain 
CBLKO-CgCBLBC373A/+ mice. TO generate inducible CBLdKO-UBC mice, Cbl floxed/floxed (Cblfl/fl) 
and Cblb-/- mice were crossed to UBC-Cre-ERT2 transgenic mice. Animal 
experimentation was done in accordance with the Canadian Council of Animal Care and 
approved by the Institut de Recherches Cliniques de Montreal (IRCM) Animal Care 
Committee. 
3.8.2 Plasmids, cell lines and culture 
cDNA encoding Irf4 was PCR amplified and cloned into plasmid p3xFlag-CMVTM 7 
expression vector. cDNAs encoding Cbl and Cbl-b were separately cloned into pCDNA 
vector. For the construction of IRF4 overexpression vector, cDNA encoding Irf4 was 
cloned into MSCV-MIGR-GFP retroviral vector. IkB-GFP fusion protein retrovirus 
expression vector was kindly provided by Dr. F. Huang. Hemagglutinin (HA)-tagged 
ubiquitin vector was a gift from Dr. R. Chen. To prepare retrovirus, Phoenix cells were 





µg) by Calcium precipitation, according to previous publication[281]. For 40LB culture, 
naïve WT and CBLdKO-Mb1 cells were purified from WT (C57BL-6 or C57BL/6 Mb1-Cre tg) 
and CBLdKO-Mb1) mice by a magnetic column (StemCell Technologies), respectively. GC B 
cells were purified by FACS sorting. Purified B cells were seeded onto irradiated (900 
RAD) 40LB cells described previously. B cells were cultured at 37oC for five days, 
trypsinized and replated onto a fresh 40LB plate for two more days before being 
subjected to FACS analysis.  
3.8.3 Immunization and GC B cell purification 
To test T-dependent antibody responses and germinal center reaction, 6 to 10 week-old 
mice were immunized with either 109 sheep red blood cells (SRBCs) (Innovative 
Research) in PBS or NP36-KLH (BioSources) precipitated in alum adjuvant (Imject Alum, 
ThemoScientific) by i.p. injection. Mice were analyzed at different days after 
immunization. To examine the expression of CBLs in GC B cells, SRBC immunized 
mice were sacrificed at day 8 and B cells were enriched by a magnetic column, stained 
with anti-B220, CD138, GL7, Fas, CXCR4 and CD86. GC (B220+ GL7hi Fashi) B cells were 
then purified by FACS sorting on a FACS Aria or Moflo. To obtain a large quantity of 
GC B cells for in vitro stimulation and culture, mice were sequentially immunized at day 
0 (1x108 SRBCs) and day 5 (1x109 SRBCs) by i.v. injection. Immunized mice were 
sacrificed at day 12, B cells were enriched by a magnetic B cell enrichment column 
(StemCell) and subsequently sorted as B220+ CD138- GL7+ cells. Purity of the isolated 
GC B cells was confirmed by FACS analysis and was shown to be more than 95% pure 





3.8.4 Flow cytometric analysis and cell sorting 
Total splenic cells or splenic B cells were re-suspended in FACS buffer (5%BSA in PBS 
(PH=7.2)) and stained with the corresponding antibodies on ice for 30 min. Cells were 
washed twice with FACS buffer and then subjected to analysis on a BD Fortessa or Cyan 
or to cell sorting on a FACS Aria or Moflo. The following antibodies were used for the 
staining: anti-B220, anti-GL7, anti-CD11c, anti-CD11b, anti-Gr1, anti-F4/80, anti-
NK1.1, anti-IRF4, anti-Igl, anti-TCRb, anti-CD3e, anti-CD86, and anti-CD38 
(eBioscience); anti-Fas, anti-CD138, anti-BCL6, anti-CXCR4, anti-IgG1, anti-IgD (BD 
Pharmingen); NP8-PE (BioSearch). High affinity and total NP-binding B cells and plasma 
cells were stained with NP8-PE, NIP5APC, and NP38-PE (BioSearch), respectively. 
Specificity of NIP5–APC and NP38-PE to NP-specific but not to carrier protein specific 
BCRs was confirmed using GC B cells from OVA or NP16-OVA immunized mice 
(Figure 3.14 D). To analyze nuclear proteins BCL6 and IRF4, total splenic cells were 
first stained for B220, Fas, and GL7, fixed and permeabilized with FOXP3 staining 
buffer according to the manufacturer’s instructions (eBioscience), and then stained with 
anti-BCL6 and IRF4. For cell cycle analysis, mice were injected intravenously with 1 mg 
of BrdU (BD Pharmingen) in DPBS. Cells were then surface stained with corresponding 
antibodies, and BrdU labeled cells were stained using an anti-BrdU kit according to the 
manufacturer’s protocols (BD Pharmingen). To track newly generated PCs in vivo by cell 
surface molecule-labeling and tracking assay, NHS-Biotin (1 mg/mouse) (Sigma) in 
DPBS was injected intravenously into NP36-KLH immunized mice at day 12 





molecules on the cell surface of naïve B, GC B and plasma cells were visualized by 
staining with streptavidin-PE-CY7, together with anti-B220, anti-GL7, anti-Fas, and anti-
CD138, and analyzed on a FACS, respectively. 	
3.8.5 qPCR and RNA-Seq analysis 
To study the gene expression profiling, naïve B cells and GC (B220+CD138-GL7+Fas+) B 
cells from wildtype and CBLdKO-Cg mice were purified by FACS sorting. Total RNAs from 
sorted cells (pooled from three mice) was extracted using an RNEasy Mini Kit (Qiagen), 
and reversely transcribed into cDNA using a Reverse-Transcription kit (Invitrogen) 
according to manufacturer’s instructions, respectively.  
 
RNA-seq was performed using the Illumina TruSeq Stranded mRNA Kit according to 
manufacturer’s instructions on an Illumina HiSeq 2000 sequencer. Read quality was 
confirmed using FastQC v0.10.1. Read alignment was performed using TopHat v2.0.10 
on the mouse GRCm38/mm10 genome. Differential expression analysis was performed 
with DESeq2 from the raw alignment counts calculated with featureCounts. 
Differentially expressed genes were defined as genes with a logFC(counts)|>2 and counts 
> 500 in both experiments. Shown are log2 (counts) expression values of 982 
downregulated and 51 upregulated genes in CBLdKO-Cg than in WT GC B cells. 
A SYBR Green PCR mix (Thermo Scientific) and gene-specific primers were used for 
quantitative RT-PCR analysis (20-50 ng cDNA per reaction). All reactions were done in 





analyzed by the change-in-threshold (2-ΔΔCT) method, with b-Actin or GAPDH as 
‘housekeeping’ reference genes, respectively. 
3.8.6 Immunofluorescence 
Spleens were embedded in optimum cutting temperature compound (Sakura) and flash-
frozen in liquid nitrogen. Tissue sections were cut on Cryotome (Leica), fixed in ice-cold 
acetone (Sigma), blocked with PBS+5%BSA for 1 hour at 25°C, and stained with anti-
CBL (Santa Cruz), anti-CBL-B (Santa Cruz), anti-CD35 (BD Pharmingen), anti-B220 
(BD Pharmingen), and/or PNA (VectorLab), in different combination. The following 
secondary antibodies were used to detect primary antibodies: anti-Rabbit Alexa-568 
(Invitrogen), Streptavidin Alexa-488 (Invitrogen), Streptavidin Alex-633 (Invitrogen). 
Images were acquired on a Zeiss LSM700 or 710 confocal microscope. 
For intracellular staining of IRF4, GC B cell or stimulated GC B cells were purified by 
FACS sorting. Cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100, 
blocked with PBS+5% BSA, and stained with anti-IRF4 (Santa Cruz), followed by anti-
Goat Alexa 568 secondary antibody. Cell nucleus was counter stained with DAPI. Images 
were acquired on a Zeiss LSM710 confocal. 
3.8.7 Ig VH 186.2 gene isolation and DNA sequencing 
GC (B220+, Fas+, GL7+, Igl+) B cells were isolated by FACS from three NP36-KLH 
immunized WT and CBLdKO-Cg mice, respectively, at day 12 after immunization. Genomic 
DNA was extracted from the sorted cells using a QuickExtractTm DNA Extraction Solution 





DNA by PCR using specific primers for the 5’ end of VH186.2 gene and 3’ end of JH2 
gene according to a previous protocol. PCR products were gel extracted and cloned into a 
TOPO vector (Invitrogen). High quality traces were analyzed using MacVector for base 
pair mismatches and deletions as compared to the germline VH186.2 gene sequence. Only 
mismatches mutations in the productive VH186.2-JH2 joints were counted as mutations. Ig 
VH sequences were analyzed using the IMGT/V-QUEST system to identify the W33L 
mutation. Primers used were: VH 186.2: 5’-AGCTGTATCATGCTCTTCTTGGCA -3’; 
JH2: 5’-AGATGGAGGCCAGTG AGGGAC -3’. 
3.8.8 Enzyme-linked immunospot (ELISPOT) assay and enzyme-linked 
immunosorbent assay (ELISA) 
Total splenic or bone marrow cells were cultured at 37°C in antigen pre-coated 96-well 
Multiscreen-HA filter plates (Millipore) overnight. Spots of antibody secreting cells were 
stained with rabbit anti-mouse IgM or IgG1 antibodies conjugated to horseradish 
peroxidase (Invitrogen), and then developed by addition of AEC substrate (BD 
Pharmingen). Plates were washed extensively and spots were counted on a dissect 
microscopy. The antigens used for plate coating were NP4-OVA and NP30-OVA, 
respectively. Anti-NP ELISAs were performed as described previously[234].  
3.8.9 Immunoprecipitation and Immunoblot analysis 
Cells were lysed in TNE buffer (50mM Trise; 140mM NaCl; 5mM EDTA; 0.5% SDS), 
and immunoblotting was performed following standard procedures. For 





overnight at 4°C with the appropriate antibodies (1µg), followed by precipitate the 
protein-antibody complexes by incubating with protein G agarose (Invitrogen) for 
another 1 hour at 4°C. Immunoprecipitates were washed four times with TNE buffer, 
boiled in 40 µl loading buffer and immunoblotted to a PVDF membrane for Western blot 
analysis. The following antibodies were used for biochemical study: anti-IgM F(ab)2 
(BioSource); anti-CD40 [89]; anti-CBL (SantaCruz); anti-IRF4 (SantaCruz); anti-Lamin 
B (SantaCruz); anti-BLIMP1 (SantaCruz); anti-HA (SantaCruz); anti-CBL-B (Cell 
signaling); anti-b Actin (abcam); anti-Flag (Sigma). Horseradish-peroxidase-conjugated 
goat anti-rabbit, goat anti-mouse or donkey anti-goat antibody was used as a secondary 
antibody, respectively. Membranes were developed with an enhanced chemiluminescence 
detection system (GE Healthcare). 
A Nuclear extraction kit was used to fractionate nuclear and cytoplasmic proteins 
according to manufacturer’s instructions (Active motif).  
3.8.10 Generation of bone marrow chimeric mice 
To generated IRF4 over-expression or IkB-GFP expressing bone marrow chimeric mice, 
retroviral stocks were prepared by transfection of Phoenix cells with MSCV-MIGR1 
(empty vector), MSCV-IRF4 or MSCV-IkB-GFP retroviral vector together with the 
packaging vector pCL-Eco by the standard calcium transfection. Viral supernatants were 
collected 48 h and 72 h after the transfection, respectively. To obtain bone marrow stem 
cells, donor mice were treated with 5-FU (5 mg/mouse, i.p.). Four days later, bone 





After two-rounds retroviral spin-infections, bone marrow cells were adaptively 
transferred into lethally irradiated (10 Gy) Rag1-/- recipient mice. Six weeks later, mice 
were subjected to different immunization regimens.  
To generate CBLdKO-UBC chimeric mice, 1.5x107 splenic B cells from either ER-Cre tg 
(control) or CBLfl/fl CBL-B-/- ER-Cre tg (CBLdKO-UBC) mice were transferred into µMT 
mice by i. v. injection. Chimeric mice were immunized i.p. with NP-KLH in Alumjet 
adjuvant the next day (day 0), and given daily tamoxifen (200µg/g body weight) from 
day 7-10 by oral administration. Mice were sacrificed at day 12, and splenic cells were 
subjected for FACS analysis. High affinity NP (NIP5-binding) GC B cells and PCs were 
identified by cell surface and intracellularly staining, respectively, using NIP5-APC in 
combination with surface markers for GC B cells (B220+ GL7hi Fashi) or PCs (B220-/lo 
CD138+Lin-). 
3.8.11  Cell division and differentiation assay  
Purified B cells were labeled with CellTrace fluorescent according to manufacturer’s 
instructions. Cells were cultured on 40LB feeder for five days and then labeled with 
CellTrace fluorescent according to manufacturer’s instructions. Labeled cells were plated 
on a fresh 40LB plate and cultured for two more days. Cultured B cells were harvested 
and cell proliferation was analyzed on a FACS. To examine culture B cell differentiation 
to PCs, cells were stained with B220, CD138, and IRF4. IRF4 and CD138 positive cells 





3.8.12  Statistics Analysis 
Statistical analyses were performed with a two-tailed, unpaired Student’s t-test or Mann-
Whitney test with the assumption of equal sample variance, with GraphPad Prism V7 
software. A P value <0.05 was considered statistically significant. 
 
3.9 Figures and Figure Legends 
	
Figure 3.1 Differential Expression of CBL and CBL-B in GC DZ and LZ B Cells 
 (A) qPCR analysis of Cbl and Cbl-b expression in WT naïve and GC B cells. Results 
were normalized to actin. Expression in naïve B cells was arbitrarily defined as 1. n=3. 
(B) Western blot analysis of CBL and CBL-B expression in WT naïve and GC B cells. 





and the LZ were stained by PNA and anti-CD35, respectively. CBL and CBL-B were 
visualized in red (Scale bar, 35µm). (D) Western blot analysis of CBL and CBL-B 
expression in DZ and LZ GC B cells. DZ and LZ GC B cells were sorted by FACS as 
B220+GL7hiFashiCXCR4hiCD86lo and B220+GL7hiFashiCXCR4loCD86hi B cells, respectively. 
n=2.* p<0.05. 
 
Figure 3.2 Analyses of CBL and CBL-B expression in GC subsets 
 (A) Soring strategy of GC and none-GC B cells from SRBC immunized mice (day 8) for 
western blot analysis. (B) Western blot analysis of CBL and CBL-B expression in in vitro 
activated B cells, including non-stimulated, anti-IgM F(ab)2, anti-CD40 and anti-CD40 
plus anti-IgM F(ab)2 stimulated cells for 24 hrs. Shown are representative experiment out 
of two. (C) Sorting strategy of DZ and LZ GC B cells from SRBC immunized mice (day 
8) for western blot or qPCR analyses. (D) qPCR analysis of Cbl and Cbl-b expression in 
WT DZ and LZ GC B cells. Results were normalized to Actin. Expression in DZ GC B 
cells was arbitrarily defined as 1. Data are mean ± SEM of two independent experiments. 






Figure 3.3 B cell compartments in CBLdKO-Cg mice, influence of mutant alleles Cbl-/-, 





 (A) Western blot analysis of CBL and CBL-B deletion in GC B cells. WT and CBLdKO-Cg 
mice were immunized with SRBC. Splenic GC B cells were isolated by FACS as 
B220+GL7hi Fashi cells. (B) Immunofluorescent staining of CBL and CBL-B deletion in 
GC B cells. Spleen sections from SRBC immunized mice (day 12) are stained with PNA, 
CBL or CBL-B, and B220. Scale bar represents 33µm. (C, D) Flow cytometric analysis 
of spleen B cell subsets in WT and CBLdKO-Cg mice. Shown is FACS analysis (top panel) 
and statistics (bottom panel) of anti-CD21 vs CD23 staining of marginal zone and 
follicular B cells (C) or anti-IgM vs IgD staining of follicular B cells, respectively. N.S.: 
not significant. (E) Cell cycle analysis of WT and CBLdKO-Cg GC B cells. WT and CBLdKO-Cg 
mice were immunized with NP-KLH for 12 days and given BrdU for 1 hour by i. v. 
injection. Shown are the contour maps (left) and statistics of BrdU vs 7AAD staining of 
the gated B220+ Fashi GL7hi GC B cells. Data reflect mean ± SEM of three independent 
experiments. N.S.: not significant. (F) Influence of IgCg-Cre tg on GC development. 
Shown are Fas vs GL7 staining of total GC B cells (top panel) and high affinity GC B 
cells (bottom panel) in WT, IgC g-Cre and CBLdKO-Cg mice at day 11 after NP-KLH 
immunization. Statistic of absolute number are shown at the right. Data reflect mean ± 
SEM of two independent experiments with four mice per group. **: p<0.001; ***: 
p<0.0001. (unpaired student t test). (G) FACS analysis of total GC B cells (top panel) 
and high affinity IgG1+ GC B cells (bottom panel) in WT, Cbl-/-, Cbl-b-/- and CBLdKO-Cg mice 
at day 11 after NP-KLH immunization. Statistic of absolute cell numbers are shown at 
the right. Data reflect mean ± SEM of three independent experiments with five mice per 







Figure 3.4 Impaired antibody affinity maturation in CBLdKO-Cg mice 
 (A) The kinetics of serum total anti-NP30 antibody titers of IgM and IgG1 isotypes. (B) 
The kinetics of serum high affinity anti-NP4 antibody titers of IgM and IgG1 isotypes. (C) 
Antibody affinity maturation of IgG1 antibody. The maturation index is defined by the 
ratios of anti-NP4 vs anti-NP30 antibody titers. n=5. (D) ELISPOT analysis of splenic 
ASCs against NP30 or NP4-BSA antigen at day 14 after immunization. n=5. (E) The 
developmental kinetics of GC B cells in WT and CBLdKO-Cg mice after NP-KLH 
immunization. Shown is contour maps (top panel) of GC B cells at day 7 and the 
statistics (bottom bars) of GC B cells postimmunization. n=4. (F) Analysis of apoptotic 
GC B cells. Apoptotic GC B cells were visualized by anti-active form Casp staining. 
Shown are contour plots (top panel) and statistical (bottom bars) of Casp+ GC B cells 
among total B220+GL7+Fashi B cells. n=4. (G) Defective development of high affinity 
BCR expressing GC B cells (Gated as: Lin-B220+NP8-PE+CD38+IgG1+) in CBLdKO-Cg mice. 
Shown are flow cytometric analysis (left) and statistics of high affinity (NP8-binding) 






Figure 3.5 GC B cell purification gates and VH186.2 gene mutation analyses 
 (A) Soring strategy. Igl1+ GC B cells were first gated as B220+Fashi GL7hi from NP-KLH 
immunized mice (day14).  DNAs isolated from purified cells were PCR amplified for 
V186.2 genes and subjected for DNA sequencing. (B) Soring strategy of NP specific GC 
B cells. B220+ Fashi GL7hi NP38-PE+ GC B cells were purified from NP-KLH immunized 
mice (day14) for V186.2 gene sequencing. (C) Frequency of VH186.2 genes carrying 
W33L mutation in NP-specific GC B cells. Shown is pie presentation of VH186.2 genes 
with W33L mutation from NP-specific GC B cells from WT and CBLdKO-Mb1 mice. Statistics 
was conducted using Fisher’s exact test. *: p<0.05. Data represent 32 and 25 VH186.2 







Figure 3.6 Impaired selection of high affinity BCRs but not SHM by the CBLdKO-Cg 
mutation 
 (A) Pie presentation of the frequency of SHM in VH186.2 genes. VH186.2 genes with 
different numbers of SHM are shown in different degrees of shade. The total numbers of 
VH genes analyzed are indicated in the centers of the pies. (B) Frequency of replacement 
vs silent mutations in VH186.2 genes. Each dot represents data from one individual 
VH186.2 gene. (C) Representation of VH186.2 clones with W33L mutation. The number of 
W33L clones among VH186.2 sequences is shown in the center of pie chart and was 
compared using Fisher’s exact test. **p<0.001. Data are from pooled five mice each 
group. (D) Ratios of replacement vs silent (R/S) mutations in VH186.2 coding genes. (E) 
Development of NIP5 and NP38-binding GC B cells at different time points of GC reaction. 
Shown (top panel) are flow cytometric analyses of splenic NP38 or NIP5-binding cells in 
gated 220+ GL7hi Fashi GC B cells at day 8 and day 14 post NP-KLH immunized. Bottom 
left and middle: statistics of NP38 and NIP5-binding GC B cells at day 8 and 14 after 
immunization, respectively. Bottom right: Percentages of high affinity NP (NIP5-binding) 
GC B cells among total NP specific (NP38-binding) GC B cells at day 8 and day 14 after 
immunization. Data are mean± SEM (E) and are representative of two independent 







Figure 3.7 Influence of CBL ablation on the Development and differentiation of GC 
B cell subsets 
 (A) Immunofluorescent staining of splenic GC. WT and CBLdKO-Cg mice were immunized 
with NP36-KLH. Shown are the spleen cross sections of immunized mice (day 12) stained 
with anti-CD35 (red), PNA, and anti-B220. Scale bar represents 33 µm. (B) Flow 
cytometric analyses (left) and statistics [254] of GC DZ and LZ B cells. Total splenic 
cells from the immunized WT and CBLdKO-Cg mice were stained with anti-B220, GL7, Fas, 
CXCR4, and CD86. DZ and LZ B cells in the contour plots are gated CXCR4hi CD86lo and 
CXCR4lo CD86hi cells, respectively. Data reflect mean ± SEM of two independent 
experiments with four mice per group. N.S.: not significant. (C) FACS analysis of PC 
precursors (characterized as: B220+Fashi GL7hi CD138+ or B220+FashiGL7hiBcl6-/lo) in WT and 
CBLdKO-Cg GC B cells. Shown are dot plots (left) and statistics analysis. Data reflect mean ± 
SEM of two independent experiments with at least four mice per group. *: p<0.05; **: 






Figure 3.8 Analysis of B cell proliferation and PC genesis 
 (A) BrdU labeling of GC B. WT and CBLdKO-Cg mice were immunized for 12 days, and 
injected with BrdU i. v. for twenty-four hours. Proliferation of GC B cells was evaluated 
by BrdU+ staining. Shown are flow cytometric analysis (left) and statistics of BrdU+ 
(B220+ GL7hi Fashi) GC B cells. Data reflect mean ± SEM of two independent experiments 
with eight mice per group. (B) Analysis of newly generated PCs in un-immunized WT 
and CBLdKO-Cg mice 24hrs post BrdU i.v. injection. Newly generated PCs was evaluated by 
BrdU+ staining. Shown are flow cytometric analysis (left) and statistics of BrdU+ (Linage-
CD138+) PCs. Data reflect mean ± SEM of two independent experiments with four mice 
per group. (C) Enhanced PCs (Linage-IgD-CD138+) differentiation in CBLdKO-UBC mice. 





days. Tamoxifan was then give daily from day 7-10 to delete CBL. Mice were analyzed 
on day 12 after immunization.  Shown are contour map (left) and statistics analysis of 
total CD138+ PCs and plasma blasts. Data reflect mean ± SEM of two independent 
experiments with five mice per group. ***: p<0.0001 (unpaired student’s t test). (D) 
Enhanced development of high affinity antigen specific PCs (Linage-IgD-CD138+NIP5-
APC+) in CBLdKO-UBC mice. Mice were the same as in (C). Shown are contour map (left) and 
statistics analysis of high affinity NP antibody (NIP5-binding) producing PCs. Data reflect 
mean ± SEM of two independent experiments with at least five mice per group. *: 
p<0.05(unpaired student’s t test). (E) In vitro PC genesis stimulated by soluble anti-
CD40 or anti-IgM. Purified B cells were cultured and stimulated with either soluble anti-
CD40 or anti-IgM F(ab)2 for 3 days. Plasma blast-like cells generated in the culture were 
stained with anti-B220 and CD138 and then analyzed on a FACS. Shown is CD138 vs 
B220 staining of the cultured cells. The percentages of plasma blast-like (B220+CD138+) 
cells are indicated in each plot. (F) Intracellular Ig, BCL6, and IRF4 staining of in vitro 
generated PCs and GC (iGC) B cells. CBLdKO-Mb1 B cells were cultured 40LB feeder cells for 
7 days to generate iGC (CD138- B220+) and PCs (CD138+ B220+/-). Cells were either 
stained cell surface staining (Left column in left panel) or cell surface staining followed 
by intracellular staining for IgE+G1 (Right column in left panel), IRF4 (left column in 
right panel), and BCL6 (right column in right panel). The experiment has been performed 
two times. (G) B cell proliferation upon anti-CD40 and BCR stimulation. Purified B cells 
were labeled with CellTrace and cultured in the presence of soluble anti-CD40 or anti-
IgM F(ab)2. Cell proliferation was measured at days 3 and 4 by FACS based on CellTrace 
dilution. Shown are histograms of CellTrace fluorescence intensity of WT (grey shadow) 
and CBLdKO-Mb1 (red line) B cells. (H) Cell division dependent PC genesis. B cells were 
labeled with CellTrace and cultured on 40LB feeder cells as described in Figure 9F. 
Shown are histograms of PCs/plasma blasts (CD138+ cells) generated in each cell division 









Figure 3.9 Premature termination of GC B cell fate and expedited PC 
differentiation in the absence of CBLs 
 (A) In vivo newly generated PCs identified by BrdU labeling assay. Shown are flow 
cytometric (top panel) and statistics analyse (bottom bars) of splenic newly generated 
PCs after 24 hours BrdU labeling, identified as Lin-BrdU+CD138+ cells. n=10. (B) The in 
vivo rates of PC genesis presented as the total numbers of newly generated PCs either per 
spleen (left) or per hour in the spleen. n = 7. (C) Flow cytometric analyses of total (top 
panel), and NIP5-binding (bottom panel) GC B cells at day 12 without (left) or with ER-
Cre mediated CBL ablation. Statistics are shown as bars. (D) In vitro PC differentiation 
of WT and CBLdKO-Mb1 B cells in 40LB feeder cell culture. Shown are flow cytometric (left) 
and statistical analyse of (CD138+B220hi/lo) PCs/plasmablasts-like cells. n=5. (E) 
Comparison of In vitro differentiation of freshly isolated WT and CBLdKO-Cg GC B cells. 
Shown are flow cytometric (left) and statistical analyse of PCs (B220-
CD138hi)/plasmablast-like (B220+CD138hi) cells generated in the culture. n=4. (F) Cell 
division dependent B-cell differentiation to PCs in 40LB feeder culture system. Shown 
are dot plots (top left) and histogram analyses (top right) of IRF4 expression in cell 
divisions 1st, 2nd, 3rd, and 4th WT or CBLdKO-Mb1 B cells identified by Cell Trace dilution. 
Bottom: Statistical analysis of PC genesis in each cell division. n=4.  * p<0.05; ** 






Figure 3.10 Gene expression profiles of WT vs CBLdKO-Cg GC B cells; Comparison of 
CD40 and BCR induced signaling in WT and CBLdKO-Cg GC B cells 
 (A) RNA-seq analysis of mRNA expression in WT and CBLdKO-Cg GC B cells. WT and 
CBLdKO-Cg mice were immunized with SRBC. mRNAs were extracted from GC 
(B220+GL7hiFashi) B cells isolated by FACS sorting at day 12 after immunization. Shown 
are heat maps of genes that are down (left) and up regulated in CBLdKO-Cg B cells compared 
to WT controls, respectively. (B) Comparison of the mRNA expression profiles of the 
genes related to GC B and PC identities. WT and CBLdKO-Cg mice were immunized with 
NP36-KLH. At day 12, total splenic B cells were stimulated with either anti-CD40 or anti-
IgM F(ab)2 for 5 min. Cells were first stained with anti-B220, GL7, and Fas, fixed and 
permeablized, and then intracellularly stained with antibodies against active forms of 
Akt, S6 kinase, and Erk1/2, respectively. For canonic NF-kB activity, a fusion gene 
encoding IkB and EGFP was introduced into WT and CBLdKO-Cg BM stem cells by retroviral 
vector. Transfected BM stem cells were transferred into lethally irradiated Rag1-/- mice to 
generate BM chimeric mice. Splenic GC B cells were stimulated with anti-CD40 or BCR, 
and NF-kB activity in GC B cells was measured by FACS based on IkB-GFP expression. 
(C) Phospho-flow analyses of Akt, S6 kinase, and Erk activation in GC B cells after anti-
CD40 or anti-IgM stimulation. (D) Flow cytometric analysis of IkB degradation in GC B 
cells stimulated with anti-CD40 or BCR for 5mins. The steady state IkB-GFP expression 
was set as control. IkB-GFP degradation rate(100%)= (percentage of steady state GFP+- 






Figure 3.11 Post-transcriptional regulation of GC differentiation program by CBLs 
 (A) qPCR analysis of GC B cell and PC identity genes in WT and CBLdKO-Cg GC B cells. 
Data were from FACS purified splenic B220+GL7+Fas+ GC B cells of pooled from 3x WT 
and CBLdKO-Cg mice at day 14 after SRBC immunization. (B) Comparison of the expression 
of protein synthesis and secretion related genes in WT and CBLdKO-Cg GC B cells. (C-E) 
Western blot and flow cytometric analyses of IRF4 expression in WT and CBLdKO-Cg GC B 
cells. (C) Western blot analysis of IRF4 in WT and CBLdKO-Cg GC B cells. n=4. (D and E) 
Flow cytometric analyses of IRF4 vs BCL6 expression in GC B cells without (D) or with 
(E) anti-CD40 and BCR stimulation. Shown are contour maps (left) and statistics of 
IRF4hiBCL6lo and BCL6hi cells among total gated GL7hiFashi GC B cells. n=6. (F) Western 
blot analysis of IRF4 expression in WT and CBLdKO-Cg GC B cells with or without anti-






Figure 3.12 Regulation of nuclear IRF4 ubiquitination and expression by CBLs 
 (A and B) Confocal microscopic analysis of cytosolic and nuclear IRF4 in WT and 
CBLdKO-Cg GC B cells without (A) or with (B) anti-CD40 and BCR stimulation. The 
statistical analyses show the percentages of nucleus vs total IRF4. Each dot represents 
one cell. (C) Western blot analysis of nuclear vs cytosolic IRF4 in WT and CBLdKO-Cg GC B 
cells before and after anti-CD40 and BCR stimulation. n=2. (D) Asymmetric expression 
of CBL and CBL-B vs IRF4 proteins in WT GC B cells before and after CD40 and BCR 
stimulation. n=3. (E) Co-immunoprecipitation and Western blot analysis of CBL and 
CBL-B association with Flag tagged IRF4 (IRF4-Flag). n=2. (F) IRF4 ubiquitination by 
CBL or CBL-B. Shown is Western blot analysis of ubiquitinated IRF4-Flag 
immunoprecipitated from 239T cells cotransfected with either CBL or CBL-B. n=3. (G) 
Association of IRF4 with CBL or CBL-B in freshly isolated GC B cells. n=2. (H) 







Figure 3.13 Impaired development of high affinity GC B cells in CBLKO-CgCBL-B-/C373A or 
IRF4-MSCV BM chimeric mice 
 (A-C) Inactivation of the ubiquitin ligase function of CBLs in GC B cells recapitulates 
GC phenotypes found in CBLdKO-Cg mice (day 12 after NP-KLH immunization). (A) The dot 
plots (left) and statistical analyses of Fas+GL7+ GC B cells among total splenic B220+ 
cells. (B) The flow cytometric (left) and statistical analyses of the high affinity (NP8-
binding) GC B cells among total B220+ cells. (C) The statistics of splenic total (anti-NP30-
binding antibody) and high affinity (NP4–binding antibody) secreting plasma cells 
(ASCs). n=5. (D-F) Ectopic expression of IRF4 abolishes high affinity antibody 
producing GC B cell development in MSCV-IRF4 BM chimeric mice after NP-KLH 
immunization (day 12). WT BM stem cells were transduced with either MIGR-MSCV-
GFP (empty) or MSCV-GFP-IRF4 retroviral vector and used to generate BM chimeras. 
(D) The dot plots (left) and statistical analyse of Fas vs GL7 staining of gated B220+ IgD- 
splenic GC B cells. (E) The contour plot (left) and statistical analyses of high affinity 
(NP8-binding) IgG1 GC B cells in BM chimeras with (GFP+) without (GFP-) retrovirus 
infection. (F) The histogram analysis of GFP+B220-CD138+ splenic PCs among total GFP+ 
splenocytes in empty MSCV and MSCV-IRF4 infected BM chimeras. n=5-6. * p<0.05; 






Figure 3.14 CBLKO-CgCBLB-/C373A GC development and IRF4 ectopic expression 
 (A) FACS analysis of total GC B cells (top panel) and high affinity IgG1+ GC B cells 
(bottom panel) in WT, CBLKO-CgCBL-B-/+ and CBLKO-CgCBL-B-/C373A mice at day 12 after NP-
KLH immunization. Statistics of absolute cell number are shown at the right. Data reflect 
mean ± SEM of four mice per group. *: p<0.05; **: p<0.001; ***: p<0.0001. (unpaired 
student t test) (B) Western blot analysis of IRF4 expression in IRF4-MSCV infected B 
cells (GFP+B220+). WT B cells (GFP-B220+) and MSCV-IRF4 (GFP+B220+) B cells were 
purified by FACS sorting. Shown are one representative experiment out of total two. (C) 
Purity analysis of GC B cells. GC B cells were first enriched by a B cell enrichment 
Magnetic column and then purified by FACS sorting as B220+CD138-GL7+ GC B cells 
and B220+CD138-GL7- non-GC B cells. Purity of both GC and non-GC B cells were 
evaluated based on GL7 vs Fas staining. Shown is FACS plots of Fas vs GL7 staining of 
one representative experiment. (D) Analysis of testing NP38-PE and NIP5-APC 
specificity. GC B cells were from OVA or NP20-OVA immunized mice and stained with 
NIP5-APC or NP38-PE together with anti-B220, Fas, and GL7. Shown are NIP5 or NP38 
binding cells among gated B220+ Fashi GL7hi cells. Experiment represents data from two 


































CBL and CBLB are E3 ubiquitin ligases that are expressed in haematopoietic cells. 
Multiple studies have shown that CBL proteins act as negative regulators for both TCR- 
and BCR-mediated signalling pathways, in which CBL and CBL-B exhibit a redundant 
regulatory role. In the second chapter, I found that CBLdKO-Mb1 mice displayed a 
significant reduction of T-independent and T-dependent immune responses. The impaired 
T-independent antibody response was mainly due to the lack of MZ B cells, which is the 
main cell population that may respond to T-independent antigens. Additionally, the CBL 
double deficient naïve FO B cells failed to differentiate into GC B cells upon either 
soluble or particle T-dependent antigen immunization. My study demonstrated that CBL 
proteins are required for naïve B cell antigen presentation to cognate CD4+ T cells. CBL 
proteins specifically target BCR-associated proteins Iga and Igb for ubiquitination and 
then promote the degradation of BCR-antigen complexes upon BCR stimulation. In the 
absence of CBL proteins, the internalization and sorting of BCR-antigen complexes to 
lysosomes are blocked. As the consequence, the mutant B cells cannot form a cognate 
interaction with pre-Tfh cells due to the lack of antigenic-peptide-loaded MHC, thus 
resulting in a deficient GC reaction. Blocking the ubiquitin ligase function of CBL 
through mutating the RING finger domain or blocking the ubiquitination of Iga through 
point mutagenesis could recapitulate the deficiency of the GC reaction as CBLdKO-Mb1 
mice. Thus, we provided evidence that the CBL-mediated ubiquitin ligase function, not 





Previous studies in our laboratory showed that the ablation of Cbl and Cblb in mature B 
cells results in the development of SLE-like autoimmune disease. This finding was 
evidenced of the high level of serum autoantibodies against double-stranded DNA and 
nuclear antigen, as well as the high level of IgG1 antibody deposited in the kidney. This 
result indicated that CBL proteins control the B cell-intrinsic checkpoint for tolerance. 
Surprisingly, CBLdKO-Mb1 mice did not develop SLE-like autoimmune disease and 
showed a prolonged lifespan compared to the mice from the previous study, in which 
CBL was deleted by using a CD19-Cre allele [215]. The reason for this discrepancy 
might reflect the fact that the ablation of CBL and CBL-B in B cells at different 
developmental time points could lead to two completely different outcomes. CD19-Cre 
allele drives Cre recombinase expression in approximately 30-40% of bone marrow 
immature B cells and in 80% of mature B cells [282]. The deletion of CBL proteins at the 
mature splenic B cell stage could lead to the generation of B cells with auto-reactive BCR 
since the majority of the deletions occurred after the negative selection. In contrast, the 
Mb1-driven Cre showed more than 90% of deletion in bone marrow immature cells. 
Although the ablation of CBL proteins could disrupt B cell tolerance, the majority of 
CBL-deficient immature B cells with auto-reactive BCRs would be eliminated by 
negative selection during B cell development. This means only the cells with normal 
BCRs can further give rise to splenic mature B cells. Additionally, different genetic 
backgrounds may also contribute to this discrepancy. CBLdKO-Mb1 mice have a C57BL/6 





and 129 genetic background, which had been shown to exhibit a relatively higher 
susceptibility to autoimmune diseases [283]. 
It has been shown that antigen-experienced FO B cells in lymph nodes can interact with 
cognate CD4+ T cells through MHCII/peptide, which promotes the further interaction 
between co-stimulatory molecules such as CD40-CD40L, SLAM-SLAM and ICOS-
ICOSL. Although it is generally believed that this T-B cognate interaction is critical for 
Tfh and GC B cell development, the consequences of B-cell-dependent CD4+ T cell 
activation are still controversial, as B cells have been shown to be poor CD4+ T cell 
activators compared to professional APCs and may tolerate CD4+ T cells [284, 285]. 
However, other studies and our study showed that B cells can activate and promote the 
proliferation of CD4+ T cells in vitro[286]. The optimal Tfh cell differentiation requires 
antigen presentation by both DCs and B cells. Consistent with our results, Terri M. 
Laufer’s group showed that the antigen presentation by DCs promotes the upregulation of 
Bcl6 in activated CD4+ T cells and promotes T cell differentiation into pre-Tfh cells. 
However, without cognate interaction with antigen-specific B cells, these Bcl6+ T cells 
could not further upregulate CXCR5, PD-1 and GL7 to differentiate into distinctively Tfh 
cells [287]. These results thus support that the antigen presentation from activated B cells 
is necessary for pre-Tfh cells to complete their differentiation. It should be noted that 
although DCs cannot promote active CD4+ T cells to fully differentiate into Tfh cells, 
administration of processed peptides to MHC II B-cell-specific knockout mice can 
restore the Tfh development and GC reaction [288], indicating that the development of 





signalling. However, at the T-B border and in the GC, B cells with antigen-specific BCRs 
have a greater advantage of acquiring antigens from FDCs than from other APCs, thus 
making them a prior choice for antigen presentation to T cells, compared with DCs. This 
model was further supported by our results on the physiological level, since the CBLdKO-
Mb1 mutation does not affect the MHCII expression on B cells. Consistently, the 
administration of processed OVA323-339 peptides to our CBLdKO-Mb1 mice partially 
restored both Tfh and GC B cell development, which further supported the notion that 
CBL proteins regulate the T-B cognate interaction through an antigen-presentation-
dependent mechanism. Since the administration of processed antigenic peptides can only 
partially rescue GC deficiency, this result also indicated that the CBL proteins may also 
play important roles in the maintenance and differentiation of GC B cells. However, the 
possibility that the excessive OVA peptides directly bind to MHCII on other APCs 
should be considered, which may overcompensate for the B-cell-mediated Tfh 
differentiation in CBLdKO-Mb1 mice. To exclude this possibility, we will use a transgenic 
mouse model in which MHCII is restrictively expressed on DCs and B cells for rescue 
experiments in a future study.  
Interestingly, we found that CBL dko mice possessed a relatively normal number of GC 
B cells at day 8 post-immunization. The mutant GC B cells proliferated normally in vivo, 
suggesting that CBL proteins are not required for BCR-mediated antigen presentation 
within developing GC B cells. Indeed, we also found that Cbls-deficient iGC B cells 
showed a comparable capacity to promote the proliferation of the cognate OT-II CD4+ T 





antigen complex degradation was apparently normal in Cbls-deficient iGC B cells 
(Figure 4.1B). These results thus raise the possibility that other ubiquitin ligases are 
involved in BCR-mediated antigen uptake and processing or that the ubiquitination is not 
required for the process in GC B cells. A previous study using a large-scale imaging 
system revealed that naïve and memory B cells gather antigen towards the immune 
synapse centre before internalization, while GC B cells extract antigens through a distinct 
pathway using small peripheral clusters[239]. Consequently, GC B cells exhibit reduced  
	
Figure 4.1 Intact antigen presentation capacity in Cbls-deficient iGC 
 (A). Flow cytometry analysis of iGC antigen presentation to cognate OT-II CD4+ cells 
after mimic antigen treatment. 40LB-induced iGC B cells were incubated with mini 
antigen for 30mins at 37°C. The antigen experienced iGC B cells were co-cultured with 
CFSE labelled OT-II CD4+ cells for 48h and 72h. (B) Quantification of antigen sensor 
degradation in WT and CBLdKO-Mb1 iGC at various time points. (n=3). iGC B cells were 
incubated with antigen-DNA sensor for 30min on ice. Then incubated at 37°C for various 







antigen internalization and degradation rates compared to naïve B cells. In this regard, we 
speculated that CBL proteins are the key regulators for optimal and efficient antigen 
internalization and degradation in naïve but not GC B cells. Optimal antigen 
internalization and processing is critical for the initial activation of naïve B cells. 
Furthermore, whether the ubiquitination of the BCR complexes is involved in this 
process remains to be determined. Upon anti-IgM stimulation, non-GC and naïve B cells 
show dramatically increased BCR signalling. In contrast, GC B cells show defects in the 
early events of BCR signalling, such as defects in the phosphorylation of SYK, BLNK, 
Iga and Igb [276].  Instead, both SH2 domain-containing phosphatase (SHP-1) and SH2 
domain-containing inositol 5 phosphatase (SHIP-1) are hyper-phosphorylated in GC B 
cells. Other studies have shown that the individual BCR is dedicated to either BCR 
signalling or antigen presentation depending on the ITAM-mediated signalling. 
Accordingly, defective phosphorylation of Iga and Igb in GC B cells may suggest that 
the antigen presentation of GC B cells is not dependent on the phosphorylation of Iga 
and Igb. Future studies are needed to further investigate the function of Iga and 
Igb proteins in GC B cells. 
Previous studies have focused on dissecting the function of Iga and Igb proteins in BCR 
signalling. The Iga-Igb dimer is non-covalently associated with membrane Ig through 
polar residues in the transmembrane domain of Ig. It has been shown that the cytoplasmic 
tails of these two proteins contain an ITAM motif that is critical for the recruitment of 
tyrosine kinases Syk and Lyn to activate downstream signalling. By targeting the ITAM 





BCR endocytosis and impaired T-dependent immune responses. This finding indicates 
that the ITAM of these two proteins are critical for the regulation of BCR internalization, 
which negatively affects BCR signalling. Furthermore, these results also indicate that the 
optimal BCR internalization is required for the T-dependent immune response [45, 230]. 
The non-ITAM tyrosine 204 mutation exhibits a unique defect in T-independent B cell 
activation, proliferation and antibody response, while the BCR capping, antigen 
internalization, antigen presentation and T-dependent antibody response remains 
unaffected. In our study, the targeted mutation of three lysine residues (K161R, K167R 
and K217R) on the cytoplasmic tail of Iga displayed normal surface BCR expression and 
similar BCR signalling, except for slightly reduced Ca2+ signalling. Interestingly, the Iga 
mutant mice showed a dramatically reduced GC B cell population upon NP36-KLH 
immunization due to the impaired BCR-mediated antigen presentation process. Our 
results demonstrated the unique cell intrinsic role of Iga ubiquitination in the formation 
of GC B cells (Figure 4.2). However, we cannot rule out the possibility that mutations on 
Iga may affect the kinetics of GC reaction since we just examined the GC formation at 
day 10 post-immunization. To further demonstrate the important role of Iga 
ubiquitination in GC B cell initiation, GC B cell kinetic study will be performed in the 
future study. 
The first two lysine residues (at position 161 and 167) were critical for the development 
of GC B cells, whereas the K217R mutation did not affect the initiation of GC B cells. 
These observations indicated that the ubiquitination of lysine residues 161 and 167, not 





needed to further clarify the potential contribution of other E3 ubiquitin ligases, such as 
ITCH and GRAIL, to the ubiquitination of Iga-mediated GC initiation. Interestingly, 
although GC B cells were unable to be generated in K167R mutant mice, one novel 
CD38hiGL7+Fas- population was presented. We speculated that this novel population was 
the precursor of GC B cells, which accumulated at this stage due to the impaired antigen 
presentation and T-B cognate interaction. This further supports the idea that T cell ‘help’ 
is critical for full GC B cell differentiation (Figure 4.2). However, extensive studies are 
needed for the further characterization of this precursor population. 
	
Figure 4.2 CBL proteins regulate the initiation of GC reaction through B cell 
intrinsic mechanism 
Within B cell follicle, some B cells are activated by T-dependent antigen experienced 
APCs and acquire antigens through BCR-dependent mechanism. Activated B cells 
migrated to T-B border and interact with cognate pre-Tfh cells. The selected B cells and 
pre-Tfh cells migrate back to B cell zone and form GC while the un-selected B cells 
differentiate into short-lived PCs. CBL proteins are critical for T-B cognate interaction 
since CBLs regulate naïve B cell antigen presentation to CD4+ T cells. In naïve B cells, 
CBLs specifically regulate BCR internalization and degradation through targeting BCR-






Finally, although our western blot showed ubiquitination of both Iga and Igb proteins 
upon BCR stimulation, the blockage of Iga ubiquitination alone was sufficient to 
recapitulate the GC deficiency in CBLdKO-Mb1 mice. This result may have two possible 
explanations: first, the ubiquitination of both Iga and Igb is required for optimal antigen 
internalization, degradation and presentation; however, Iga and Igb may act at different 
levels of the same regulatory pathway; second, the ubiquitination of Iga but not Igb is 
required for this biological process. Recently, Marcus Clark’s group showed that Igb 
ubiquitination was required for the sorting of the BCR complex to the MHCII antigen-
presenting compartment. Although the normal T-dependent antibody response against 
NP-CGG was shown in Igb mutant mice, a proper antibody response against an influenza 
viral infection was unable to be mounted [289]. The class-switched antiviral 
neutralization antibody is secreted by PCs, which are mainly derived from GC B cells. 
The impaired antiviral antibody response in Igb mutant mice indicated that the 
ubiquitination of Igb is critical for the GC reaction. Additionally, it has been shown that 
Iga is relatively upregulated in activated B cells and GC B cells with decreased mRNA 
expression, while the Igb protein is dramatically downregulated in GC B cells. This 
finding indicates that Iga and Igb may have different functions in B cell activation. To 
investigate the individual biological function of Iga and Igb ubiquitination, the targeted 





Antigen-specific antibodies are essential for the host defence against infectious viruses 
and microbes. Antibodies against self-antigens, called autoantibodies, are responsible for 
various autoimmune diseases such as SLE, Graves’ disease and rheumatoid arthritis 
(RA). The pathogenesis of RA is dependent on rheumatoid factor (RF)-specific B and T 
cells. Multiple studies have shown that autoantibody-secreting PCs can be generated from 
T-dependent and T-independent immune responses. Thus, B cells are the primary 
therapeutic target in RA. For instance, rituximab can completely deplete CD20+ B cells in 
the peripheral blood, and this effect can last for several months [290-292]. However, anti-
CD20 therapy is not sufficient to treat RA patients with a high number of pre-plasma 
cells before treatment, suggesting that the anti-CD20 therapy cannot eliminate 
plasmablasts. Recent studies have demonstrated that RF-specific B cells are not only 
responsible for the generation of PCs but also act as APCs to stimulate CD4+ T cell 
expansion and differentiation [293, 294]. Furthermore, RF-specific B cells display a 
significantly enhanced antigen-uptake capacity compared to that of professional APCs. 
These B cells take up antigen-Ig immune complexes via the BCR. Takemura and 
colleagues showed that the T-cell response in RA synovitis is dependent on B cells [295]. 
These characteristics propose CBL proteins as a potential therapeutic target for RA 
treatment. Since my study demonstrated the tight regulation of cognate T-B interaction 
by CBL proteins through a B cell antigen-presentation mechanism, it will be necessary to 
screen for compounds to inhibit the CBL E3 ubiquitin ligase function. These inhibitors 
may directly target RF-specific B cells, consequently blocking their antigen presentation 





the T-dependent immune response, the inhibitors can also block the T-independent 
immune response, based on my results. Thus, my study provides some new insights for 
RA treatment. 
High-affinity IgG1 antibody-producing cells are generated through a GC reaction, where 
the GC B cells carrying BCRs with different affinities compete for antigens and Tfh cells 
help B cells in the LZ region to undergo affinity-based selection and maturation. I found 
that the LZ GC B cells selectively displayed enhanced CBL and CBLB expression 
compared to naïve B and DZ GC B cells. This finding suggests that CBL proteins may 
have a critical function in LZ GC B cell affinity selection. Indeed, the ablation of CBL 
proteins specifically in GC B cells selectively blocked the development of GC B cells 
that express high affinity BCRs, while the low-affinity and un-switched antibody 
secreting cells were expanded. I further demonstrated that CBL protein-mediated 
ubiquitin ligase activity was required for this regulatory mechanism since the C373A 
mutation in the RING finger domain of CBL proteins, which inactivates CBL ligase 
activity, was sufficient to recapitulate this phenotype. These findings together provide 
strong support for the conclusion that CBL proteins define a checkpoint in GC LZ B 
cells, which controls antibody affinity-based selection in a ubiquitination-dependent 
manner (Figure 4.3). 
GC B cell proliferation and selection occur in the DZ and LZ, respectively, and are 
tightly controlled by multiple layers of regulations. Previous studies showed that the 
transcription factor FOXO1 is critical for the formation and/or maintenance of the GC 





GC B cells leads to disrupted GC architecture and CSR and reduced proliferation, but 
normal SHM [147, 148, 151]. Consistently, the enforced constitutive activation of PI3K 
completely recapitulated the phenotype. These studies showed the important role of the 
BCR-PI3K-FOXO1-CXCR4/BATF signalling pathway in the regulation of affinity 
maturation and selection. Moreover, another downstream target of PI3K transcription 
factor, c-Myc, was shown to be required for the re-entry of GC B cells from the LZ to the 
DZ for clonal expansion and SHM [84]. These studies demonstrated the essential role of 
BCR affinity in the clonal expansion and selection of GC B cells. In parallel, the function 
of CD40 receptor-mediated NF-kB signalling in GC B cells is required. Specifically, the 
subunit c-REL is required for the maintenance of the GC reaction through upregulating 
the metabolic programme to adapt the enhanced biosynthesis of DNA, protein and lipids 
in these highly proliferative GC B cells [168, 296]. In contrast, another subunit RELA is 
critical for the differentiation of PCs through the upregulation of BLIMP1. In addition, 
two subunits of the NF-kB canonical pathway p50 and p65 can directly bind to the 
promoter region of IRF4 and activate its transcription upon CD40 stimulation [173]. 
Taken together, the current model suggests that BCR signalling is responsible for GC B 
maturation and selection, while CD40 signalling is required for the differentiation of GC 
B cells. However, this model is challenged by a recent study in which the BCR and CD40 
signalling were both shown to be required for the termination of the GC B programme. 
These findings gave rise to the following question: how can GC B cells sense and 
distinguish proliferation and differentiation signals? My study provided new insights on 





without sufficient maturation, mutation and CSR, but not proliferation in vivo and in 
vitro, which suggests that CBL proteins suppress the early onset of the PC differentiation 
programme. Surprisingly, the deficiency of CBLs did not affect BCR-induced mitotic 
signalling and CD40-induced canonical NF-kB pathways. Consistently, the mRNA level 
of IRF4 was comparable between WT and CBLdKO-Cg GC B cells, but IRF4 proteins were 
highly increased in CBLdKO-Cg GC B cells, which suppress the BCL6-related GC B 
programme and promote the PC programme. Since the CBLs can directly target IRF4 for 
ubiquitination, the highly expressed CBL proteins in LZ GC B cells can eradicate the 
IRF4 protein to maintain their GC B cell identify. Interestingly, I found that CD40 and 
BCR stimulation can rapidly downregulate CBL proteins and upregulate IRF4 in GC B 
cells, which can trigger the initiation of the PC programme.  
Recent two-photon microscopy studies revealed that GC B cells circulated between the 
LZ and DZ region based on the dynamic expression of chemokine receptors. The 
underlying molecular mechanism remains unclear, but it was shown that transcription 
factors FOXO1 and c-Myc are required for this critical behaviour of GC B cells. The 
Cbls-deficient GC B cells showed impaired GC selection for the W33L key mutation and 
increased PC genesis both in vivo and in vitro, indicating that these GC B cells cannot 
undergo a sufficient round of DZ-LZ circulation. In this regard, CBLs seem to represent 
new regulators that control the exit checkpoint of the DZ-LZ circulation. It would be 
necessary to directly investigate whether CBL proteins can shortcut this DL-LZ 
circulation by using two-photon microscopy or photoactivation technology. In addition, 





programme. GCs have a similar microenvironment to that of tumours, with limited 
oxygen and nutrient availability, which requires reprogramming of their metabolism for 
adaptation to this environment. For example, the HIF-family-related pathway was shown 
to be critical for sensing the hypoxic environment in the GC region to further support GC 
B proliferation and maturation, as blocking HIF pathways suppressed GC B cell survival, 
CSR and differentiation [297]. Moreover, PCs displayed a unique metabolic programme 
to sustain the production of a large quantity of immunoglobulins and the unfolded-protein 
response [164].  Therefore, metabolic regulation was also involved in the generation of 
PCs through a GC-dependent pathway. It would be interesting to determine whether the 
CBL proteins can regulate PC differentiation through a metabolism-related mechanism. 
Once the affinity maturation and selection of GC B cells reach a certain point, the BCR 
and CD40 trigger the signals to promote the exit from the GC reaction and the 
differentiation into PCs or memory B cells. Although recent transcriptome studies have 
shown the dynamic transcription regulation of BCL6, IRF4 and BLIMP1 in the 
generation of plasmablasts, the initial signal driving the GC B cell programme to the PC 
programme is still controversial. Our data clearly showed that the downregulation of 
BCL6 and the upregulation of IRF4 (BCL6loIRF4hi) in a small proportion of GC B cells 
were considered the precursors of plasmablasts. Interestingly, this plasmablast precursor 
was dramatically expanded in mutant mice compared to WT mice, suggesting that the 
CBL proteins control the formation of this population. Consequently, the CBL dko mice 





Upon CD40 and BCR stimulation, the CBL proteins were rapidly degraded in both the 
cytosol and nucleus, which led to the upregulation of IRF4. The upregulation of IRF4  
	
Figure 4.3 CBL proteins regulate the initiation of PC program 
CBL proteins are preferentially expressed in LZ GC B cells comparing to DZ GC B cells. 
After acquiring antigen and T-cell help, majority of LZ GC B cells with moderate BCR 
and CD40 stimulation migrate back to DZ for clonal expansion and SHM. Upon strong 
BCR and CD40 stimulation, a small proportion of high affinity BCR-expressing LZ GC 
B cells downregulate CBLs and BCL6 expression, leading to accumulation of IRF4 
protein. Eventually, these IRF4 highly expressing plasmablast precursors further 
differentiate into PCs.  
 
protein not only suppressed Bcl6 transcription but also further promoted the expression of 
IRF4 and BLIMP1 proteins. These two master transcription factors of PCs could push 





regulation of the IRF4 concentration in LZ GC B cells is the earliest event of bias to PC 
fate commitment through a robust BCR- and CD40-controlled CBL expression.  
My findings demonstrated that CBL proteins are dynamically regulated in DZ and LZ 
GC B cells, which is critical for GC selection and maturation. Although the CBL proteins 
were markedly upregulated in LZ GC B cells, the mRNA level of Cbl and Cblb was 
comparable to that in naïve B, DZ and LZ GC B cells, which indicates that the expression 
of CBLs may be post-transcriptionally regulated. This finding raised an interesting 
question: how is the CBL expression spatially and temporally regulated during the GC 
affinity selection? Three lines of evidence indicate that CD40-mediated signalling is 
responsible for the degradation of CBLs. In human B cells, CD40 stimulation induces the 
strongest expression of c-Src kinase compared to other stimuli[298]. Along this line, c-
Src interacts with CBL and promotes the ubiquitination of CBL both in vitro and in vivo 
[299]. However, since the c-Src kinase lacks the RING finger domain, the function of Src 
in this process is more likely to be sorting CBL to proteasomal destruction by cooperating 
with other E3 ubiquitin ligases. The direct downstream targets of CD40 contain TRAFS 
or cIAPs, both of which contain the RING finger domain and can regulate the 
downstream signalling through ubiquitination [279]. Additionally, TRAF2 and TRAF6 
are physically associated with CBLB upon CD40 stimulation. Then, we speculated that 
Scr and TRAF work cooperatively to degrade CBL proteins through a ubiquitination-
dependent machinery. Alternatively, CD40 can also downregulate CBL expression 
through a microRNA-dependent mechanism by inducing miR155. It has been shown that 





CBL proteins leads to impaired antibody selection and maturation, it would be interesting 
to investigate if the over-expression of CBL proteins in GC B cells can improve the GC 
maturation.  
Due to the rapid development of molecular immunology, more than 120 inherited 
primary immunodeficiency diseases have been characterized in the past six decades[300]. 
Among them, one group of immunodeficiency diseases such as hyper-IgM syndromes 
(HIGMs), X-linked agammaglobulinaemia (XLA) and common variable 
immunodeficiency (CVID) are related to B cell defects. Patients with these genetic 
defects are vulnerable to recurrent infections with encapsulated pathogens. It is necessary 
to understand the precise molecular defects that lead to the B-cell-related 
immunodeficiency, which would promote translational research. For example, six genes 
are identified as biomarkers for the hyper-IgM syndromes (HIGMs): Cd40l, Cd40, Acida, 
Ung, Ikkg and Nfkbia [301-310]. The HIGMs are characterized by impaired CSR and 
SHM or by impaired SHM alone. Interestingly, our CBL dko mice also displayed a 
similar immunodeficiency. It would be necessary to investigate if CBL proteins or their 
RING finger domains are mutated in patients with HIGMs. If so, the CBLs could become 





























5.1  Conclusions 
GCs are critical micro-lymphoid organs responsible for the production of high affinity 
antibody producing PCs and memory B cells. Due to its importance in immune 
surveillance, autoimmunity, and B cell tumours, numerous efforts have been invested in 
understanding how the GC reaction is regulated under physiological and pathological 
conditions. My studies have provided some new insights into the mechanisms of this 
regulation. Using various genetic mutant mice, I have demonstrated that E3 ubiquitin 
ligases CBL proteins play redundant, however, critical roles at different levels of the GC 
reaction. First, at the entry checkpoint of the GC reaction, CBL proteins are required for 
the establishment of the cognate interaction between antigen specific B cells and CD4+ T 
cells. My further studies have shown that CBL proteins control this interaction through 
regulating BCR-mediated antigen internalization and sorting to the lysosomes for 
degradation, and they do so by promoting the ubiquitination of the BCR-associated Iga 
and Igb. In the absence of CBL proteins B cells cannot internalize BCR-bound antigen 
and present antigen to T cells, consequently impeding the T-B cell interaction and 
disabling the development of Tfh cells and initiation of GCs. Secondly, I have 
demonstrated that CBL proteins control antibody affinity maturation and they do so at the 
exit checkpoint of GC reaction. In this direction, my studies have revealed that the 
expression of CBL proteins is dynamically regulated during GC zoning cycle, with the 
highest expression found in the LZ relative to the DZ B cells. Such an up-regulation 





transcription factor, in the LZ B cells, consequently preventing the premature termination 
of the GC cycle which is essential for B cells to acquire SHM and undergo affinity 
selection. My studies have shown further that CBL proteins are essential for the 
ubiquitination and degradation of IRF4 and ectopic expression of IRF4 is sufficient to 
abolish antibody affinity maturation. Strong BCR and CD40 signalling lead to 
degradation of CBL proteins and concomitant up-regulation of IRF4. Thus, these studies 
support a model that CBL proteins function as a critical B cell intrinsic sensor that 
regulate GC affinity selection by detecting the BCR affinity cues delivered as BCR and 
CD40 signalling.  
5.2 Future Directions 
While my studies have established several critical roles of CBL proteins in the entry and 
exit checkpoints of the GC reaction, several questions remain unresolved by these 
studies:  
Firstly, in my studies I have found that CBL ubiquitin ligase activity is required for Tfh 
cell development and GC initiation (Figure 2.11 A and B) and both Iga and Igb are 
ubiquitinated by CBL proteins (Figure 2.10 A and B). However, my mutagenesis studies 
have shown that blockade of Iga ubiquitination alone is sufficient to block antigen 
presentation by B cells as well as the development of GCs (Figure 2.13 G and 2.14 A). 
These experiments thus raise an important question as to whether Igb ubiquitination is 
required for B cell antigen presentation. My current hypothesis is that Igb ubiquitination 





redundant. This hypothesis can be tested by mutagenesis studies of Igb, in analogous to 
the experiment of Iga mutagenesis studies described in Figure 2.13 and 2.14. For this 
purpose, I have generated Igb ko mice and can test this hypothesis by introducing into the 
Igb B cells a mutant form of Igb that cannot be ubiquitinated. I will then examine the 
antigen presentation by these mutant B cells and Tfh and GC development in the mutant 
mice that carry such a mutation.  
Secondly, while my studies have shown that CBL-mediated ubiquitination of Iga and Igb 
is necessary for naïve B cell antigen presentation, ablation of CBL proteins in GC B cells 
did not prevent GC B cell proliferation which generally believed to be dependent on GC 
B cell-Tfh interaction (Figure 3.3 E and 3.4 E). This finding thus suggests either that Iga 
and Igb ubiquitination is not required for antigen internalization and processing by 
activated B cells or that other intracellular ubiquitin ligases are involved in Iga and Igb 
ubiquitination. To address this question, I have generated several conditional Iga and Igb 
mutant constructs, which may specifically turn-on the mutant Iga or Igb in GC B cells. 
Since these mutant Iga and Igb cannot be ubiquitinated, it will allow me to test whether 
ubiquitination of Iga and Igb is required for antigen presentation of activated GC B cells 
and GC B cell proliferation.  
Thirdly, in chapter 3 my studies have shown that CBL proteins control the affinity 
maturation of GC B cells and they may do so by prematurely turning-on the PC program 
in LZ GC B cells. Although I have found that CBL proteins are dynamically regulated at 





mechanisms employed by B cells to control CBL expression. My hypothesis is that in LZ 
B cells CBL protein levels are regulated by protein ubiquitination, either by themselves 
or by other ubiquitin ligases or de-ubiquitinases and this regulation depends on BCR and 
CD40 signalling strength. To examine whether this is the case, I will conduct further 
biochemical studies to examine whether CBL proteins are ubiquitinated and whether 
BCR and CD40 stimulation changes the status of CBL ubiquitination. Co-
immunoprecipitation combined with proteomics studies will be used to identify other 
unknown ubiquitin ligases or de-ubiquitinases that regulate CBL ubiquitination.   
Finally, since my studies have shown that the level of CBL proteins in GC B cells dictate 
the selection of high affinity GC B cells, it will be interesting to examine whether 
increased CBL expression alone may help to improve antibody affinity maturation. Along 
this line, I will use genetic approach to increase CBL expression in GC B cells and then 
examine whether this modulation boosts antibody affinity maturation in mice. If so, it 
will suggest that we may improve the efficiency of vaccination to weak antigenic 
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